Print

Search Results: (255 results)

Study of a New InvestigationaI Inhibitor to Treat People with Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/300/study-of-a-new-investigationai-inhibitor-to-treat-people-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors

The study will test if an investigational treatment, XL309, is safe and works when used alone or in combination with a PARP inhibitor to treat people with some advanced solid tumors. The study is enrolling people with BRCA1 or BRCA2 inherited mutations and have HER2-negative breast cancer, prostate cancer, pancreatic cancer, high grade ovarian, fallopian tube or primary peritoneal cancer; or other solid tumors with certain genetic mutations. 

NePtune: Using PARP Inhibitors Before Surgery in Localized Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/314/neptune-using-parp-inhibitors-before-surgery-in-localized-prostate-cancer

Treatment
Treatment study for people with intermediate- or high-risk prostate cancer with certain tumor mutations

This research study is enrolling prostate cancer patients who plan to undergo surgery to have their prostate removed (radical prostatectomy) and whose cancer has one of the listed gene mutations: BRCA1, BRCA2, PALB2, RAD51B, RAD51C, RAD51D, RAD54L2, BARD1, FANCA or BRIP1.

Social Support and Coping Strategies Among LGBTQIA+ Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/303/social-support-and-coping-strategies-among-lgbtqia-cancer-patients

Surveys, Registries, Interviews
This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients

This study explores how different levels of support systems influence coping strategies among LGBTQIA+ cancer patients, specifically patients who are over the age of 18, actively diagnosed with cancer, and reside in the United States.

PROMISE Registry: A Prostate Cancer Registry of Outcomes and Germline Mutations for Improved Survival and Treatment Effectiveness

https://www.facingourrisk.org/research-clinical-trials/study/149/promise-registry-a-prostate-cancer-registry-of-outcomes-and-germline-mutations-for-improved-survival-and-treatment-effectiveness

Surveys, Registries, Interviews
A screening registry for people diagnosed with prostate cancer

PROMISE is a nationwide registry of prostate cancer patients with inherited mutations; screening approximately 5,000 participants with a prostate cancer diagnosis. The PROMISE team is studying how these mutations affect patient outcomes and hope to help patients learn more about their disease, the treatments that they may benefit most from, and any research studies that they may be eligible for.

Cognitive Training for Breast Cancer Survivors with Memory and Thinking Problems

https://www.facingourrisk.org/research-clinical-trials/study/312/cognitive-training-for-breast-cancer-survivors-with-memory-and-thinking-problems

Quality of Life
How well cognitive training helps breast cancer survivors with their memory and thinking problems

This study will explore how well cognitive training helps breast cancer survivors with their memory and thinking problems caused by cancer.

Denosumab for Breast Cancer Risk Reduction in Women With an Inherited BRCA1 Mutation (The Breast Cancer Prevention Study)

https://www.facingourrisk.org/research-clinical-trials/study/196/denosumab-for-breast-cancer-risk-reduction-in-women-with-an-inherited-brca1-mutation-the-breast-cancer-prevention-study

Prevention
Prevention study enrolling women ages 25-55 with a BRCA1 mutation

This is a study to test the effectiveness of a drug (denosumab) on preventing the development of breast cancer in women with an inherited BRCA1 mutation.

Denosumab is a drug that is currently used to treat bone loss in order to reduce the risk of broken bones in healthy people, and is also used to reduce new bone growths in cancer patients whose cancer has spread to their bones. Research has shown that denosumab may also reduce the risk of developing breast cancer in women with an inherited BRCA1 mutation.

Olaparib with Cediranib or Ceralasertib for People with Advanced or Metastatic Breast Cancer and with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/304/olaparib-with-cediranib-or-ceralasertib-for-people-with-advanced-or-metastatic-breast-cancer-and-with-a-brca1-or-brca2-mutation

Treatment
Treatment study for people with advanced breast cancer who have a BRCA1 or BRCA2 genetic mutation and who were previously treated with a PARP inhibitor

This study is for people with advanced or metastatic breast cancer, have a BRCA1 or BRCA2 genetic mutation and were previously treated with a PARP inhibitor. The study will examine how effective  Olaparib in combination with Cediranib or Ceralasertib is in reducing the size of cancer and determining the length of time patients respond well to the treatment.

Pancreatic Cancer Screening Study (CAPS5)

https://www.facingourrisk.org/research-clinical-trials/study/222/pancreatic-cancer-screening-studycaps5

Prevention
Screening study for people at high risk for pancreatic cancer

CAPS5 is a study looking at screening for early cancer in people with an elevated lifetime risk of developing pancreatic cancer. The goal is to study biomarkers derived from images and tissue samples (blood, pancreas fluid, duodenal fluid) for the early detection of pancreatic cancer and precancerous lesions.

 

A Study to Compare Two Surgical Procedures in Women with BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer (SOROCk)

https://www.facingourrisk.org/research-clinical-trials/study/101/a-study-to-compare-two-surgical-procedures-in-women-with-brca1-mutations-to-assess-reduced-risk-of-ovarian-cancer-sorock

Prevention
Ovarian cancer prevention for women with a BRCA1 mutation who still have their ovaries

SOROCk [NRG-CC008] is a clinical trial studying if removal of just the fallopian tubes can reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes among women with an inherited BRCA1 mutation. The main benefit of removing only the fallopian tubes and not the ovaries is to prevent surgically-induced menopause. The study will also examine various patient-reported quality of life outcomes. Researchers believe that most ovarian cancers first begin in the fallopian tubes, suggesting that removing the fallopian tubes only may prevent the development of ovarian cancer. This concept has never been formally testing in a clinical trial.

PATROL Study: Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease

https://www.facingourrisk.org/research-clinical-trials/study/291/patrol-study-prostate-cancer-screening-for-people-at-genetic-risk-for-aggressive-disease

Prevention
Screening study for people with a mutation linked to prostate cancer risk

The PATROL (Prostate Cancer Screening for People AT Genetic Risk FOr Aggressive Disease) study is for people at risk for prostate cancer because they carry one or more genes that are known or suspected to increase prostate cancer risk: BRCA2, HOXB13, ATM, BRCA1, MLH1, MSH2, MSH6, PALB2, PMS2, CHEK2, RAD51D, or TP53.

Mastectomy Decision Support Study

https://www.facingourrisk.org/research-clinical-trials/study/313/mastectomy-decision-support-study

Surveys, Registries, Interviews
Interviews with women who underwent a bilateral mastectomy

The purpose of this study is to get participants’ opinions on the content, format, and design of educational materials that inform about the emotional consequences of undergoing a bilateral mastectomy.

Ethical Challenges in Genetic Testing for Terminally Ill People and their Families

https://www.facingourrisk.org/research-clinical-trials/study/315/a-study-on-ethical-challenges-in-genetic-testing-for-terminally-ill-patients-and-their-families

Surveys, Registries, Interviews
Interview of palliative care patients and/or their adult family members who have been offered and involved in genetic testing or counseling

This study will interview palliative care patients and/or their adult family members (spouse, parents, children, siblings) who have been offered and involved in genetic testing or counseling related to the condition for which the patients are receiving palliative care.

Combining the Immunotherapy Dostarlimab and PARP Inhibitor Niraparib for Advanced or Metastatic Breast, Ovarian or Pancreatic Cancer with an Inherited or Tumor BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/231/immunotherapy-and-parp-inhibitor-for-advanced-or-metastatic-breast-ovarian-or-pancreatic-cancer-with-a-brca-mutation

Treatment
Treatment study for people with advanced breast, ovarian or pancreatic cancer and an inherited or tumor BRCA mutation

This study is looking at the effectiveness of combining a PARP inhibitor called niraparib and an immunotherapy called dostarlimab for treating people with an inherited BRCA mutation (found with genetic testing) or a tumor mutation (found through tumor testing) who have breast, pancreatic, ovarian, fallopian tube or primary peritoneal cancer that is metastatic or advanced and cannot be removed by surgery (unresectable).

The DETECT Study: Detecting Endometrial Cancer in Tampons

https://www.facingourrisk.org/research-clinical-trials/study/306/the-detect-study-detecting-endometrial-cancer-in-tampons

Prevention
Early detection of endometrial cancer in women over 45 years of age who are undergoing hysterectomy surgery at the University of Alabama

This study will test whether endometrial samples from tampons can be used for early detection of endometrial cancer and is open to women over 45 years of age who are undergoing hysterectomy surgery (surgery to remove the uterus)

Lynch Syndrome Vaccine Study

https://www.facingourrisk.org/research-clinical-trials/study/273/testing-a-combination-of-vaccines-for-cancer-prevention-in-lynch-syndrome

Prevention
Testing a combination of vaccines for cancer prevention in Lynch syndrome

This study is being done to assess the safety and effectiveness of a series of vaccines (Tri-Ad5), together with another drug (N-803) that magnifies the body’s response to vaccines, to see if there is an effect on the risk of developing colon and other cancers in LS patients.

UPLIFT: Cancer Caregivers Study

https://www.facingourrisk.org/research-clinical-trials/study/309/uplift-cancer-caregivers-study

Surveys, Registries, Interviews
Survey for cancer caregivers of an LGBTQIA+ family member or friend

Survey for cancer caregivers of an LGBTQIA+ family member or friend to understand the impact of caregiving on the mental, physical, and financial well-being of LGBTQ+ people providing unpaid care

Effectiveness of Lymph Node Mapping to Reduce the Risk of Swelling in the Legs in Patients with Stage I Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/310/effectiveness-of-lymph-node-mapping-to-reduce-the-risk-of-swelling-in-the-legs-in-patients-with-stage-i-endometrial-cancer

Treatment
People with stage I endometrial cancer who are having a hysterectomy

This study compares the effect of sentinel lymph node mapping to standard lymph node dissection in reducing the risk of swelling in the legs (lymphedema) in patients undergoing a hysterectomy for stage I endometrial cancer.

FORCE Survey for People at Increased Risk for Colorectal, Pancreatic or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/287/survey-for-people-at-increased-risk-for-breast-or-gynecologic-cancer-due-to-an-inherited-mutation


Survey for people at high risk for Colorectal, Pancreatic or Prostate Cancer

FORCE is conducting a short survey to better understand the unmet needs of people who are at high risk for colorectal, pancreatic or prostate cancer. You can take the survey here. 

Studies for People with ER-Positive, HER2-Negative Advanced or Metastatic Breast Cancer (TACTIVE-U)

https://www.facingourrisk.org/research-clinical-trials/study/279/treatment-studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-tactive-u

Treatment
Treatment for ER-positive, HER2-negative metastatic breast cancer

Researchers at Pfizer and Arvinas are conducting the TACTIVE-U studies for people with ER-positive, HER2-negative advanced or metastatic breast cancer who have received at least one prior round of treatment and no more than two prior rounds of treatments for advanced or metastatic disease. One of these rounds of treatment must have included a CDK4/6 inhibitor (e.g., Kisqali, Verzenio, Ibrance). The TACTIVE-U studies are looking at the safety of an oral study medicine, ARV-471 (also known as vepdegestrant), and how well it works when combined with other breast cancer medicines.

The LiFT UP Li-Fraumeni & TP53: Understanding & Progress Study

https://www.facingourrisk.org/research-clinical-trials/study/307/the-lift-up-study

Surveys, Registries, Interviews
Study looking at cancer risk for people with Li-Fraumeni syndrome

The LiFT UP Study is a research project for individuals and families from around the world. The goal is to learn more about adults and children who have a change in the TP53 gene in their blood to better predict their specific cancer risks. 

Study of a New Treatment Called ONM-501 Alone and in Combination with Cemiplimab in People with Triple Negative Breast Cancer, Advanced Solid Tumors and Lymphomas

https://www.facingourrisk.org/research-clinical-trials/study/311/study-of-a-new-treatment-called-onm-501-alone-and-in-combination-with-cemiplimab-in-people-with-triple-negative-breast-cancer-advanced-solid-tumors-and-lymphomas

Treatment
Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

Study of a new drug called ONM-501 for people with triple negative breast cancer, advanced solid tumors or lymphomas

Registry to Discover New Treatments and Developmental Processes of Colorectal and Endometrial Cancer in Patients with Hereditary Cancer

https://www.facingourrisk.org/research-clinical-trials/study/301/registry-to-discover-new-treatments-and-developmental-processes-of-colorectal-and-endometrial-cancer-in-patients-with-hereditary-cancer

Surveys, Registries, Interviews
Study to collect and save data, cancer samples, and cancer family health histories from people who screen for colorectal endometrial cancer

This research registry will collect and save data, cancer samples and family health history information to discover new ways cancer develops. It will look to find new genes that could be used for treatments and preventing cancer for people with hereditary cancer.

PreCharge: Digital Program for People Affected by Hereditary Cancer

https://www.facingourrisk.org/research-clinical-trials/study/292/precharge-digital-program-for-people-with-hereditary-cancer-syndromes


Study to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being

PreCharge is an IRB approved, nationwide study funded by the National Cancer Institute. The purpose of this study is to test a digital program designed to help people affected by hereditary cancer and who have not been diagnosed with cancer improve their mental and emotional well-being.

The Phoenix Trial: Cemiplimab for Patients with Localized dMMR Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/299/the-phoenix-trial-cemiplimab-for-patients-with-localized-dmmr-colon-cancer

Treatment
This study will examine how well Cemiplimab works for patients with localized colon cancer who have dMMR

This study will examine the effectiveness and safety of cemiplimab, a treatment given prior to surgery. Participants will undergo endoscopy after the therapy and take CT scans to assess the effects of the therapy. The study also will compare genes of pretreatment cancer samples between patients who responded well to the therapy and patients who did not.

A clinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer: VERITAC-2

https://www.facingourrisk.org/research-clinical-trials/study/269/studies-for-people-with-er-positive-her2-negative-advanced-or-metastatic-breast-cancer-veritac-studies


A clinical trial for ER-positive, HER2-negative advanced breast cancer

Researchers at Pfizer and Arvinas are conducting the VERITAC-2 cinical trial for people with ER-positive, HER2-negative advanced (locally advanced or metastatic) breast cancer that has profressed after previous treatment. This clinical trial is specifically for people who have already been treated with CDK4/6 inhibitor* therapy in combination with hormone therapy for their locoregional recurrent/metastatic disease.

* CDK4/6 inhibitors include medications called palbociclib (IBRANCE®), ribociclib (KISQALI®), and abemaciclib (Verzenio®).

ShareForCures®: Susan G. Komen's People-Powered, Data-Driven Breast Cancer Research Registry

https://www.facingourrisk.org/research-clinical-trials/study/295/shareforcures-susan-g-komens-people-powered-data-driven-breast-cancer-research-registry

Surveys, Registries, Interviews
Registry for anyone diagnosed with breast cancer

Today, researchers are learning about breast cancer from a small subset of patients, who are not representative of all breast cancer patients. ShareForCures® is an online registry that offers people who have been diagnosed with breast cancer a way to participate in research by connecting information about themselves with their breast cancer diagnosis, medical records, genomics. Participation is open to anyone adult, living in the United States, and who has been diagnosed with breast cancer.

The Risk Factor Analysis of Hereditary Breast and Ovarian Cancer In Women with BRCA1, BRCA2 or PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/120/the-risk-factor-analysis-of-hereditary-breast-and-ovarian-cancer-in-women-with-brca1-brca2-or-palb2-mutations

Surveys, Registries, Interviews
Study for people who have a BRCA1, BRCA2, or PALB2 genetic mutation

Those who carry the BRCA1, BRCA2 or PALB2 gene mutations experience a higher lifetime risk of developing breast and ovarian cancer, but we need to know more about the other genetic and non-genetic factors that may also influence risk. This study follows women with these gene mutations over time, striving to build the evidence we need to help them and others make better decisions to protect their health.

Cancer Prevention Vaccine (Nous-209) for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/278/cancer-prevention-vaccine-nous-209-for-people-with-lynch-syndrome


Prevention study for people with Lynch syndrome

This study is testing a vaccine, known as the Nous-209 vaccine, which is intended to decrease the chances that people with Lynch syndrome will develop polyps that can turn into cancer.

Testing a Vaccine for Treating or Preventing Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/285/treatment-study-for-people-with-stage-2-or-3-triple-negative-breast-cancer-at-high-risk-for-recurrence

Treatment
Treatment study for people with stage 2 or 3 triple-negative breast cancer at high risk for recurrence

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Study of the Drug Sovilnesib in People with Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/308/study-of-the-drug-sovilnesib-in-people-with-ovarian-cancer

Treatment
Treatment study for people with platinum-resistant ovarian cancer

This study will test the safety and effectiveness of the drug sovilnesib in patients with ovarian cancer.

A Survey on Options for Managing Cancer Risk Among Women with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/119/a-survey-on-options-for-managing-cancer-risk-among-women-with-a-brca1-or-brca2-mutation

Surveys, Registries, Interviews
A survey for women with a BRCA1 or BRCA2 mutation

Women with a BRCA1 or BRCA2 mutation are at higher risk of developing breast and/or ovarian cancer compared to women in the general population. There are various options available to these women to help reduce or manage these risks, including preventive surgery. We are conducting an important new study to examine and understand cancer prevention decisions and outcomes in these women.

High Dose Testosterone Treatment for People with Metastatic Prostate Cancer and an ATM, CDK12 or CHEK2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/294/high-dose-testosterone-treatment-for-people-with-metastatic-prostate-cancer-and-an-atm-cdk12-or-chek2mutation

Treatment
People who have metastatic castration-resistant prostate cancer with an ATM, CDK12, or CHEK2 mutation

This study will examine how well an increased dose of testosterone treatment works for people with metastatic castration-resistant prostate cancer (mCRPC) with an ATM, CDK12, or CHEK2 genetic mutation. Participants will continue to receive the medication as long as their cancer doesn’t get worse and they do not experience severe side effects.

Roadmap to Parenthood: A Study about Fertility and Family-Building After Cancer

https://www.facingourrisk.org/research-clinical-trials/study/302/roadmap-to-parenthood-a-study-about-fertility-and-family-building-after-cancer

Surveys, Registries, Interviews
A survey for people aged 18-45, assigned female at birth, and history of a cancer diagnosis

Roadmap to Parenthood is a remote, survey-based study. Eligible participants must be aged 18-45, assigned female at birth, and history of a cancer diagnosis. this study to evaluate an online tool developed to educate and provide support to women and people assigned female at birth who are interested in family building after cancer. This study involves the completion of four online surveys. All study procedures are done remotely.

The Experience of Genetic Testing Among Latinas with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/305/the-experience-of-genetic-testing-among-latinas-with-a-brca1-or-brca2-mutation


Interviews with Latinas who have a BRCA1 or BRCA2 mutation

This goal of this study is to interview Latinas, who have been diagnosed with BRCA1 or BRCA2 mutation, and explore their experience with genetic testing

Screening Study for Men at High Genetic Risk for Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/72/men-at-high-genetic-risk-for-prostate-cancer

Prevention
Prostate screening with MRI for men with Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or a BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or other mutation

The National Institutes of Health has a clinical trial for men at high genetic risk for prostate cancer. This is trial is for men without prostate cancer, ages 30 to 75, who have tested positive for Lynch syndrome (MLH1, MSH2, MSH6, PMS2, EPCAM) or BRCA1, BRCA2, HOXB13, ATM, NBN, TP53, BRIP1, CHEK2, PALB2, RAD51C, RAD51D, or FANC (FANCA, FANCB, FANCC, FANCD2, FANCE, FANCF, FANCG, FANCI, FANCL, and FANCM). The trial involves screening MRI of the prostate every two years and biopsy of the prostate if the MRI is abnormal. There is no cost for travel or study-related tests. 

A Pilot Study Investigating the Views of Key Stakeholders on Somatic and Germline Cancer Testing

https://www.facingourrisk.org/research-clinical-trials/study/298/individuals-views-on-somatic-and-germline-testing


This is a survey research study enrolling people with a history of cancer, cancer genetic testing, and an inherited mutation or variant of uncertain significance (VUS) in a hereditary cancer gene

This is a survey research study enrolling people with a history of cancer, cancer genetic testing, and an inherited mutation or variant of uncertain significance (VUS) in a hereditary cancer gene (e.g., APC, ATM, BARD1, BRCA1, BRCA2, BRIP1, CDH1, CDKN2A, CDK4, CHEK2, EPCAM, HOXB13, MLH1, MSH2, MSH6, MUTYH, NBN, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53).

Carboplatin Chemotherapy before Surgery for Patients with High-Risk Prostate Cancer and an Inherited BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/286/swog-s2210-carboplatin-chemotherapy-before-surgery-for-patients-with-high-risk-prostate-cancer-and-an-inherited-brca1-or-brca2-gene-mutation

Treatment
Treatment before surgery for people with high-risk prostate cancer and an inherited BRCA1 or BRCA2 gene mutation

This study tests how well carboplatin before surgery works in treating patients with high-risk prostate cancer who have inherited BRCA1 or BRCA2 gene mutations. The purpose of the study is to treat men with BRCA1 or BRCA2 mutations who are at higher risk of prostate cancer after surgery (removal of the prostate) compared to patients without these mutations.

Study of a New Immunotherapy Treatment Called NC410 in People with Different Types of Advanced or Metastatic Cancers

https://www.facingourrisk.org/research-clinical-trials/study/251/study-of-an-immunotherapy-treatment-in-individuals-with-advanced-or-metastatic-solid-tumors

Treatment
People with advanced or metastatic colorectal, endometrial, ovarian, stomach, esophageal or other cancers

This study will test the safety and effectiveness of using a new immunotherapy drug called NC410 to treat people with different types of metastatic or advanced cancers that cannot be removed by surgery. The study is open to people with colorectal, endometrial, ovarian, stomach, esophageal, head and neck and other cancers that:

A Study of the Drug REC-4881 For Treating People with Advanced Cancers with an APC or AXIN1 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/290/a-study-of-the-drug-rec-4881-for-treating-people-with-advanced-cancers-with-an-apc-or-axin1-mutation

Treatment
Treatment study for people with advanced cancer with an APC or AXIN1 mutation

This study is looking at how well the research drug REC-4881 works and how safe it is for the treatment of people with advanced or metastatic cancers with an APC or AXIN1 mutation.

Comparing Screening Methods for Detection of Early-Stage Gastric Cancer in People with a CHD1 Genetic Mutation

https://www.facingourrisk.org/research-clinical-trials/study/293/comparing-screening-methods-for-detection-of-early-stage-gastric-cancer-in-people-with-a-chd1-genetic-mutation


Gastric cancer screening study for people with a CHD1 inherited mutation

This study will compare a new technique of screening for a type of inherited gastric cancer known as diffuse hereditary gastric cancer (DHGC) to see if it can identify cancer better than the current recommended screening. 

Studying a Combination of Three Drugs to Treat Previously Untreated Metastatic Colorectal Cancer which Is MSI-High and Has a BRAF V600E Mutation

https://www.facingourrisk.org/research-clinical-trials/study/252/comparing-three-drugs-in-patients-with-metastatic-colorectal-cancer-who-have-not-had-prior-treatment

Treatment
Study for metastatic colorectal cancer that has not yet been treated

This study is being done to learn about the effects of using three study medicines together as treatment for metastatic colorectal cancer that has been previously untreated.

Interviews with Young Women with a BRCA Mutation About Their Breast Cancer Risk Management Experiences

https://www.facingourrisk.org/research-clinical-trials/study/297/interviews-with-young-women-with-a-brca-mutation-about-their-breast-cancer-risk-management-experiences


Young women with a BRCA mutation

This research study focuses on young women’s emotional experiences when considering or engaging in strategies to manage increased breast cancer risk.

Testing the Safety And Action of the Investigational Drug REC-4881 in People With Familial Adenomatous Polyposis (FAP) (TUPELO Study)

https://www.facingourrisk.org/research-clinical-trials/study/288/testing-the-safety-and-action-of-the-investigational-drug-rec-4881-in-people-with-familial-adenomatous-polyposis-fap

Prevention
Prevention study for people with an APC mutation and FAP who have had colectomy surgery

This study is looking at how safe and effective the research drug REC-4881 is for treating polyps in people with Familial Adenomatous Polyposis (FAP). Participants will receive the oral drug REC-4881. A participant's dose will depend on when they join the study. 

Using ctDNA Blood Test for Earlier Detection and Treatment of Recurrence or Spread after Treatment for Stage 3 Colon Cancer

https://www.facingourrisk.org/research-clinical-trials/study/283/using-ctdna-for-earlier-detection-and-treatment-of-recurrence-or-spread-after-treatment-for-stage-3-colon-cancer

Treatment
Monitoring and treatment study for people who completed treatment for stage 3 colon cancer

The usual care after a person with stage 3 colon cancer has had surgery and chemotherapy is to begin active surveillance. This is a time when no additional treatment is given, but instead patients have frequent imaging scans to see if their cancer has come back.

This study is looking at whether a blood test known as circulating tumor DNA (ctDNA) can find signs of remaining cancer or recurrence after treatment earlier than standard active surveillance. People in the study who have evidence of cancer in their ctDNA test may receive additional treatment based on their test results. The goal of this study is to learn if using ctDNA and additional treatment improves outcomes in people after treatment for stage 3 colon cancer. Currently, testing with ctDNA is not part of standard of care to determine if colon cancer treatment was successful or if there is a recurrence. 

Study of a New Treatment Called TNG348 in People with Advanced or Metastatic Cancer and with a BRCA1 or BRCA2 Mutation or HRD Positive Tumor

https://www.facingourrisk.org/research-clinical-trials/study/296/study-of-a-new-treatment-called-tng348-in-people-with-advanced-or-metastatic-cancer-and-with-a-brca1-or-brca2-mutation-or-hrd-positive-tumor


Treatment for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor

The study will test the safety and effectiveness of a new drug called TNG348 used alone or in combination with Olaparib (a PARP inhibitor.) The study is for patients who have advanced breast, ovarian, pancreatic, and prostate cancer and a BRCA1 or BRCA2 mutation or have an HRD positive tumor.

Exploring How People of Caribbean Descent Share Information About Their Genetic Mutations with Family Members

https://www.facingourrisk.org/research-clinical-trials/study/275/exploring-how-people-of-caribbean-descent-share-information-about-their-genetic-mutations-with-their-family-members

Surveys, Registries, Interviews
Survey and interview for people of Caribbean descent who tested positive for a genetic mutation linked to cancer.

We're looking into how families share information among Caribbean individuals who have a genetic mutation linked to an increased risk of cancer. The goal is to understand the experiences of Caribbean people dealing with a higher chance of developing cancer. This study will help us figure out how genetic counselors can better support Caribbean patients and their family members in handling this genetic information. If you're interested, you can participate by filling out a survey. If you're eligible, we might reach out to you for a 45-60 minute interview. 

Comparing a Combination of Drugs for Treatment of HER2-positive Colorectal Cancer as First Line Treatment in the Metastatic Setting

https://www.facingourrisk.org/research-clinical-trials/study/274/treatment-of-her2-positive-colorectal-cancer-as-first-line-treatment-in-the-metastatic-setting

Treatment
People with HER2-positive colorectal cancer who have not yet received treatment in the metastatic setting

This study is being done to decide if the drug Tukysa (Tucatinib) combined with other cancer drugs works better than the standard of care, which is chemotherapy treatment for people with a specific type of colorectal cancer called HER2 positive colorectal cancer. The study also aims to understand the side effects of the combination of these drugs in treatment. The combination of drugs being used are Tukysa (Tucatinib), Herceptin (Trastuzumab), and mFOLFOX6, which is a combination of Oxaliplatin, Leucovorin, Levoleucovorin, and Fluorouracil.

Study of Colorectal Cancer and Genetics in Hispanic and Latino People (ENLACE Study)

https://www.facingourrisk.org/research-clinical-trials/study/276/study-of-colorectal-cancer-and-genetics-in-hispanic-and-latino-people-enlace-study

Treatment
Hispanic and Latino people diagnosed with colorectal cancer

The ENLACE study will learn more about colorectal cancer in Hispanic people so that treatment can be improved. Results may help your doctor choose your treatment and help you find out if you are eligible for a clinical trial. Your results may also help family members understand their cancer risks. People will have blood drawn and complete a questionnaire to join the study. Genetic testing will be done on your blood and the tissue from your tumor biopsy or surgery to test the genes that you inherited. You do not have to pay for the genetic testing. You will receive the results of your test from your oncologist and genetic counseling may be recommended. Two weeks and one year after talking with your doctor about your test results, you will complete follow-up questionnaires either in person or over the phone. 

Testing a Vaccine for Preventing or Treating Triple-Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/284/testing-a-vaccine-for-treating-or-preventing-triple-negative-breast-cancer

Prevention
Prevention study for people with a BRCA1, BRCA2 or PALB2 inherited mutation who are planning to undergo risk-reducing mastectomy

Researchers are studying the affects of this breast cancer vaccine on the immune system in two groups of people:

Pancreatic Cancer Early Detection for People at High Risk

https://www.facingourrisk.org/research-clinical-trials/study/227/pancreatic-cancer-early-detection-for-people-at-high-risk

Prevention
Registry and biobank for high risk people undergoing pancreatic cancer screening

The study will collect clinical information, family history, and samples (blood, saliva or cheek swab) from people and families at risk for pancreatic cancer. Collecting this information and samples will create a resource to drive research necessary for early detection and prevention of pancreatic ductal adenocarcinoma (PDAC).

Young, Empowered & Strong: Web-Based Symptom Monitoring and Self-Management for Young Adult Breast Cancer Survivors (YES Study)

https://www.facingourrisk.org/research-clinical-trials/study/199/young-empowered-strong-web-based-symptom-monitoring-and-self-management-for-young-adult-breast-cancer-survivors

Quality of Life
Women diagnosed with breast cancer between the ages of 15-39

The goal of this study is to measure whether a web-based patient-reported symptom monitoring and self management portal, Young, Empowered & Strong (YES), improves the quality of life of young breast cancer survivors when compared to standard of care symptom management. 

Collecting Blood and Stool Samples to Detect Colorectal Cancer or Precancerous Polyps in Lynch Syndrome Patients, CORAL Study

https://www.facingourrisk.org/research-clinical-trials/study/256/early-detection-of-colorectal-cancer-for-people-with-lynch-syndrome

Prevention
People with Lynch Syndrome at risk for colon cancer

This study will colect blood and stool samples to detect colorectal cancer or precancerous polyps in people with Lynch syndrome and those diagnosed with early onset colorectal cancer, diagnosed younger than 50 years old. 

Study of the PARP inhibitor AZD9574 Alone and Combined with Other Cancer Medicines to Treat People with Advanced Solid Cancers (CERTIS1 Study)

https://www.facingourrisk.org/research-clinical-trials/study/282/study-of-the-parp-inhibitor-azd9574-alone-and-combined-with-other-cancer-medicines-to-treat-people-with-advanced-solid-cancers-certis1-study

Treatment
Treatment study for people with advanced breast, ovarian, pancreatic or prostate cancer or gliomas

This research involves studying a drug called AZD9574 on its own and in combination with other anti-cancer drugs in people with advanced cancer that has come back or progressed. AZD9574 is a type of targeted therapy known as a PARP inhibitor. The study aims to understand the safety, tolerance, how the drug moves in the body, how it affects the body, and its initial effectiveness.

The WISDOM Study: Women Informed to Screen Depending on Measures of Risk

https://www.facingourrisk.org/research-clinical-trials/study/45/wisdom-study

Prevention
Study to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule

The goal of the Wisdom Study is to determine if breast cancer screening can be made better by personalizing each woman’s mammogram schedule, compared to the current one-size-fits-all, annual approach. The Wisdom Study is designed to end the confusion about when to start and how often to have a mammogram. 

LIVING WELL: A Web-Based Program to Improve Quality of Life in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/270/living-well-a-web-based-program-to-improve-quality-of-life-in-ovarian-cancer-survivors

Quality of Life
A research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors

A free research program offering mindfulness, coping, and healthy lifestyle skills for ovarian cancer survivors. The goal of the study is to determine if the program can improve quality of life. You can participate from your home!

Preferences Survey for Women With an Inherited BRCA Mutation and Without a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/239/preferences-survey-for-women-with-an-inherited-brca-mutation-and-without-a-cancer-diagnosis


Online survey for women with a BRCA1 or BRCA2 inherited mutation and no personal history of cancer.

We hope to understand women’s preferences about the benefits and effects of cancer-preventing surgeries. In this survey of women ages 25-50 with an inherited BRCA1 or BRCA2 mutation and no personal history of cancer, we present scenarios and ask participants to make hypothetical choices. Your responses will help us to design educational tools for people who are at high risk of breast and ovarian cancer who face personal decisions about cancer prevention.

MRI Screening in Men at High Risk of Developing Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/260/screening-in-men-at-high-risk-of-developing-prostate-cancer

Prevention
Screening using MRI for men at risk of developing prostate cancer

This study will determine if prostate magnetic resonance imaging (MRI) will find prostate cancer in men at high risk of developing prostate cancer.

My Best GI Eating Study

https://www.facingourrisk.org/research-clinical-trials/study/258/my-best-gi-eating-study

Prevention
Diet and weight loss study for people who are overweight and at increased risk of colorectal cancer

This study will test three different diets in people who are overweight and who have an increased risk of colorectal cancer. The study will look at whether these diets improve eating and possibly lead to weight loss. 

 

Studying People and Families Affected by Li-Fraumeni Syndrome (TP53 Mutation )

https://www.facingourrisk.org/research-clinical-trials/study/267/observing-people-who-have-li-fraumeni-syndrome-tp53-genetic-mutation

Surveys, Registries, Interviews
Registry for people with Li-Fraumeni syndrome (LFS) or from LFS families

The goal of this study is to identify whether Li-Fraumini syndrome (LFS), which has a high lifetime cancer risk, has any other causes besides the TP53 mutation. The study involves people with Li-Fraumeni syndrome and people from families with Li-Fraumeni syndrome filling out questionnaires with their medical information.

Registry to Promote Health Equity for People of African Ancestry with Breast or Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/277/registry-to-promote-health-equity-for-people-of-african-ancestry-with-breast-or-prostate-cancer

Surveys, Registries, Interviews
This is a registry for people of African ancestry who have breast or prostate cancer

The purpose of this research is to study and understand the genetic and molecular causes of breast and prostate cancer in people with African ancestry. People in this study will complete a questionnaire about their environments and lifestyles. You will also give a blood sample and permission for the study team to access a piece of your cancer tissue from the center where you were treated. These blood and tissue samples will be used for molecular and genetic testing to look for changes that are only seen in the tumor as well as look for genetic changes that a person may have been born with, known as inherited gene mutations. Results of these tests will be provided to you. You will be followed by the study team for one year.

A Surveillance Program for Women at High Risk for Breast Cancer (CAPSBRACA)

https://www.facingourrisk.org/research-clinical-trials/study/271/a-surveillance-program-for-women-at-high-risk-for-breast-cancer-capsbraca

Surveys, Registries, Interviews
Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor

Screening study for women at risk for breast cancer due to an inherited mutation or other risk factor. The study will create a registry of women at high risk of breast cancer. A registry collects data about specific populations to understand them better. This study will also look at whether an abbreviated MRI works as well as a full MRI for screening women at high risk of breast cancer.

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High-Risk Women (TUBA/WISP II)

https://www.facingourrisk.org/research-clinical-trials/study/205/risk-reducing-salpingectomy-with-delayed-oophorectomy-as-an-alternative-to-risk-reducing-salpingo-oophorectomy-in-high-risk-women

Prevention
Prevention study for women at high risk for ovarian cancer

This study is looking at whether removal of the fallopian tubes (salpingectomy) followed by removal of the ovaries (oophorectomy) at a later date closer to the time of natural menopause may reduce the risk of ovarian cancer nearly as much as removing both the ovaries and fallopian tubes at the same time (salpingo-oophorectomy) among women with an inherited BRCA1, BRCA2, BRIP1, RAD51C or RAD51D mutation. Removing the fallopian tubes only first and the ovaries at a later time closer to natural menopause may lessen menopausal symptoms while still lowering the risk for ovarian cancer.

 

Coaching for Family Caregivers of People with Advanced Cancer from Rural and Minority Communities

https://www.facingourrisk.org/research-clinical-trials/study/272/quality-of-life-study-for-caregivers-involving-in-person-or-telephone-coaching-sessions

Quality of Life
Quality of life study for caregivers involving in-person or telephone coaching sessions

This study is for families with patients who have newly-diagnosed advanced cancer. African American family caregivers and family caregivers living in rural communities will be eligible. Navigators working with an outpatient palliative care team, provide six health coaching sessions either in person or over the phone to help with managing stress and coping, getting and asking for help, improving caregiving skills, and decision-making/advance care planning Monthly follow-up is also provided from diagnosis through early bereavement.

Testing the Drug Obeticholic Acid for Familial Adenomatous Polyposis

https://www.facingourrisk.org/research-clinical-trials/study/289/testing-the-drug-obeticholic-acid-for-familial-adenomatous-polyposis

Prevention
Prevention study for people with an APC mutation and FAP or AFAP who have polyps in remaining tissue after colectomy surgery

This study is looking at whether obeticholic acid (OCA) is safe and has a beneficial effect on the number of polyps in the small bowel and colon in people with familial adenomatous polyposis (FAP). OCA is a drug similar to a bile acid the body's liver makes. Researchers believe OCA may help keeping cancer from developing. OCA is already FDA approved to treat a type of liver disease. There have been studies showing that OCA decreases inflammation and fibrosis. However, it is not yet known whether OCA works on reducing the number of polyps in patients with FAP.

Study for Women at Increased Risk of Developing Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/257/study-for-women-at-increased-risk-of-developing-breast-cancer


This study will create a system to assess an individual’s risk of breast cancer

This study will create a system to assess an individual’s risk of breast cancer based on random sampling of normal breast tissue as well as determine new and help understand previously identified risk biomarkers.

A Randomized Study of Robotic-Assisted Nipple Sparing Mastectomy vs. Standard Surgery Nipple Sparing Mastectomy for Early Stage Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/263/a-randomized-study-of-robotic-assisted-nipple-sparing-mastectomy-vs-open-surgery-nipple-sparing-mastectomy-for-early-stage-breast-cancer

Treatment
Nipple sparing mastectomy with reconstruction for women with early-stage breast cancer

This study will compare robotic-assisted nipple sparing mastectomy (NSM) to standard surgery NSM for women with early-stage breast cancer. Eligible women will be randomly placed into one of two groups and either undergo the robotic-assisted procedure or undergo the standard of care open surgery for NSM. Participants will be followed for 5 years.

Testing a Vaccine for Cancer Prevention in People with a BRCA1 or BRCA2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/172/testing-a-vaccine-for-cancer-prevention-in-people-with-a-brca1-or-brca2-mutation

Prevention
People with a BRCA1 or BRCA2 mutation

This study will look at a new vaccine known as INO-5401 used alone or combined with a second vaccine called INO-9012. The study will test if the vaccine is safe (without large side effects) and test a new way of giving vaccines. It will also test whether the vaccine activates the immune system. A goal of this research is to reduce cancer risk in people with a BRCA1 or BRCA2 mutation. Additional studies will be needed to learn if this vaccine approach lowers cancer risk in mutation carriers. 

Survey about Motivations and Barriers to Talking with Family Members about Inherited Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/280/survey-about-goals-of-inherited-cancer-risk-disclosure-in-families-with-an-inherited-gene-mutation

Surveys, Registries, Interviews
Survey for people with an inherited gene mutation

This study aims to understand the different goals and motivations individuals with an inherited gene mutation have when talking about their genetic cancer risk with family members in a conversation.

A Study of Targeted Therapies for Patients With Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/245/a-study-of-different-targeted-therapies-for-patients-with-recurrent-or-persistent-endometrial-cancer

Treatment
This study is for people with recurrent endometrial cancer

This study is to test the safety and effectiveness of different kinds of targeted therapy with or without atezolizumab (or Tecentriq) in individuals with recurrent or persistent endometrial cancer. Participants will be placed into study groups based on their tumor.

 

Intimacy and Self-Esteem Among Sexual and Gender Minority Cancer Survivors (RISE-SGM)

https://www.facingourrisk.org/research-clinical-trials/study/265/an-interview-about-intimacy-and-self-esteem-for-sexual-and-gender-minority-cancer-survivors


A one-time interview study to explore experiences with sexual functioning, sexual relationships, sexual self-concept, and self-esteem of 18-39-year-old sexual and/or gender minority cancer survivors

Relationships, Intimacy, and Self-Esteem among Sexual and Gender Minority Cancer Survivors (RISE) is a research study that focuses on the experiences of 18-39-year-old sexual and/or gender minority cancer survivors. Participants will be asked to complete an interview on relationships, self-esteem, and intimacy.

A Study Comparing Two Anti-inflammatory Medications Naproxen or Aspirin for Cancer Prevention in Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/281/studying-the-use-of-naproxen-and-aspirin-for-cancer-prevention-in-people-with-lynch-syndrome

Prevention
Prevention study for people with Lynch syndrome

The trial is enrolling people with Lynch syndrome. On average, the length of this study will last one year from the start of enrollment to completion. The study will measure  the effect of naproxen or aspirin on the immune cells in the gastrointestinal tract of people with Lynch syndrome. The trial will also evaluate any symptoms from the medications and any other changes of the colon and rectum.

Kindred Study

https://www.facingourrisk.org/research-clinical-trials/study/255/kindred

Surveys, Registries, Interviews
Interviews with African American people who tested positive for a genetic mutation

We are talking with African American adults about cancer genetic testing, including those that have received a positive cancer genetic testing result and people with a family member who received testing. We are learning about new and improved ways to support African American individuals and families before, during and after they participate in cancer genetic testing.

Testing an Immunotherapy, Pembrolizumab, in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/234/testing-an-immunotherapy-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced cancers

This study is looking at the effectiveness of an immunotherapy, pembrolizumab, in treating people who have been diagnosed with advanced solid tumors that have progressed on standard-of-care therapy.

TAPUR Study: Testing FDA Approved Drugs Targeting Tumor Biomarkers in People with Advanced Stage Cancer

https://www.facingourrisk.org/research-clinical-trials/study/262/tapur-study-testing-fda-approved-drugs-targeting-tumor-gene-abnormalities-in-people-with-advanced-stage-cancer

Treatment
Cancer treatment study for people with advanced solid tumors

The TAPUR Study aims to describe the safety and efficacy of Food and Drug Administration (FDA)-approved, targeted anticancer drugs prescribed for treatment of patients with advanced cancer that has a potentially actionable genomic alteration.

Survey For Individuals With A Hereditary Cancer Genetic Testing Result That Was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/261/survey-for-individuals-with-a-hereditary-cancer-genetic-testing-result-that-was-later-reclassified


Survey for people whose genetic test results were reclassified

Researchers are conducting an online survey to look into the personal experiences of people who received reclassfied genetic testing results for hereditary cancer gene mutations. 

Self -Perception and Intimacy After the Cancer Experience (SPICE)

https://www.facingourrisk.org/research-clinical-trials/study/247/self-perception-and-intimacy-after-the-cancer-experience-spice

Surveys, Registries, Interviews
Online survey for cancer survivors ages 18-39 years old about sexual health

SPICE is an online survey that asks questions about your sexuality, sexual health knowledge, interpersonal relationships, and body image. Participants will be asked questions about their body image, impact of cancer, relationships, and how they feel about their sexuality.

Metastatic Castration Resistant Prostate Cancer Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/240/metastatic-castration-resistant-prostate-cancer-clinical-trial

Treatment
This clinical trial is studying a potential treatment for men with metastatic castration resistant prostate cancer.

Metastatic prostate cancer that no longer responds to hormone therapy is called metastatic castration resistant prostate cancer (mCRPC). This clinical trial may be an option for you if you have been diagnosed with mCRPC that has spread or gotten worse since your last treatment. Participants will be randomly assigned to receive the current standard of care medicine, enzalutamide, or PF-06821497 (study medicine) orally in combination with enzalutamide.

Breastfeeding and Breast Cancer Screening in People at High Risk: Knowledge and Perspectives

https://www.facingourrisk.org/research-clinical-trials/study/238/survey-for-women-at-high-risk-for-breast-cancer-on-knowledge-and-perspectives-about-breast-cancer-risk-factors-and-screening

Surveys, Registries, Interviews
Online survey for women with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, STK11 or TP53 inherited mutation.

Researchers at the Mayo Clinic and McGill University are partnering with FORCE on a survey of women who have inherited mutations in BRCA1, BRCA2 or other genes (including PALB2, ATM, CHEK2, and others) related to increased breast cancer risk. We are interested in the effects of testing positive for an inherited mutation on decisions about the timing of pregnancy, breastfeeding, breast cancer screening and risk-reducing surgery. 

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

https://www.facingourrisk.org/research-clinical-trials/study/175/niraparib-before-surgery-in-treating-patients-with-high-risk-localized-prostate-cancer-and-dna-damage-response-defects

Treatment
High-risk localized prostate cancer

This study will look at how well the PARP Inhibitor niraparib works, when given before a radical prostatectomy, for people with high-risk prostate cancer that has not spread to other parts of the body, and who have a tumor mutation in any of the following genes:BRCA1/2, ATM, CDK12, CHEK1/2 FANCA, FANCD2, FANCL, GEN1, NBN, PALB2, RAD51, RAD51c, and BRIP1.

.

Opening the Conversation

https://www.facingourrisk.org/research-clinical-trials/study/228/opening-the-conversation

Quality of Life
Online communication program for breast and gynecologic cancer survivors and their partners

This is a clinical trial sponsored by the American Cancer Society that will test the helpfulness of two programs designed to teach breast and gynecological cancer survivors and their partners to communicate and cope with physical, emotional, and relationship challenges after cancer. The programs are conducted entirely via Zoom videoconference, so travel is not required to participate.

Cancer Screening for People With Intellectual Disability: Exploring Parent and Caregiver Perspectives

https://www.facingourrisk.org/research-clinical-trials/study/268/parent-and-caregiver-perspectives-on-cancer-screening-for-people-with-intellectual-disabilities


Survey for parents and caregivers to share perspectives on cancer screening for people with intellectual disabilities

Our goal is to understand the experiences of people with intellectual disability in regard to screening for cancer, for example colonoscopies for colon cancer and mammograms for breast cancer. For people not being screened, we hope to learn about any barriers faced.

Treating Metastatic Solid Tumors with an Inherited or Acquired Gene Mutation Using the PARP Inhibitor Talazoparib

https://www.facingourrisk.org/research-clinical-trials/study/230/treating-metastatic-solid-tumors-with-an-inherited-or-acquired-gene-mutation-using-the-parp-inhibitor-talazoparib

Treatment
Treatment study for people with advanced solid tumors

This study is looking whether the drug Talazoparib (also known as Talzenna) is safe and effective for treating people with advanced solid cancers (including breast, gastric, ovarian, pancreatic, prostate or other solid tumors) in people with an inherited mutation (found through genetic testing) or an acquired mutation (found with biomarker testing) in ATM, ATR, BRCA1, BRCA2, BRIP1, BAP1, BARD1, CDK12, CHEK1, CHEK2, IDH1, IDH2, MRE11A, NBN, PALB2, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RAD54L or other genes.

Comparing the Safety and Effectiveness of a New Hormonal Therapy in Patients with HER2-Negative, ER-Positive Early Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/254/comparing-the-safety-and-effectiveness-of-secondary-treatments-in-patients-with-her2-negative-early-breast-cancer


Treatment study for people with early-stage breast cancer

This study is comparing safety and effectiveness of a new drug called giredestrant compared to standard hormone therapy in people with early-stage, ER-positive breast cancer. 

What Factors Influence Survivors’ Guilt in Individuals Who Tested Negative for a Known Hereditary Cancer Syndrome?

https://www.facingourrisk.org/research-clinical-trials/study/264/survey-for-people-who-received-a-negative-genetic-test-result-for-a-known-mutation-in-the-family


People who received a negative genetic test result

This study is to understand the experiences of people who have received a negative genetic test result for a known familial hereditary cancer mutation (i.e., a “true negative” result) and determine what factors influence the presence of survivors’ guilt in these individuals.

Survey for People Diagnosed with Breast Cancer to Provide Feedback on a New Type of Clinical Trial

https://www.facingourrisk.org/research-clinical-trials/study/226/survey-for-people-diagnosed-with-breast-cancer-to-provide-feedback-on-a-new-type-of-clinical-trial

Surveys, Registries, Interviews
Survey for people diagnosed with stage 0 - stage 3 breast cancer

Stanford researchers invite people diagnosed with stage 0 to stage 3 breast cancer to take this 15 minute survey to share your thoughts about the advantages and disadvantages of participating in a new type of clinical trial called “a window opportunity” trial. will use this information to help design future clinical trials.

Effect of Acupuncture on Memory and Thinking Difficulties after Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/219/effect-of-acupuncture-on-memory-and-thinking-difficulties-after-breast-cancer

Quality of Life
Acupuncture study for people with memory issues who completed treatment for stage 0-3 breast cancer

The purpose of this study is to test whether acupuncture can improve thinking and memory difficulties in breast cancer survivors. Researchers will look at whether  acupuncture improves memory, thinking and sleep in breast cancer survivors. This study will also look at the link between lack of sleep and thinking difficulties.

Restoring Sensation after DIEP Flap Reconstruction

https://www.facingourrisk.org/research-clinical-trials/study/217/restoring-sensation-after-diep-flap-reconstruction

Prevention
Study for people undergoing DIEP flap reconstruction

The goal of this study is to look at how well a nerve graft works for improving sensation to the reconstructed breast after mastectomy in people undergoing DIEP flap reconstruction (deep inferior epigastric perforator flap). 

 

A Randomized Study of Olaparib or Placebo in Patients with Surgically Removed Pancreatic Cancer who have a BRCA1, BRCA2 or PALB2 Mutation (APOLLO)

https://www.facingourrisk.org/research-clinical-trials/study/140/olaparib-or-placebo-in-patients-with-surgically-removed-pancreatic-cancer-who-have-a-brca1-brca2-or-palb2-mutation

Treatment
Treatment study for pancreatic cancer in people with a BRCA1, BRCA2, or PALB2 mutation

The usual approach for patients with curable (i.e., non-metastatic) pancreatic cancer is a combination of surgery, FDA-approved chemotherapy, radiation (in select cases), then surveillance monitoring. This means that patients are typically monitored by their oncologist for evidence that the cancer has returned (recurrence), but they receive no additional treatment after the completion of surgery and chemotherapy.

The purpose of EA2192 / APOLLO is to compare the usual approach (observation) to treatment for one year with a drug called olaparib, in patients with BRCA1, BRCA2 or PALB2 mutation. EA2192 / APOLLO will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if olaparib delays cancer recurrence compared to the usual approach of surveillance.

Comparing Three Drugs as Late-Stage Treatment for Individuals with Metastatic Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/246/comparing-the-drugs-opdualag-and-stivarga-as-late-stage-treatment-for-individuals-with-metastatic-colorectal-cancer


treatment study for people with metastatic colorectal cancer

This study is being done to look at how well a combination of three drugs works for the treatment of metastatic colorectal cancer in patients who have had their cancer come back or get worse after treatment. The study is open to people who have had at least one, but no more than four courses of treatment in the metastatic setting. 

Tools To Be Fit: Tools to Improve Nutrition and Physical Activity for Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/171/tools-to-be-fit-tools-to-improve-nutrition-and-physical-activity-for-colorectal-cancer-survivors

Quality of Life
Bladder, breast, colon, endometrial, kidney (renal cell carcinoma), ovarian, prostate, or rectal cancer

Eating well and being physically active may help prevent cancer recurrence. Tools To Be Fit is a study to figure out what tools work best for helping cancer survivors improve their diet and exercise. Participants will get access to a combination of tools such as text messages, a wearable physical activity tracker, apps, health coaching, and coaching for a support person in the participant’s life.

Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/244/treatment-for-advanced-or-recurrent-endometrial-cancer


Comparing an Immunotherapy Drug, Pembrolizumab With Chemotherapy in Advanced or Recurrent Endometrial Cancer

This study is to test the safety and effectiveness of treatment with pembrolizumab, also known as Keytruda, compared to a combination of chemotherapy treatments in women with deficient mismatch repair (dMMR) advanced or recurrent endometrial cancer who had not previously been treated with prior chemotherapy treatments. The study is being conducted to determine if  pembrolizumab is better than the combined chemotherapy in terms of Progression Free Survival (PFS).

 

Testing Immunotherapy Treatments for Recurrent Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/253/testing-cancer-treatments-in-recurrent-endometrial-cancer


Treatment study for people with endometrial cancer that has returned

This study tests the combination of two immunotherapy drugs compared to one immunotherapy drug to shrink tumors in patients with endometrial cancer that has returned after not being detected for a period of time (recurrent). The study is enrolling people with a biomarker known as dMMR.

Factors Influencing Disparities in Quality of Life among People of Color Affected by Cancer

https://www.facingourrisk.org/research-clinical-trials/study/223/factors-influencing-disparities-in-quality-of-life-among-people-of-color-affected-by-cancer

Surveys, Registries, Interviews
Survey for people of color who have completed treatment for cancer

This study focuses on cancer survivors’ needs during the transition into a new normal life after the completion of cancer treatment. The goal is to explore ways in which we can improve physical activity and diet among cancer survivors and address their challenges to develop and maintain an active and healthy lifestyle.

We specifically would like to work with and for cancer survivors who self-describe as people of color to understand how social structures, stress and environmental factors impact health behaviors and subsequent quality of life.

Prostate Cancer Genetic Risk Evaluation and Screening Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/180/prostate-cancer-genetic-risk-evaluation-and-screening-study-progress

Prevention
People at high risk for prostate cancer due to an inherited mutation

This study will look at how enhanced prostate cancer screening using MRI will improve early detection rates and further understanding of how inherited mutations can lead to development of prostate cancer.

Investigating the Use of Self-Acupressure for Fatigue in Ovarian Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/242/investigating-the-use-of-self-acupressure-for-fatigue-in-ovarian-cancer-survivors


University of Michigan researchers are investigating the use of self-acupressure for fatigue in ovarian cancer survivors.

Study using acupressure for people experiencing fatigue after ovarian cancer treatment.

NUV-868 Alone and in Combination With PARP Inhibitors in Patients With Advanced Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/204/nuv-868-alone-and-in-combination-with-parp-inhibitors-in-patients-with-advanced-solid-tumors

Treatment
Treatment study for people with advanced solid tumors, including triple-negative breast, ovarian, pancreatic and prostate cancer

This study will test how safe and effective the experimental drug NUV-868 is by itself and in combination with a PARP inhibitor in people with advanced solid tumors. The first part of the study will include people with any solid tumor type, and the second part will include people with triple-negative breast, ovarian, pancreatic or prostate cancers only. 

Study of Physical Activity at Home for Relief from Neuropathy Caused by Taxanes in People with Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/220/physical-activity-at-home-for-relief-from-neuropathy-caused-by-taxanes-in-people-with-breast-cancer


Quality of life study for breast cancer patients experiencing neuropathy from chemotherapy

Chemotherapy-induced peripheral neuropathy (CIPN) symptoms include numbness combined with tingling sensations, persistent shooting, stabbing, or burning pain even in the absence of an obvious cause, lower extremity muscle weakness, and impaired balance. Resistance exercise has shown promising results; however, the effect of exercise on CIPN remains understudied. This study will look at the effects of gain and balance training and resistance exercise (using bands) on gait, balance, and lower extremity muscle strength after a 16-week home-based exercise program compared to educational materials without an exercise program.

 

Treating Metastatic Prostate Cancer with Chemotherapy or PARP Inhibitor in People with Mutations (COBRA)

https://www.facingourrisk.org/research-clinical-trials/study/210/treating-metastatic-prostate-cancer-with-chemotherapy-or-parp-inhibitor-in-people-with-mutations-cobra

Treatment
Treatment study for mCRPC with an inherited or tumor mutation in BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L

This study is comparing carboplatin chemotherapy to the drug, olaparib (a type of targeted therapy) as first-line treatment for metastatic castration-resistant prostate cancer in people with a BARD1, BRCA1, BRCA2, BRIP1, CHEK1, FANCL, PALB2, RAD51B, RAD51C, RAD51D or RAD54L inherited mutation found through genetic testing, or tumor mutation found through biomarker testing.

Blood Markers of Early Pancreas Cancer

https://www.facingourrisk.org/research-clinical-trials/study/141/blood-markers-of-early-pancreas-cancer

Prevention
Observational study for people with family history of pancreas cancer or an inherited mutation linked to pancreatic cancer risk

The purpose of this study is to try to find markers of early pancreatic cancer for individuals at higher-than-average risk, expedite the diagnosis in individuals with symptoms, and substantially improve an individual's chance of surviving the disease.

Women's Sexuality After Gynecological Cancer Treatments

https://www.facingourrisk.org/research-clinical-trials/study/243/womens-sexuality-after-gynecological-cancer-treatments


Virtual or in-person interview to share personal experiences of sexuality after gynecological cancer treatment(s).

Explore women's lived experiences of sexuality after gynecological cancer treatment(s).

Helping Latinas Understand Their Risk for Breast Cancer and Get Breast Cancer Care

https://www.facingourrisk.org/research-clinical-trials/study/250/helping-latinas-understand-their-risk-for-breast-cancer-and-get-breast-cancer-care

Prevention
Latinas with a high risk of breast cancer

This study will teach Latinas with a high risk of breast cancer about how diet, exercise, ethnicity, genetics and screening and prevention guidelines may impact their likelihood for developing breast cancer. The study will test ways of teaching participants about breast cancer and risk factors, comparing the current standard of care to new personal educational sessions. Bilingual and bicultural staff are available for the phone study to make the study open to both English and Spanish speakers.

Combined Pembrolizumab & Quavonlimab (MK-1308A) Versus Other Treatments in People With MSI-High or dMMR Stage IV Colorectal Cancer

https://www.facingourrisk.org/research-clinical-trials/study/181/combined-pembrolizumab-quavonlimab-mk-1308a-versus-other-treatments-in-people-with-msi-high-or-dmmr-stage-iv-colorectal-cancer


Stage 4 colorectal cancer

The purpose of this study is to assess the efficacy and safety of co-formulated pembrolizumab/quavonlimab versus four other treatments in patients with Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Metastatic (stage IV) Colorectal Cancer.

Upright MRI for Prostate Cancer Screening

https://www.facingourrisk.org/research-clinical-trials/study/259/upright-mri-for-prostate-cancer-screening

Prevention
Screening for prostate cancer using upright MRI

This study will compare the effectiveness of an upright magnetic resonance imaging (MRI) compared to prostate specific antigen (PSA) and current MRI imaging for prostate cancer screening.

Study of Oral Drug Bazedoxifene Plus Conjugated Estrogens for Treating Hot Flashes in Women at High Risk for Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/218/bazedoxifene-plus-conjugated-estrogens-for-hot-flashes-in-women-at-high-risk-for-breast-cancer

Quality of Life
Women at high risk for breast cancer due to ATM, CDH1, CHEK2, NBN, NF1, PALB2, PTEN, STK11, P53 or PTEN mutation who have hot flashes

Bazedoxifene is a type of drug known as a selective estrogen receptor modulator (SERM) that is similar to the drug tamoxifen. A combination of bazedoxifene and estrogen taken orally has been used to control hot flashes. This study will look at hot-flashes, quality of life and breast changes in high-risk women taking the combination of drugs compared with women not taking the combination of drugs. Women will be selected at random to participate in the group receiving the drug and the group not receiving the drug. The study will involve breast imaging, blood tests and small sampling of breast tissue at the beginning and end of the study. 

Combination ATR inhibitor and PARP Inhibitor in Recurrent Ovarian Cancer (CAPRI)

https://www.facingourrisk.org/research-clinical-trials/study/156/combination-atr-inhibitor-and-parp-inhibitor-in-recurrent-ovarian-cancer-capri


Recurrent ovarian cancer

This study will look at how well patients with recurrent ovarian, primary peritoneal or fallopian tube cancer respond to treatment with a targeted therapy known as an ATR inhibitor when combined with the PARP inhibitor Olaparib.

Research Opportunity for Previvors and their Romantic Partners

https://www.facingourrisk.org/research-clinical-trials/study/207/research-opportunity-for-previvors-and-their-romantic-partners

Surveys, Registries, Interviews
Interview for people with inherited mutations who had risk-reducing mastectomy and their partners

Researchers at the University of Kentucky are hoping to learn more about the relational experiences of individuals with hereditary breast cancer mutations who have navigated a double mastectomy while in a committed romantic relationship. They are particularly interested in the couples’ experience related to sexual intimacy before and after prophylactic surgical procedures. You do not have to live in Kentucky to participate. 

BRCA 1 and BRCA 2: Interviews on Genetic Testing and Individual Experiences

https://www.facingourrisk.org/research-clinical-trials/study/169/brca-1-and-2-interviews-on-genetic-testing-and-individual-experiences

Surveys, Registries, Interviews
People with or without cancer who have had or are considering BRCA testing

This study seeks to interview individuals who come from families with high cancer risk and/or who have tested positive for a BRCA1 or BRCA2 genetic mutation. We are also interested in individuals who may be contemplating BRCA 1/2 genetic testing; those who feel they lack access to genetic testing or who feel they lack information and social and medical support with regard to getting access to genetic testing; those who have been diagnosed with breast cancer who may be at high risk for a range of hereditary cancer. We are especially hoping to reach racially and ethnically diverse males and females whose experiences are often left out of research studies.

Cancer Experience Registry

https://www.facingourrisk.org/research-clinical-trials/study/248/cancer-experience-registry

Surveys, Registries, Interviews
Online survey for patients and caregivers focusing on multiple aspects of cancer

Online survey for patients and caregivers focusing on multiple aspects of cancer to understand its emotional, physical, practical, and financial impact, so we can identify and address gaps in care and support.

SHARON: A Clinical Trial for Metastatic Cancer With an Inherited BRCA or PALB2 Mutation Using Chemotherapy and Patients’ Own Stem Cells

https://www.facingourrisk.org/research-clinical-trials/study/117/sharon-a-clinical-trial-for-metastatic-cancer-with-an-inherited-brca-or-palb2-mutation-using-chemotherapy-and-patients-own-stem-cells

Treatment
Advanced pancreatic cancer or stage 4 breast cancer in people with a BRCA1 or BRCA2 mutation

The purpose of this study is to see whether the combination of melphalan, BCNU, hydroxocobalamin, ascorbic acid, and autologous (self) bone marrow stem cell infusion, is safe and effective for treating patients with advanced pancreatic cancer or Stage IV, HER2-negative breast cancer who have a BRCA1, BRCA2 or PALB2 inherited mutation. All of these treatments are given intravenously (by vein). This study is open to people who have already received a PARP inhibitor, as well as those who have not. There are no restrictions on the number of prior treatments a patient has received before enrolling.

TALAPRO-3: A Clinical Trial in Men with Metastatic Castration-Sensitive Prostate Cancer (mCSPC) and DNA Damage Repair (DDR) Gene Alteration

https://www.facingourrisk.org/research-clinical-trials/study/153/talapro-3-a-clinical-trial-in-men-with-metastatic-castration-sensitive-prostate-cancer-mcspc-and-dna-damage-repair-ddr-gene-alteration


Metastatic castration-sensitive prostate cancer

The TALAPRO-3 trial is assessing whether the study drug, talazoparib, is effective and safe when given in combination with enzalutamide as a treatment option for men with metastatic castration-sensitive prostate cancer and a DDR gene alteration.

For more information about the study, visit www.Talapro3ClinicalTrial.com

Study of Two Drugs in ER+ and/or PR+ Cancers With PI3K and/or PTEN Tumor or Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/249/study-of-two-drugs-in-er-andor-pr-cancers-with-pi3k-andor-pten-tumor-or-inherited-mutations


People with advanced breast or endometrial or ovarian cancer

This study is investigating if the study drug copanlisib, when used in combination with fulvestrant, is safe and effective for people with certain advanced ER-positive and/or PR-positive cancers.  People with PI3K and/or PTEN changes in tumor tissue or inherited mutations are eligible.

IGNITE-TX - Identifying Individuals for Genetic Testing for Familial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/266/helping-people-with-a-genetic-mutation-in-brca1-brca2-or-lynch-syndrome-talk-to-their-family-members-about-their-risk-for-cancer-and-find-the-best-way-to-get-family-members-tested

Prevention
People with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome who have relatives who have not been tested

The IGNITE-TX study is all about helping people with a genetic mutation in BRCA1, BRCA2 or Lynch syndrome talk to their family members about their risk for cancer and find the best way to get family members tested.

Paid Research Interview Opportunity: Stage III or IV Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/237/paid-research-interview-opportunity-patients-receiving-neoadjuvant-or-first-line-treatment-for-ovarian-cancer


Interview for people with stage III or IV ovarian cancer

Modus Outcomes is seeking patients with stage III or IV ovarian cancer to participate in online interviews. We will ask you questions about your symptoms and how ovarian cancer impacts your life. Then, we will ask for feedback on questionnaires used in ovarian cancer studies.

All of Us Research Program

https://www.facingourrisk.org/research-clinical-trials/study/197/all-of-us-research-program

Surveys, Registries, Interviews
Anyone age 18 or over can participate in this research study

The All of Us Research Program is seeking one million people from across the U.S. to help build one of the most diverse health databases in history. We welcome participants from all backgrounds. People who join will share information about their health, habits, and what it’s like where they live. By looking for patterns, researchers may learn more about what affects people’s health.

Testing the Targeted Therapy Elimusertib in Combination with Chemotherapy for Advanced Cancers

https://www.facingourrisk.org/research-clinical-trials/study/232/testing-a-targeted-therapy-in-combination-with-chemotherapy-for-advanced-solid-tumors


Treatment study for people with advanced cancers

This study is looking at how well the drug elimusertib (a type of targeted therapy known as an ATR inhibitor) works when combined with chemotherapy for treating people with advanced cancers, including urothelial, ovarian, gastric, endometrial, triple-negative breast cancer and others.

Treating Early-Stage HER2-Negative Breast Cancer with a PARP Inhibitor (Niraparib) and Immunotherapy (Dostarlimab) in People with a BRCA or PALB2 Mutation

https://www.facingourrisk.org/research-clinical-trials/study/158/treating-early-stage-breast-cancer-with-a-parp-inhibitor-niraparib-and-immunotherapy-dostarlimab-in-people-with-a-brca-or-palb2-mutation

Treatment
Treatment before surgery for people with early-stage breast cancer & a BRCA1, BRCA2 or PALB2 mutation

This study will look at how well the drugs Niraparib (a PARP inhibitor) and Dostarlimab (an immunotherapy) treat early-stage breast cancer in people with an inherited BRCA1, BRCA2 or PALB2 mutation.  

Effects of Occupational Therapy Telehealth Intervention on Cancer-Related Cognitive Impairment in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/225/effects-of-occupational-therapy-telehealth-intervention-on-cancer-related-cognitive-impairment-in-breast-cancer-survivors


Telehealth study for breast cancer survivors with memory issues

The purpose of this study is to look at the effects and ease of use of occupational therapy delivered by telehealth on activity performance, memory and quality of life in breast cancer survivors. Participants will complete all sessions from home via Zoom videoconferencing. This is a 2-arm randomized control trial, which means that each participant will be randomly assigned to one of two groups. Participants will complete the same number of sessions regardless of which group they are assigned to.

Perceptions of an Online Platform to Facilitate Sharing of Family Health History

https://www.facingourrisk.org/research-clinical-trials/study/241/perceptions-of-an-online-platform-to-facilitate-sharing-of-family-health-history


Online survey for people with an ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, PMS2, PTEN, RAD51C, RAD51D, STK11, TP53 inherited mutation or Lynch syndrome.

Online survey for people with a family history of hereditary breast and ovarian cancer and Lynch syndrome about online health history-sharing.

Androgen Suppression With Abiraterone, Leuprolide, PARP Inhibitor and Stereotactic Radiotherapy in Prostate Cancer (ASCLEPIuS)

https://www.facingourrisk.org/research-clinical-trials/study/177/androgen-suppression-with-abiraterone-leuprolide-parp-inhibitor-and-stereotactic-radiotherapy-in-prostate-cancer-asclepius


Newly diagnosed prostate cancer grade group 3-5

This study will look at treating men with high risk prostate cancer using the PARP inhibitor, niraparib combined with prostate stereotactic body radiotherapy (SBRT), abiraterone, leuprolide, and prednisone. Phase 1 of this study will look at the best dose of niraparib for this treatment combination. The phase 2 portion of this study will look at the 3-year PSA recurrence free-survival rate of the patients who received this combined therapy.

PARP Inhibitor (Niraparib) in Patients with Inherited or Tumor PALB2 Mutations in Advanced Solid Tumors (PAVO)

https://www.facingourrisk.org/research-clinical-trials/study/183/parp-inhibitor-niraparib-in-patients-with-inherited-or-tumor-palb2-mutations-in-advanced-solid-tumors-pavo


Any advanced or metastatic solid tumor except ovarian or prostate

PAVO is an open-label Phase II study investigating if the study drug, a PARP inhibitor called niraparib (Zejula), is safe and effective for certain people who have been diagnosed with an
advanced solid tumor with either an inherited or tumor PALB2 mutation.

Investigational PARP Inhibitor AZD5305 Alone or Combined With Other Anti-cancer Agents in People With Advanced Solid Tumors (PETRA)

https://www.facingourrisk.org/research-clinical-trials/study/176/investigational-parp-inhibitor-azd5305-alone-or-combined-with-other-anti-cancer-agents-in-people-with-advanced-solid-tumors-petra

Treatment
Advanced ovarian, breast, prostate or pancreatic cancer

PETRA is studying a new PARP inhibitor AZD5305 taken either alone or combined with other treatments in people with advanced ovarian, breast, prostate or pancreatic cancer with an inherited or tumor mutation in: BRCA1/2, PALB2, RAD51C or RAD51D. The treaments participants receive will depend on their cancer type, mutation and when they join the study.

Opening the Conversation Study

https://www.facingourrisk.org/research-clinical-trials/study/214/opening-the-conversation-study


Videoconference sessions that address cancer related concerns for couples

This study will adapt and evaluate an intervention designed to help young couples cope with and communicate about cancer-related reproductive and sexual health concerns.

 

Project MTFM: Medical Tattooing Following Mastectomy

https://www.facingourrisk.org/research-clinical-trials/study/233/project-mtfm-medical-tattooing-following-mastectomy


Survey for breast cancer survivors following mastectomy

This study aims to better understand how breast cancer surgery can impact mental health and wellness. We will also explore how breast cancer survivors view breast cancer surgery and medical tattooing following. Participation includes an optional information session and consultation with a medical tattoo artist. 

Inherited Cancer Registry (ICARE): Contribute to Research While Staying Informed

https://www.facingourrisk.org/research-clinical-trials/study/195/inherited-cancer-registry-icare-contribute-to-research-while-staying-informed

Surveys, Registries, Interviews
People with an inherited mutation or cancer in the family

ICARE is a registry of individuals interested in participating in inherited cancer research, through which data and samples are collected to contribute to research. Participants are also provided with ongoing research and clinical updates and informed about other research opportunities for which they might be eligible. Participants are recruited across the United States and beyond. There is no cost to participate, and all materials can be completed online.

Adding Pembrolizumab to Olaparib to Treat Pancreatic Cancer in People with an Inherited BRCA Mutation

https://www.facingourrisk.org/research-clinical-trials/study/164/adding-pembrolizumab-to-olaparib-to-treat-pancreatic-cancer-in-people-with-an-inherited-brca-mutation

Treatment
Metastatic pancreatic cancer and a BRCA1 or BRCA2 mutation

This study is researching whether adding the immunotherapy drug Pembrolizumab (Keytruda) to the PARP inhibitor Olaparib (Lynparza) works better than olaparib alone in treating people with metastatic pancreatic cancer who also have an inherited BRCA1 or BRCA2 mutation.  

Retifanlimab (Immunotherapy) Alone or Combined with Other Therapies for Advanced Endometrial Cancer that Progressed on or after Platinum Chemotherapy (POD1UM-204)

https://www.facingourrisk.org/research-clinical-trials/study/165/retifanlimab-alone-or-with-other-agents-for-advanced-endometrial-cancer-that-progressed-with-platinum


Advanced endometrial cancer

This study is for people with advanced or metastatic endometrial cancer that has progressed on or after platinum-based chemotherapy. Participants will receive retifanlimab (a type of immunotherapy) alone or in combination with other immunotherapies or targeted therapies.

A New Risk Measurement Tool for Those at High Risk for Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/236/a-new-risk-measurement-tool-for-those-at-high-risk-for-ovarian-cancer


This study is using a new type of genetic test to measure ovarian cancer risk

This study is using a new type of genetic test to measure ovarian cancer risk in women who have inherited genetic mutations that increase their risk for ovarian cancer or women who have an ovarian cyst or other non-cancerous masses (adnexal mass). NOTE: This study is no longer enrolling patients. 

Treatment with ATR Inhibitor for Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/157/treatment-with-atr-inhibitor-for-advanced-or-metastatic-solid-tumors

Treatment
Advanced solid tumors

This study will look at how well a new oral targeted therapy known as an ATR inhibitor works on advanced or metastatic solid tumors with mutations in genes linked to DNA damage repair. The study will look at response to treatment with the drug ART0380 in combination with the chemotherapy agent, gemcitabine. 

Exploring the Psychosocial Implications of Individuals with a Genetic Test Result that was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/229/exploring-the-psychosocial-implications-of-individuals-with-a-genetic-test-result-that-was-later-reclassified


Interview for people who's genetic test results were reclassified

Researchers at Bay Path University are conducting virtual/phone interviews with individuals who have received a reclassified genetic test result to cancer related genes. This study will help researchers learn the psychosocial implications and experiences of those who have received a reclassified genetic test result when undergoing hereditary cancer gene testing, (for example, your original genetic test results showed a variant of uncertain significance that was later found to be harmful or harmless). 

Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient (dMMR/MSI-High) Cancers Resistant to Prior PD-L1 Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/151/nivolumab-and-relatlimab-in-advanced-msi-h-cancers-resistant-to-prior-pd-l1-inhibitor

Treatment
Solid tumors that are MSI-High and resistant to prior immunotherapy

The purpose of this study is to evaluate the safety, effectiveness, and tolerability of using the immunotherapy drugs nivolumab and relatlimab in patients with microsatellite instability high (MSI-H) solid tumors resistant to prior PD-L1 therapy.

Both nivolumab and relatlimab are a type of immunotherapy known as immune checkpoint inhibitors. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.

Developing a Test for the Detection of Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/137/developing-a-test-for-the-detection-of-ovarian-cancer

Prevention
Prevention study for women with a BRCA1 or BRCA2 mutation who are scheduled for risk-reducing salpingo-oophorectomy

The purpose of this study is to develop a test for early detection of ovarian cancer. Two patient populations are included in this study: women scheduled for surgery or testing for suspected but undiagnosed ovarian/fallopian tube cancer, and women with a BRCA1 or BRCA2 mutation who are scheduled for a risk-reducing salpingo-oophorectomy. The study will examine DNA from a washing of the uterus (womb) and proteins found in the blood to see if they can detect ovarian cancer.

Treating Recurrent or Metastatic Endometrial Cancer with an Immunotherapy in Combination with a PARP Inhibitor or a Chemotherapy Drug

https://www.facingourrisk.org/research-clinical-trials/study/235/treating-recurrent-or-metastatic-endometrial-cancer-with-an-immunotherapy-in-combination-with-a-parp-inhibitor-or-a-chemotherapy-drug


Treatment study for metastatic endometrial cancer

This study will determine the effectiveness of an immunotherapy called Avelumab, in treating recurrent or metastatic endometrial cancer. One group of participants will receive Avelumab, a second group of participants will receive the combination of Avelumab and Talazoparib, and a third group of participants will receive the combination of Avelumab and Axitinib. The effectiveness of the study drugs will be measured through tumor biopsies. NOTE: This study is no longer enrolling patients.

Chemotherapy, Bevacizumab, and/or Atezolizumab for Patients With Deficient DNA Mismatch Repair (dMMR or MSI-H) Metastatic Colorectal Cancer, the COMMIT Study

https://www.facingourrisk.org/research-clinical-trials/study/126/chemotherapy-bevacizumab-andor-atezolizumab-for-dmmr-msi-h-metastatic-colorectal-cancer-commit-study

Treatment
This is a treatment study is for people with metastatic colorectal cancer

This study is for people with metastatic colorectal cancer. The study will compare how well treatment with a combination of chemotherapy agents and an immunotherapy agent works compared with treatment using an immunotherapy agent alone. This study is focused on patients who are determined to be mismatch-repair deficient (dMMR) or have an MSI-H diagnosis, which are commonly seen in people with Lynch syndrome.

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients with an Inherited Genetic Risk Due to a BRCA1, BRCA2, PALB2 or ATM Mutation

https://www.facingourrisk.org/research-clinical-trials/study/121/screening-for-pancreatic-cancer-in-patients-with-an-inherited-brca1-brca2-palb2-or-atm-mutation

Prevention
Pancreatic cancer screening for people at high risk and with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation

Improved screening for pancreatic cancer in high-risk groups, such as people with an inherited BRCA1, BRCA2, ATM, or PALB2 mutation, may help find cancer early and improve survival rates. People enrolled in this study will undergo screening using endoscopic ultrasound or MRI of the abdomen.

Studying the Targeted Therapy Olaparib Given with Radium-223 for Advanced Prostate Cancer with Bone Metastasis

https://www.facingourrisk.org/research-clinical-trials/study/198/studying-the-medication-olaparib-given-with-radium-223-for-advanced-prostate-cancer-with-bone-metastasis


People with castration-resistant prostate cancer with bone spread

This study is measuring the best dosage for and side effects of the drug combination Olaparib and radium-223 to treat men with metastatic, castration-resistant prostate cancer that has spread to the bones. 

Olaparib in Treating Patients With Metastatic Biliary Tract Cancer With Aberrant DNA Repair Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/129/olaparib-in-treating-patients-with-metastatic-biliary-tract-cancer-with-aberrant-dna-repair-gene-mutations

Treatment
Treatment study for people diagnosed with metastatic biliary tract (bile duct) cancer and who have an inherited or tumor mutation in ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others

This study will look at how well the drug olaparib works in treating people who have been diagnosed with biliary tract (bile duct) cancer that has spread to other places in the body and who also have an inherited or tumor mutation in certain genes, including ATM, BRCA 1/2, BRIP1, CHEK2, RAD51C, RAD51D, PALB2, PTEN, NBN and others.  

Validating a Blood Test for Early Ovarian Cancer Detection in High-risk Women and Families: MicroRNA Detection Study (MiDE)

https://www.facingourrisk.org/research-clinical-trials/study/138/validating-a-blood-test-for-early-ovarian-cancer-detection-in-high-risk-women-and-families

Prevention
Screening study for women with a BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM mutation

The goal of MiDe is to develop a clinical diagnostic test to detect early onset ovarian cancer, as currently, there are no good screening or early detection tests available. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US. The study is enrolling people with an inherited mutation with a gene linked to ovarian cancer, such as BRCA1, BRCA2, BRIP1, PALB2, RAD51C, RAD51D, PMS2, MLH1, MSH2, MSH6, or EPCAM. Participants can be expected to provide up to 4 tubes of blood every 6 months for up to 5 years. We can collect these samples through mobile phlebotomy all around the US.

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC) (CheckMate 8HW)

https://www.facingourrisk.org/research-clinical-trials/study/112/nivolumab-nivolumab-plus-ipilimumab-or-chemotherapy-for-microsatellite-instability-high-msi-h-metastatic-colorectal-cancer-checkmate-8hw

Treatment
People with metastatic colorectal cancer that is MSI-High

The purpose of this study is to compare the benefit of the combination of immunotherapy agents Nivolumab plus Ipilimumab in patients who have Microsatellite Instability High (MSI-H) or Mismatch Repair Deficient (dMMR) metastatic colorectal cancer versus using Nivolumab as a single therapy or chemotherapy. 

Pembrolizumab and Olaparib for People With Metastatic Pancreatic Cancer with Homologous Recombination Deficiency or Exceptional Response to Platinum Chemotherapy

https://www.facingourrisk.org/research-clinical-trials/study/127/pembrolizumab-and-olaparib-for-metastatic-pancreatic-cancer-with-homologous-recombination-deficiency-or-exceptional-response-to-platinum-chemotherapy

Treatment
Treatment study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy

This is a study for people diagnosed with metastatic pancreatic cancer with Homologous Recombination Deficiency, or whose disease has responded well to first-line or second-line platinum therapy. The goal of this study is to look at whether combining the immunotherapy drug, pembrolizumab and the PARP inhibitor, olaparib is a more effective treatment for this cancer than taking olaparib alone.

 

Serum Biomarkers to Characterize the Effects of Therapy on Ovarian Reserve in Premenopausal Women With Early-stage Breast Cancer or BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/109/blood-tests-to-measure-ovarian-reserves-in-women-with-a-brca-mutation-or-women-treated-for-early-stage-breast-cancer

Prevention
Study for premenopausal women with early-stage breast cancer and high-risk women with BRCA mutations and no evidence of breast or ovarian cancer

The purpose of this study is to see how cancer treatment affects the ovaries, such as the impact on conceiving a child or the early onset of menopause. Comparatively, the study will also look at high-risk women with BRCA1/2 mutations (and no evidence of breast or ovarian cancer).

The study will check blood levels of hormones that the ovaries produce and will use questionnaires to gather information about participant menstrual cycles, health, and pregnancies. 

Talazoparib for People with Metastatic Breast Cancer Who Have Acquired (Somatic) BRCA Mutations

https://www.facingourrisk.org/research-clinical-trials/study/100/talazoparib-for-people-with-metastatic-breast-cancer-who-have-acquired-somatic-brca-mutations

Treatment
This is a study for people with metastatic breast cancer without a known mutation in BRCA1 or BRCA2, who learn they have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy

This is a study for patients with metastatic breast cancer who do not have an inherited mutation in BRCA1 or BRCA2 but who are are found to have a BRCA1 or BRCA2 acquired tumor mutation (somatic mutation) found through liquid biopsy. Patients are treated with talazoparib, a well-tolerated oral PARP inhibitor that targets the BRCA1and BRCA2 mutation to determine whether this treatment (which is already approved for germline BRCA1 and BRCA2 carriers) is effective in this population.

Chemotherapy, Immunotherapy and PARP Inhibitor for the Treatment of Metastatic Aggressive Variant Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/200/chemotherapy-immunotherapy-and-parp-inhibitor-for-the-treatment-of-metastatic-aggressive-variant-prostate-cancer-avpc


Treatment in people with aggressive metastatic prostate cancer

This study will look at how well the combination of chemotherapy drugs (such as cabazitaxel and carboplatin), a PARP inhibitors (niraparib), and an immunotherapy agents (cetrelimab) works for treating people with a rare type of prostate cancer known as aggressive variant prostate cancer (AVPC). The research will compare the benefits of giving niraparib with or without cetrelimab, after treatment with chemotherapy.

A Randomized Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Breast, Ovarian, Prostate and Pancreatic Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/102/a-randomized-study-of-an-ehealth-delivery-alternative-for-cancer-genetic-testing-for-hereditary-predisposition-in-metastatic-breast-ovarian-prostate-and-pancreatic-cancer-patients-e-reach

Treatment

Genetic testing can be helpful to identify potential targeted treatments for some patients with metastatic cancer. But some patients have a hard time getting easy and fast testing. This study is looking at using web options to increase access to testing AND patients in this study can get genetic counseling and testing in their home! 

Interview Study: Exploring Gender Diverse Experiences of Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/186/interview-study-exploring-gender-diverse-experiences-of-hereditary-cancer-risk


People with elevated cancer risk who identify as trans* or nonbinary

Are you a gender diverse previvor or patient who would like to share your story? A Johns Hopkins genetic counseling student is conducting an interview study exploring gender diverse folks’ experiences of hereditary cancer care, with the aim of better educating providers about LGBTQ+ needs and concerns. We are conducting interviews over Zoom with individuals who qualify. If you are interested in participating, contact Sarah Roth at sarahroth@jhu.edu. NOTE: This study is no longer enrolling people.

Metastatic Prostate Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/70/metastatic-prostate-cancer-project

Surveys, Registries, Interviews
A nationwide genomic research study for men with advanced and/or metastatic prostate cancer

The Metastatic Prostate Cancer Project is a nationwide genomic research study for men with advanced and/or metastatic prostate cancer. Patients can join online and participate by sharing their medical information and samples. The goal of the project is to generate a comprehensive database that will be shared with the entire research community to accelerate discoveries in prostate cancer.

The Metastatic Breast Cancer Project

https://www.facingourrisk.org/research-clinical-trials/study/60/the-metastatic-breast-cancer-project

Surveys, Registries, Interviews
A nationwide genomic research study for people with advanced and/or metastatic breast cancer

The Metastatic Breast Cancer Project is a patient-partnered initiative that directly engages patients across the US & Canada to transform our understanding of metastatic breast cancer. Patients participate by sharing their medical information, tumor samples, and their voices, partnering with the project team to accelerate discoveries. There is no cost to participate and only minimal effort is required to have a major impact.
 

A Pancreatic Cancer Screening Study for High Risk Individuals

https://www.facingourrisk.org/research-clinical-trials/study/95/pancreatic-cancer-screening-study-for-high-risk-people

Prevention
Screening study to detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk

The purpose of this study is to screen and detect pancreatic cancer and precancer in people with either a strong family history of pancreatic cancer, or an inherited mutation associated with pancreatic cancer risk.

Magnetic Resonance Imaging (MRI) will be used to screen for early stage pancreatic cancer. Participants will also be asked to donate a blood sample at specific intervals for the creation of a blood bank necessary for the development of a blood-based screening test for pancreatic cancer. 

Differences in Family Communication about Positive Genetic Test Results Between Asian Americans

https://www.facingourrisk.org/research-clinical-trials/study/208/differences-in-family-communication-about-positive-genetic-test-results-between-asian-americans


Interview for Asian Americans with a mutation in BRCA1, BRCA2, ATM, CHEK2, PALB2 or other gene linked to breast or ovarian cancer risk

This study aims to explore family communication differences across Asian American families  about testing positive for an inherited mutation in BRCA1, BRCA2, ATM, BARD1, BRIP1, CHEK2, PALB2, PTEN, RAD51C, RAD51D, TP53 or another gene linked to hereditary breast and/or ovarian cancer. Participants will complete a 10–15-minute initial intake survey to confirm eligibility. Eligible participants will then be contacted to schedule a 30-45-minute-long interview over Zoom to explore these topics. After completion of the interview, participants will be entered into a raffle for two $50 Visa gift cards. There are no costs associated with participation. NOTE: This study is closed. 

Connect My Variant

https://www.facingourrisk.org/research-clinical-trials/study/90/connect-my-variant

Surveys, Registries, Interviews
Study for people with an inherited mutation to help them talk with relatives about their family history and genetic test results, connect them to others with the same variant and to their family trees

Researchers at the University of Washington (UW) are recruiting participants with known inherited mutation.  We aim to help participants talk to relatives (both immediate and distant) about their family history and genetic test results, to connect them with others who have the same variant, and to their family trees together.  The study provides tools and resources to help at-risk relatives get genetic testing through their own local doctors.

Physical Activity Promotion for Breast and Endometrial Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/202/physical-activity-promotion-for-breast-and-endometrial-cancer-survivors


Exercise study for breast or endometrial cancer survivors

This study is looking at whether messaging and coaching can increase activity level and how moderate-to-vigorous activity improves symptoms and quality-of-life in women diagnosed with breast or endometrial cancer. NOTE: This study is no longer enrolling. 

Genomic Services Research Program Study for People with Unexpected Genetic Results

https://www.facingourrisk.org/research-clinical-trials/study/89/study-for-people-with-unexpected-genetic-results

Prevention
This study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason

A new study is recruiting people who received unexpected genetic test results about their cancer risk after having genetic testing done for some other reason.

This is a study of people with "secondary results” from genetic testing. Secondary results are unexpected. They are not related to the reason the person had the genetic test but are shared because they may be very important to the person’s health. Most secondary results have to do with high risks for health problems that can be treated or prevented. Many of these results are related to cancer risk. If you think you have received a secondary result, you may be eligible to join this study.

Survey about Endometrial Cancer Risk and Risk-Reducing Surgery for Women with a BRCA1/2 Mutation or Mutation in the Family

https://www.facingourrisk.org/research-clinical-trials/study/185/survey-about-endometrial-cancer-risk-and-risk-reducing-surgery-for-women-with-a-brca12-mutation-or-mutation-in-the-family


Women with a BRCA mutation or from a family with a BRCA mutation

Researchers at the Mayo Clinic, McGill University and FORCE are conducting a survey of women with a BRCA1/2 mutation, or who come from a family with a known BRCA mutation but tested negative, or have not had testing. Our goal is to learn about the information needs and decisions made related to endometrial cancer risk. https://tinyurl.com/BRCAMUTATION. NOTE: This study is closed for enrollment. 

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job (TEAMWork Study)

https://www.facingourrisk.org/research-clinical-trials/study/86/talking-to-employers-and-medical-staff-about-breast-cancer-treatment-and-your-job

Quality of Life
Study for people diagnosed with cancer to help them navigate wok-related issues

The goal of this study is to improve a tool that helps cancer patients navigate work-related issues. Researchers are testing an early version of a mobile app designed to help breast cancer patients keep their jobs. The app – called TEAMWork (Talking to Employers And Medical staff about Work) – provides advice for patients who need to talk to their employers about treatment or their medical team about work. Researchers want patient feedback on what aspects of the app work well and what can be better.  

Breast Cancer Treatment in Women with PALB2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/85/breast-cancer-treatment-in-women-with-palb2-mutations

Surveys, Registries, Interviews
The PALB2 Study is an international research study to better understand breast cancer treatment among women with a PALB2 gene mutation.

The PALB2 Study is an international research study to better understand breast cancer treatment among women with a PALB2 gene mutation. Participants are asked to complete online or paper study questionnaires (every two years for 10 years) and share their family history, medical, and genetics records.

 

Testing the New Targeted Therapy CYH33 in Combination With the PARP Inhibitor Olaparib in People With Advanced Solid Tumors and DNA Damage Repair Mutations

https://www.facingourrisk.org/research-clinical-trials/study/168/cyh33-in-combination-with-olaparib-in-patients-with-advanced-solid-tumors-and-dna-damage-repair-mutations


Advanced solid tumors

This study will look at safety and effectiveness of the targeted therapy CYH33 combined with the PARP inhibitor olaparib in people with advanced cancers and a DNA damage repair (DDR) gene mutation whose cancer got worse on, or after receiving a PARP inhibitor. The study will also enroll people with recurrent, platinum resistant ovarian cancer. In addition to safety and efficacy, the study will test whether the combination of CYH33 and olaparib can block tumor growth and overcome a patient’s resistance to PARP inhibitor treatment.

Energetics and Lifestyle in Inherited Syndromes (ELLIE’s Study)

https://www.facingourrisk.org/research-clinical-trials/study/84/ellies-project

Quality of Life
A survey to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.

ELLIE’s Project is designed to look at factors that may affect cancer risk in people with inherited mutations linked to cancer. The study will look at weight, Body Mass Index, metabolism, dietary habits and activity level over the course of people’s life-time. ELLIE’s Project aims to gain a better understanding of the baseline lifestyle factors related to nutrition and physical activity in people with a hereditary cancer gene mutation.

RANKL Inhibition With Denosumab on Mammographic Density in Premenopausal Women With Dense Breasts (TRIDENT)

https://www.facingourrisk.org/research-clinical-trials/study/93/denosumab-and-mammographic-density-in-premenopausal-women-with-dense-breasts-trident

Prevention

The purpose of this study is to evaluate if denosumab can reduce the breast density of premenopausal women who have dense breasts. Denosumab is an FDA-approved injectable medication that is used to treat osteoporosis and to prevent fractures in cancer patients with bone metastases. This study could help us identify novel ways to prevent breast cancer in younger women. NOTE: This study is no longer enrolling people

Identification and Analysis of Families With Genetic Susceptibility To Cancer Registry

https://www.facingourrisk.org/research-clinical-trials/study/33/identification-and-analysis-of-families-with-genetic-susceptibility-to-cancer-registry

Surveys, Registries, Interviews
Registry for people with an inherited mutation in BRCA1 or BRCA2, or a BRCA1 or BRCA2 variant of uncertain significance, a gene mutation linked to a Lynch syndrome or an inherited mutation in another cancer risk gene

The research laboratory at the Abramson Cancer Center is studying genetic sources of cancer risk and currently has one of the largest collections (also called a registry) of families with known or suspected risk in the world. A number of research projects are performed in collaboration with this registry. Research participants receive a numerical identification number that protects their privacy. Collaborating centers do not have access to personal identifiers such as names and dates of birth because only the numerical identifiers are shared.

 

Atorvastatin ± Aspirin for Colorectal Cancer Prevention for People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/144/atorvastatin-aspirin-for-colorectal-cancer-prevention-for-people-with-lynch-syndrome


This study will look at how well atorvastatin (a cholesterol lowering agent) works with or without aspirin in preventing colorectal cancer in people with Lynch syndrome. Atorvastatin may lower the risk of developing cancers in the colon and rectum. Aspirin may reduce the risk of colon polyps and colon cancers. Giving atorvastatin and aspirin may work better at reducing the risk of colorectal cancer (CRC) in high-risk individuals with Lynch syndrome.

A Study of the Investigational Targeted Therapy ART4215 to Treat Advanced or Metastatic Solid Tumors

https://www.facingourrisk.org/research-clinical-trials/study/178/a-study-of-the-investigational-targeted-therapy-art4215-to-treat-advanced-or-metastatic-solid-tumors


Advanced solid tumors

This study is looking at how well a drug called ART4215 works either alone or when combined with the PARP inhibitor talazoparib in people with different types of advanced cancers. ART4215 is an oral targeted therapy that is designed to keep cancer cells from repairing DNA damage. 

Assessing Decisions about Uterine and Ovarian Cancer Prevention by People with Lynch Syndrome

https://www.facingourrisk.org/research-clinical-trials/study/224/assessing-decisions-about-uterine-and-ovarian-cancer-prevention-by-people-with-lynch-syndrome


Online survey for people with Lynch syndrome

This study is seeking information about the personal experiences of uterine and ovarian cancer prevention and screening for people with Lynch syndrome. An online survey will allow participants to share their experiences which will ultimately help medical practitioners be more aware about the wants, needs, and decision-making strategies used by people with Lynch syndrome to preserve their gynecological health.

EnergyPoints: A Mobile App Guiding Use of Acupressure for Cancer-related Fatigue and Sleep Disturbances

https://www.facingourrisk.org/research-clinical-trials/study/184/energypoints-a-mobile-app-guiding-use-of-acupressure-for-cancer-related-fatigue-and-sleep-disturbances


Anyone diagnosed with cancer experiencing fatigue

This study is looking at the use of acupressure to manage cancer-related fatigue and sleep disturbances. EnergyPoints is an app that teaches users how to self-administer acupressure, to manage fatigue and sleep disturbances related to cancer. The purpose of this research study is to learn from participants’ experiences using EnergyPoints, while they wear a fitness tracker to measure activity and sleep.

Adding PARP Inhibitor to Enzalutamide to Treat Men with Metastatic Prostate Cancer that is Resistant to Anti-androgen Therapy

https://www.facingourrisk.org/research-clinical-trials/study/221/adding-parp-inhibitor-to-enzalutamide-to-treat-men-with-metastatic-prostate-cancer-that-is-resistant-to-anti-androgen-therapy


Treatment study for men with metastatic prostate cancer

This study is testing the effectiveness of adding a type of targeted therapy known as a PARP inhibitor to androgen-deprivation therapy for men with metastatic prostate cancer that has become resistant to standard androgen deprivation therapy.

 

Studying Types of Therapy for Coping With Fear of Recurrence Among Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/216/studying-types-of-therapy-for-coping-with-fear-of-recurrence-among-breast-cancer-survivors


People with stage 1-3 breast cancer who completed treatment within 5 years of enrollment

Fear of cancer recurrence (FCR) is a common problem for breast cancer survivors. This study will test the effectiveness of three types of online, group therapy for breast cancer survivors with FCR. 

Nivolumab vs Placebo Combined with Neoadjuvant Chemotherapy & Adjuvant Endocrine Therapy for High-risk ER+, HER2-Negative Breast Cancer (CheckMate 7FL)

https://www.facingourrisk.org/research-clinical-trials/study/143/nivolumab-vs-placebo-combined-with-neoadjuvant-chemotherapy-adjuvant-endocrine-therapy-for-high-risk-er-her2-negative-breast-cancer-checkmate-7fl


Newly-diagnosed, non-metastatic, ER-positive, HER2-negative breast cancer

CA209-7FL: The purpose of a clinical trial is to look at whether the study drug, nivolumab, works in combination with neoadjuvant chemotherapy and adjuvant endocrine (hormone) therapy. The study will look at the safety profile of these study drug combinations and how well your body tolerates them. NOTE: This study is no longer enrolling patients. 

Diagnosis of Breast Cancer in Young Women - Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/113/diagnosis-of-breast-cancer-in-young-women-share-your-story


Researchers from the University of Illinois, Chicago Cancer Center invite breast cancer survivors who were diagnosed under the age of 45 to share their diagnosis stories. You will be asked to use your own words to share your experience on an online questionnaire. 

Abiraterone/Prednisone and Olaparib Alone or In Combination for Treatment of Metastatic Castration-Resistant Prostate Cancer With Mutations Related to DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/203/abirateroneprednisone-and-olaparib-alone-or-in-combination-for-treatment-of-metastatic-castration-resistant-prostate-cancer-with-mutations-related-to-dna-repair


Men with mCRPC with an inherited mutation or a tumor mutation in a DNA damage repair gene

This study is comparing three different treatments for men with metastatic castration-resistant prostate cancer, (mCRPC) who also have an inherited mutation or a tumor mutation in a gene that affects DNA damage repair. The study is open to men with inherited mutations found on genetic testing or tumor mutations in one of the following genes: ATM, BRCA1, BRCA2, FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A.

A Phase 2 Study of Olaparib Monotherapy in Metastatic Breast Cancer Patients with Germline or Somatic Mutations in DNA Repair Genes (Olaparib Expanded)

https://www.facingourrisk.org/research-clinical-trials/study/68/olaparib-expanded-treating-metastatic-breast-cancer-in-people-without-gbrca-mutations


Olaparib Expanded is a study looking at whether the drug Olaparib is effective treatment for people with certain types of metastatic breast cancer.  Olaparib belongs to a class of drugs known as PARP inhibitors. PARP inhibitors are particularly effective for treating tumors in people with an inherited BRCA mutation. This study is looking at whether olaparib is also effective for treating metastatic breast cancer in people who do not have an inherited BRCA mutation. Currently the study is only recruiting people with an inherited PALB2 mutation or people who test negative for an inherited mutation in BRCA1 or BRCA2 but have an acquired (somatic) BRCA1 or BRCA2 mutation found on tumor testing. 

Treatment for Metastatic Castration-Sensitive Prostate Cancer and Inherited or Tumor Mutations in DNA Damage Repair Genes (Amplitude)

https://www.facingourrisk.org/research-clinical-trials/study/209/treatment-for-metastatic-castration-sensitive-prostate-cancer-and-inherited-or-tumor-mutations-in-dna-damage-repair-genes-amplitude


Treatment for metastatic castration-sensitive prostate cancer and a tumor or inherited mutation in BRCA1, BRCA2, ATM, BRIP1, CHEK2, PALB2 or related gene

The goal of AMPLITUDE is to see if adding the PARP inhibitor niraparib to standard of care hormone therapy (Abiraterone Acetate, prednisone and androgen deprivation therapy (ADT) is safe and more effective than standard of care alone. The study is enrolling people who have metastatic castration-sensitive prostate cancer and have an inherited or tumor mutation in one of the following genes involved in DNA damage repair: BRCA2, BRCA1, BRIP1, CHEK2, FANCA, PALB2, RAD51B and RAD54L. NOTE: This study is no longer enrolling patients. 

Exploring the Fertility Preservation Needs of Individuals with Positive Genetic Test Results

https://www.facingourrisk.org/research-clinical-trials/study/211/exploring-the-fertility-preservation-needs-of-individuals-with-positive-genetic-test-results


Survey and video interview for people who tested positive for an inherited mutation

The goal of this study is to identify if there is a need for more specialized providers, specifically genetic counselors, to meet the needs of patients regarding fertility preservation and family planning prior to cancer treatment or preventative surgery. We hope to identify the appropriate setting and timeline for these services to streamline and enhance comprehensive patient care for patients with a hereditary breast or gynecologic cancer variant.

Factors Influencing Reproductive Decision-Making in Individuals with a BRCA1 or BRCA2 Gene Mutation

https://www.facingourrisk.org/research-clinical-trials/study/215/factors-influencing-reproductive-decision-making-in-individuals-with-a-brca1-or-brca2-gene-mutation


Survey for people with a BRCA1 or BRCA2 mutation

This study will survey individuals with a mutation in the BRCA1 or BRCA2 gene. We are seeking experiences and opinions of individuals regarding childbearing and reproductive choices. This will allow healthcare professionals, especially genetic counselors, to learn about what information is needed due to psychosocial and medical factors. The survey is approximately 25 minutes long to complete and is available online.

Interview Study about Barriers to Genetic Testing of Family Members in Latin America

https://www.facingourrisk.org/research-clinical-trials/study/212/interview-study-about-barriers-to-genetic-testing-of-family-members-in-latin-america


People with a hereditary cancer gene mutation and relatives living in Latin America

We are interviewing people who identify as Hispanic/Latinx/e with a genetic mutation associated with hereditary cancer and close family members who live in Latin America. This research study will describe genetic testing barriers and the communication of genetic risk to family members living in a Latin American country. The goal of this study is to improve the support that cancer genetic counselors can offer to individuals and their international family members. NOTE: This study is no longer enrolling. 

GENTleMEN Study: Genetic Testing for Men with Metastatic Prostate Cancer

https://www.facingourrisk.org/research-clinical-trials/study/63/genetic-testing-for-men-with-metastatic-prostate-cancer-gentlemen-study


The goal of this research study is to determine if online genetic education and testing with online telephone genetic counseling is an acceptable method of delivering genetic testing to men with metastatic prostate cancer.

This study involves undergoing genetic counseling and genetic testing for inherited cancer risk.

 

Pancreatic Cancer Early Detection Program

https://www.facingourrisk.org/research-clinical-trials/study/20/pancreatic-cancer-early-detection


This is a study looking at esophageal ultrasound and Magnetic Resonance Imaging (MRI) as a screening for pancreatic cancer in high risk individuals. 

Combination Drugs for Treating Metastatic Castration-Resistant Prostate Cancer with Tumor Mutation that Affect DNA Repair

https://www.facingourrisk.org/research-clinical-trials/study/206/combination-drugs-for-treating-metastatic-castration-resistant-prostate-cancer-with-tumor-mutation-that-affect-dna-repair


Treatment study for men with metastatic castration-resistant prostate cancer

The goal of this study is to compare the effectiveness of three different drug combinations to treat men with metastatic castration-resistant prostate cancer (mCRPR), who also have a mutation in a gene that affects DNA repair found through tumor testing. 

 

Pragmatic Randomized Trial of Proton vs. Photon Therapy for Patients with Non-Metastatic Breast Cancer Receiving Comprehensive nodal Radiation: A Radiotherapy Comparative Effectiveness Trial

https://www.facingourrisk.org/research-clinical-trials/study/56/radcomp-a-study-at-the-heart-of-breast-cancer-treatment


The RadComp Study, short for Radiotherapy Comparative Effectiveness, is a nationwide clinical study comparing two FDA approved radiation therapies for the treatment of breast cancer, PHoton Therapy vs. PRoton Therapy. With any radiation treatment to the breast, the heart may be exposed to radiation potentially resulting in heart problems in the future. Both Photon and Proton therapies are FDA approved; however, to date doctors do not know which therapy is better or worse in terms of reducing side effects and promoting length and quality of life after radiation.

We hope to learn: The effectiveness of proton vs. photon therapy in reducing major cardiovascular events and how treatment affects patient’s quality of life, such as financial burden, fatigue, and anxiety. These objectives were chosen as study priorities by breast cancer patients themselves.

Zoom Interviews to Explore Ideas about Long-Term Follow-Up Cancer Genetic Counseling

https://www.facingourrisk.org/research-clinical-trials/study/213/zoom-interviews-to-explore-ideas-about-long-term-follow-up-cancer-genetic-counseling


Interviews with adults that have recently met with a cancer genetic counselor in the U.S., regardless of genetic testing outcome

This study aims to explore perceptions of patients and genetic counselors about long-term follow-up in cancer genetic counseling, including if and how patients would like additional follow-up with a genetic counselor beyond the pre- and post-test counseling session. If you wish to participate, email the student investigator to schedule a voluntary 30–60-minute Zoom interview. All information will be de-identified. There are no costs associated with participation. NOTE: This study is no longer enrolling. 

UCLA Research Study: Zoom Interviews to Learn from Asian Americans Living with Metastatic Cancer

https://www.facingourrisk.org/research-clinical-trials/study/174/ucla-research-study-zoom-interviews-to-learn-from-asian-americans-living-with-metastatic-cancer


Asian Americans with metastatic cancer of any type

We would like to invite you to share your experiences to help improve the quality of life for Asian Americans diagnosed with metastatic cancer. NOTE: This study is no longer enrolling. 

Metastatic Pancreatic Cancer in US

https://www.facingourrisk.org/research-clinical-trials/study/194/metastatic-pancreatic-cancer-in-us


People with metastatic pancreatic cancer and their caregivers

Global Patients along with IQVIATM, a worldwide healthcare consulting firm, is currently conducting a research study, to better understand the experience of patients and/or caregivers of patients living with metastatic pancreatic cancer.

Interviews for People With a Genetic Test Result That was Later Reclassified

https://www.facingourrisk.org/research-clinical-trials/study/193/interviews-for-people-with-a-genetic-test-result-that-was-later-reclassified


People with a genetic test result that was later reclassified

Researchers at MD Anderson Cancer Center are conducting telephone interviews with individuals who have received modified (also known as reclassified or amended) genetic test results in any cancer related gene. We are interested in learning about the experience of receiving a modified test result and decisions made. 

Studying Crowdfunding for Cancer

https://www.facingourrisk.org/research-clinical-trials/study/187/studying-crowdfunding-for-cancer


Cancer survivors who have used crowdfunding to help cover cancer-related costs

This is a study on how the practice of crowdfunding affects the experience of having cancer. With the support of the National Science Foundation (NSF award #2021152), the researcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. earcher is interviewing cancer patients/survivors and their supporters about their use of crowdfunding platforms like GoFundMe. 

Survey: Making Decisions about Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/189/survey-making-decisions-about-genetic-testing


Survey for adults who have had genetic testing for inherited cancer risk through a doctor

You are invited to participate in an anonymous online survey about your decision to do genetic testing and how you dealt with the uncertainty of the outcome. The online survey includes a newly developed Uncertainty Management Scale (UMS) based on our years of prior uncertainty research. Knowing more about how people manage uncertainty may be helpful to society. You will be compensated $10 for completing the survey. This study is no longer enrolling. 

Interview Study about Hispanic/Latino Community Experiences Accessing Genetic Testing for Hereditary Cancer Risk

https://www.facingourrisk.org/research-clinical-trials/study/191/interview-about-hispaniclatino-community-experiences-accessing-genetic-testing-for-hereditary-cancer-risk


Hispanic/Latino people with a personal diagnosis of cancer or a family history of cancer

This study is looking at how to improve access to genetic testing among Hispanic/Latino populations in the U.S. We are conducting interviews with people in the Hispanic/Latino community who have either received genetic testing for hereditary cancer risk, or who have a family history of hereditary cancer and/or cancer diagnosis. This study could help develop policy options to inform how to improve access to genetic testing. Email Amanda Gutierrez at ag3@bcm.edu if you are interested in participating. NOTE: This study is no longer enrolling.

Targeted Therapy RP-3500 Alone or in Combination with Talazoparib or Gemcitabine in Advanced Solid Tumors with DNA Damage Repair Mutations (TRESR Study)

https://www.facingourrisk.org/research-clinical-trials/study/179/targeted-therapy-rp-3500-alone-or-in-combination-with-talazoparib-or-gemcitabine-in-advanced-solid-tumors-with-dna-damage-repair-mutations-tresr-study


Advanced solid tumors

This study is looking at how well a drug called RP-3500 works either alone or when combined with other cancer treatments in people with different types of advanced cancers with a mutation in one of the following genes: BRCA1, BRCA2, ATM, RAD51B, RAD51C, RAD51D, ATRIP, CHTF8, FZR1, MRE11, NBN, RAD17, RAD50, REV3L, SETD2 or RNASEH2. RP-3500 is a type of oral, targeted therapy known as an ATR inhibitor. The combination prescribed will depend on cancer type and mutation and when people join the study.

ATR Inhibitor BAY 1895344 Plus Niraparib Phase 1b Study in Advanced Solid Tumors and Ovarian Cancer

https://www.facingourrisk.org/research-clinical-trials/study/155/atr-inhibitor-plus-niraparib-study-in-advanced-solid-tumors-and-ovarian-cancer


Advanced ovarian cancer or other solid tumors

This study will look at how well how well people with advanced ovarian, fallopian tube or primary peritoneal cancer or other solid tumors respond to treatment with the targeted therapy BAY1895344 in combination with the PARP inhibitor niraparib.

A Survey on Health Behaviors for Women with BRCA1/2 Mutations

https://www.facingourrisk.org/research-clinical-trials/study/190/a-survey-on-health-behaviors-for-women-with-brca12-mutations


Survey for women with a BRCA1 or BRCA2 mutation

Researchers in the National University of Ireland, Galway are looking for people to take part in a survey on BRCA1/2 alteration carriers and health behaviours. The once-off survey asks questions about how you cope and what you think about health behaviours. Note: This study is closed to enrollment.

Survey: Medical Records to Save After a Cancer Diagnosis

https://www.facingourrisk.org/research-clinical-trials/study/162/survey-medical-records-to-save-after-a-cancer-diagnosis


Adults with cancer

In less than 5 minutes, learn which medical records are important to keep after a cancer diagnosis, why they are important to save, and ideas of how to keep them for you and your family.  The study has been IRB-approved by UC Irvine and is available in English and Spanish!  Note: This study is now closed to enrollment.

Investigating BRCA Previvors’ Utilization of Social Media for Health Decision Making and Social Support

https://www.facingourrisk.org/research-clinical-trials/study/173/investigating-brca-previvors-utilization-of-social-media-for-health-decision-making-and-social-support


Women with a BRCA1 or BRCA2 mutation who have never had cancer

This study investigates why women share aspects of their previvorship identity on social media platforms. We are interviewing women above 18 years old, who carry known pathogenic variants in BRCA1 or BRCA2, and share their previvor journey on social media platforms like Instagram, Facebook, Twitter, and TikTok at least once every other week. We are conducting anonymous interviews over Zoom with women who qualify. If you are interested, contact Mariah Wellman at mariah.wellman@utah.edu. NOTE: This study is no longer enrolling people. 

Survey: How Willing are You to Participate in Different Types of Clinical Trials for the Prevention of Breast Cancer?

https://www.facingourrisk.org/research-clinical-trials/study/188/survey-how-willing-are-you-to-participate-in-different-types-of-clinical-trials-for-the-prevention-of-breast-cancer


This study looks at why women at an increased risk of developing breast cancer are interested or uninterested in participating in breast cancer prevention clinical trials. The study consists of a 10-15 minute (max) anonymous questionnaire that asks hypothetical questions about participating in clinical trials with various study designs. This study’s findings may be used to better inform how to best design clinical trials aimed at the prevention of a breast cancer in the future. NOTE: This study is no longer enrolling.

Survey for Caregivers of Relatives in Families with an Inherited Mutation Linked to Cancer

https://www.facingourrisk.org/research-clinical-trials/study/150/survey-for-caregivers-of-relatives-in-families-with-an-inherited-mutation-linked-to-cancer


This anonymous survey is being conducted by researchers at the National Human Genome Research Institute of the National Institutes of Health, in collaboration with Facing Our Risk of Cancer Empowered (FORCE). The goal of this survey is to help researchers understand the caregiving experiences of families affected by hereditary cancer. By sharing your experience with us, you can help us develop more resources to improve the experience of future family caregivers.  NOTE: THIS STUDY IS NO LONGER ENROLLING.

 

Tucatinib Plus Trastuzumab in Patients With HER2+ Colorectal Cancer (MOUNTAINEER)

https://www.facingourrisk.org/research-clinical-trials/study/115/tucatinib-plus-trastuzumab-in-patients-with-her2-colorectal-cancer-mountaineer


This is a study for people who have been diagnosed with HER2-positive (HER2+) metastatic colorectal cancer (mCRC).  The goal of this study is to look at how well the drug tucatinib (Tukysa) works to improve outcomes when given with trastuzumab (Herceptin), versus how well tucatinib works when administered by itself. NOTE: This study is no longer enrolling patients. 

Using ctDNA Blood Test to Screen for Cancer DNA after Treatment for Early-Stage TNBC and/or an Inherited or Tumor BRCA Mutation; Followed by Study Comparing Niraparib with Placebo for People with Cancer DNA found in their Blood (ZEST)

https://www.facingourrisk.org/research-clinical-trials/study/170/screening-for-cancer-dna-in-the-blood-after-treatment-for-early-stage-tnbc-andor-a-brca-mutation-followed-by-study-comparing-niraparib-with-placebo-for-people-with-cancer-dna-found-in-their-blood-zest


Early-stage TNBC or early-stage breast cancer with a BRCA mutation

This study will enroll people with early-stage triple negative breast cancer or people with an inherited or acquired BRCA1 or BRCA2 mutation who have completed treatment (or are still in treatment with hormone therapy) for screening using a blood test known as circulating tumor DNA (ctDNA). Individuals who test positive for ctDNA may be eligible to participate in a randomized study to receive the PARP inhibitor, niraparib or a placebo and undergo close monitoring with imaging (CT scans). The study will look at the safety and efficacy of niraparib plus monitoring compared with placebo plus monitoring for people who test positive for cancer cells in their blood but who have no evidence of cancer recurrence. NOTE: This study is no longer enrolling. 

A National Survey to Share the Voices of Ovarian Cancer Caregivers

https://www.facingourrisk.org/research-clinical-trials/study/167/a-national-survey-to-share-the-voices-of-ovarian-cancer-caregivers


Caregivers to people with ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer.  The research hopes to identify areas for improvement in supporting the lives of people who care for patients living with ovarian cancer. By taking part in the survey your views, alongside those of other caregivers of women living with ovarian cancer will be heard. This will help generate the scientific evidence required to ensure healthcare professionals and other healthcare supporting bodies have a deep understanding about what it is like to live with advanced ovarian cancer and can help provide them with the tools to support patients, caregivers, and their families. NOTE: This survey is closed to enrollment.

Treating Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer with Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib

https://www.facingourrisk.org/research-clinical-trials/study/133/treating-metastatic-pancreatic-colorectal-gastroesophageal-or-biliary-cancer-with-chemotherapy-and-rucaparib


Metastatic colorectal, pancreatic, gastroesophageal or biliary tract cancer

This study is focused on patients with pancreatic, colorectal, gastroesophageal, or biliary (bile duct) cancer that has spread to other places in the body (metastasized). NOTE: This study is no longer enrolling patients. 

Talazoparib in Treating Patients With Recurrent, Advanced, or Metastatic Cancers and Inherited or Acquired Gene Mutations

https://www.facingourrisk.org/research-clinical-trials/study/152/talazoparib-in-treating-patients-with-recurrent-advanced-or-metastatic-cancers-and-inherited-or-acquired-gene-mutations


This study will look at how well the PARP inhibitor talazoparib works in treating patients with cancers that have returned after a period of improvement, do not respond to treatment, or have spread to other parts of the body, and have inherited mutations or tumor mutations in BRCA or other specific genes. NOTE: This study is no longer enrolling patients. 

Dostarlimab Plus Carboplatin-paclitaxel Versus Placebo Plus Carboplatin-paclitaxel for Recurrent or Primary Advanced Endometrial Cancer (RUBY)

https://www.facingourrisk.org/research-clinical-trials/study/166/dostarlimab-plus-carboplatin-paclitaxel-versus-placebo-plus-carboplatin-paclitaxel-for-recurrent-or-primary-advanced-endometrial-cancer-ruby


Metastatic endometrial cancer

This study for people with Stage III or Stage IV endometrial cancer will look at how well the combination of an immunotherapy plus targeted therapy and chemotherapy works compared with chemotherapy alone.  NOTE: This study is no longer enrolling people. 

TALAPRO-2: A study Assessing the Study Drug + Enzalutamide vs. Placebo + Enzalutamide in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC) and DNA Damage Repair (DDR) Deficiency

https://www.facingourrisk.org/research-clinical-trials/study/98/talapro-2-a-study-assessing-the-study-drug-enzalutamide-vs-placebo-enzalutamide-in-men-with-metastatic-castration-resistant-prostate-cancer-mcrpc-and-dna-damage-repair-ddr-deficiency


The TALAPRO-2 study is assessing whether the study drug is safe and effective when given in combination with enzalutamide as a treatment option for men with metastatic castration-resistant prostate cancer and DDR deficiency. NOTE: This study is no longer enrolling patients. 

A National Survey to Share the Voice and Treatment Preferences of Ovarian Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/163/a-national-survey-to-share-the-voice-and-treatment-preferences-of-ovarian-cancer-patients


Ovarian cancer

We would like to invite you to make your views heard as to the real-world burden and impact of ovarian cancer and preference for different ways of taking medication.  The research hopes to identify areas for improvement in supporting the lives of patients living with ovarian cancer and the people that care for them after 1st surgery and chemotherapy.  NOTE: This survey is closed to enrollment.

Interview: Understanding the Experiences of Black Women after Cancer Genetic Testing

https://www.facingourrisk.org/research-clinical-trials/study/160/understanding-the-experiences-of-black-women-after-cancer-genetic-testing


Black women who have tested positive for an inherited mutation

We are looking to interview Black women who have received a positive result in a cancer-associated genetic test. We want to hear your story. This research will look at Black women's experiences with cancer genetic testing. If you decide to take part in the study, you would participate in an approximately hour-long phone interview. Participants will be compensated for their time with a $20 gift card. Contact Malika Sud at msud@bu.edu for more information or to participate. NOTE: This study is now closed. 

HOPE: Olaparib, Palbociclib and Fulvestrant for BRCA-Associated, ER/PR-Positive, Her2-Negative Metastatic Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/147/olaparib-palbociclib-and-fulvestrant-for-brca-associated-erpr-positive-her2-negative-metastatic-breast-cancer


The goal of this study is to find the best dose and measure side effects of palbociclib when given together with olaparib and fulvestrant, in treating people with hormone receptor-positive (HR+), HER2-negative metastatic breast cancer who have a BRCA1 or BRCA2 mutation. Palbociclib and Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Fulvestrant is a type of treatment that may prevent breast cancer cell growth by blocking estrogen and progesterone receptor stimulation.

Fear of Recurrence, Adversity, and Pain

https://www.facingourrisk.org/research-clinical-trials/study/161/fear-of-recurrence-adversity-and-pain


We are investigating the relation of adversity, pain, and fear of cancer recurrence among adult cancer survivors. Participation involves completing a 30-minute computerized survey online from your home computer. No compensation is being offered for participation in this research study.

Enhancing Genetic Risk Assessment in Underserved Blacks and Latinas at Risk of Hereditary Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/142/breast-and-ovarian-cancer-education-research-for-african-americanblack-and-latina-women


Researchers are conducting a study to test how well education materials increase use knowledge about hereditary cancer risk. Participants will watch 90 minutes of educational videos and complete 2 short surveys. In all, this will take approximately 3 hours to complete over a two-week period. Everything will be completed over the phone or online. Compensation will be provided for participation. NOTE: This study is no longer enrolling participants. 

Treating Metastatic Pancreatic Cancer with an Inherited or Tumor BRCA1/2 or PALB2 Mutation with Niraparib and Dostarlimab

https://www.facingourrisk.org/research-clinical-trials/study/135/treating-metastatic-pancreatic-cancer-with-an-inherited-or-tumor-brca12-or-palb2-mutation-with-niraparib-and-dostarlimab


This study looks at how well the PARP inhibitor niraparib and the immunotherapy drug dostarlimab work together in treating patients with metastatic pancreatic cancer, who also have an inherited or tumor mutation in one of the following genes: BRCA1, BRCA2, PALB2, BARD1, RAD51c, or RAD51d.

AMPLIFY: a new online weight loss study specifically for cancer survivors!

https://www.facingourrisk.org/research-clinical-trials/study/139/amplify-a-new-online-weight-loss-study-specifically-for-cancer-survivors


AMPLIFY is a nation-wide, web-based diet and exercise study recruiting overweight survivors of early stage breast, prostate, ovarian, renal, colorectal and endometrial cancer and multiple myeloma. This study is enrolling qualified cancer survivors age 50 and older who are interested in becoming more active, eating better and losing weight.

Treating Advanced Solid Tumors in People with Inherited PTEN Mutations Using the Investigational Drug TAS-117

https://www.facingourrisk.org/research-clinical-trials/study/159/treating-advanced-solid-tumors-in-people-with-inherited-pten-mutations-using-the-investigational-drug-tas-117


People with advanced cancer and an inherited PTEN mutation

This study will look at how well the targeted therapy TAS-117 works for treating people with an inherited PTEN mutation and advanced or metastatic solid tumors (excluding primary brain tumors). 

Olaparib Plus Pembrolizumab Versus Chemotherapy Plus Pembrolizumab After First-Line Treatment in Advanced Triple Negative Breast Cancer (KEYLYNK-009)

https://www.facingourrisk.org/research-clinical-trials/study/148/olaparib-plus-pembrolizumab-versus-chemotherapy-plus-pembrolizumab-after-first-line-treatment-in-advanced-triple-negative-breast-cancer-keylynk-009


This study will look at how people with advanced triple-negative breast cancer (TNBC) respond to different combinations of drugs. During an initial study period participants will receive a combination of chemotherapy and immunotherapy drugs. Participants with stable cancer or an improvement will be able to continue with the study. Continuing participants will be assigned to one of two groups. One group will receive the same drug combination during the followup period. The second group will instead immunotherapy plus a type of targeted therapy known as a PARP inhibitor during the follow-up period.  NOTE: This study is no longer enrolling patients. 

Pembrolizumab Plus Lenvatinib Versus Chemotherapy for Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/114/pembrolizumab-plus-lenvatinib-versus-chemotherapy-for-endometrial-cancer


The purpose of this study is to compare the effectiveness of using a combination of the immunotherapy drug pembrolizumab (Keytruda) and the targeted therapy lenvatinib (Lenvima) in women with Stage III, IV, or recurrent endometrial cancer versus using chemotherapy treatment alone. NOTE: This study has completed enrollment

TALAVE: A Pilot Trial of Induction Talazoparib Followed by Combination of Talazoparib and Avelumab in Advanced Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/125/talave-talazoparib-followed-by-combination-of-talazoparib-and-avelumab-in-advanced-breast-cancer


TALAVE is a study for patients who have advanced or metastatic breast cancer that will not be cured by treatment with surgery or radiotherapy, and either have a BRCA1/2 mutation (germline or somatic) or have triple negative breast cancer who are not known to have a BRCA1/2 mutation. The goal of TALAVE is to look at whether giving talazoparib alone followed by talazoparib with avelumab is a safe and effective treatment for advanced breast cancer. THIS STUDY IS NO LONGER ENROLLING.

COVID-19 Breast Cancer Care Survey

https://www.facingourrisk.org/research-clinical-trials/study/145/covid-19-breast-cancer-care-survey


The purpose of this research study is to learn about how the COVID-19 pandemic has affected cancer care and quality of life in breast cancer survivors. Participants will complete an online survey and some women will be invited to participate in an online interview to learn more about their cancer treatment experiences during the pandemic. NOTE: This study is no longer enrolling. 

Omega 3 Fatty Acids in Colorectal Cancer (CRC) Prevention in Patients With Lynch Syndrome (COLYNE)

https://www.facingourrisk.org/research-clinical-trials/study/146/omega-3-fatty-acids-in-colorectal-cancer-crc-prevention-in-patients-with-lynch-syndrome-colyne


This study looks at how well omega-3 fatty acid ethyl esters (generic Lovaza) work in preventing colorectal cancer in patients with Lynch syndrome. Omega-3 fatty acids work by decreasing inflammation, or swelling, in the body, and suppressing certain chemicals in the body that are known to cause cancer. The addition of omega-3 fatty acids to patients' diets may help decrease colon inflammation or suppress cancer-causing chemicals in the body. NOTE: This study is no longer enrolling people. 

Research Study to Help Improve Family Communication About Inherited Mutations

https://www.facingourrisk.org/research-clinical-trials/study/118/research-study-to-help-improve-family-communication-about-inherited-brca1-or-brca2-mutations


The Ohio State University and FORCE want to understand if a family communication guide for people with BRCA mutations is helpful and if it’s also useful to have a video that you can text or email to family members that explains your BRCA mutation. We are currently looking for people between the ages of 18-80 who have mutation in BRCA1 or BRCA2, have an active email address, and an internet capable device like a computer, tablet, or smartphone.  Participants will be asked to complete a total of 3 surveys.  Participants will be randomly assigned to either receive just the communication guide or the guide plus the sharable.  Each survey will take 10-15 minutes (the study could take up to 1.5 hours to complete depending on how much time you spend reviewing the study materials). 

You can get more information or ask to participate in the study by sending an email to: brcashare@osumc.edu.

Phase 1/1b Study of Oral Drug PMD-026 in People with Metastatic Breast Cancer and Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/124/phase-1-study-of-oral-drug-pmd-026-in-people-with-metastatic-breast-cancer-and-metastatic-triple-negative-breast-cancer


PMD-026 is a study for people who have been diagnosed with metastatic triple negative breast cancer (mTNBC) who have no further treatment options. This research study is investigating if a study drug called PMD-026 is safe and effective for patients with mTNBC. NOTE: This study is no longer enrolling. 

Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to the Usual Radiation Treatment for Newly Diagnosed Early Stage High Intermediate Risk Endometrial Cancer

https://www.facingourrisk.org/research-clinical-trials/study/111/addition-of-pembrolizumab-to-radiation-treatment-for-newly-diagnosed-early-stage-msi-high-endometrial-cancer


The purpose of this study is to determine whether the addition of the immunotherapy agent pembrolizumab to radiation therapy is more effective than radiation therapy alone in reducing the risk of cancer recurrence in patients with newly diagnosed stage I-II endometrial cancer that is MSI-High. This study is no longer enrolling.

A Study of EDP1503 in Patients With Colorectal or Triple Negative Breast Cancer or Cancer That Came Back After Treatment with a Checkpoint Inhibitor

https://www.facingourrisk.org/research-clinical-trials/study/116/a-study-of-edp1503-in-patients-with-colorectal-cancer-breast-cancer-or-checkpoint-inhibitor-relapsed-tumors


Medicines that affect bacteria in the stomach and intestines may assist immunotherapy agents like pembrolizumab (Keytruda) in treating cancer. This study will look at the effect of a drug, EDP1503 on enhancing the anti-cancer response when used with pembrolizumab, in patients with advanced metastatic colorectal carcinoma, triple-negative breast cancer, or cancers that have recurred after a type of immunotherapy known as an immune checkpoint inhibitor. NOTE: This this study is no longer enrolling patients. 

RESTORE: A virtual study comparing 2 digital apps to improve mental and physical well-being of patients with stage I – 3 cancer

https://www.facingourrisk.org/research-clinical-trials/study/192/restore-a-virtual-study-comparing-2-digital-apps-to-improve-mental-and-physical-well-being-of-patients-with-stage-i-3-cancer


People with stage 1-3 cancer

Many cancer patients experience cancer-related distress, which includes psychological symptoms of anxiety and depression. The RESTORE study will enroll up to 415 adults who have been diagnosed with stage I-III cancer. The goal is to test how effective two different apps are at improving physical and mental health. Participants use their smartphone or tablet to download and access their assigned treatment app without ever needing to visit a clinic in person.

Abiraterone/Prednisone, Olaparib, or Abiraterone/Prednisone + Olaparib in Patients With Metastatic Castration-Resistant Prostate Cancer With DNA Repair Defects

https://www.facingourrisk.org/research-clinical-trials/study/58/parp-inhibitor-for-metastatic-prostate-cancer-with-dna-repair-defects


This is a phase II study looking at different treatment combinations for men with metastatic, castration resistant prostate cancer (mCRPC) to see which is most effective for improving progression free survival (keeping the cancer from progressing). The study will include testing for genes within the tumor to determine eligibility for the study. 

Patients with tumors that have ATM, BRCA1 and/or BRCA2 mutations or defects will be randomly assigned to one of the treatment arms of the study. Patients with tumors that have mutations in other DNA repair genes including FANCA, PALB2, RAD51, ERCC3, MRE11, NBN, MLH3, CDK12, CHEK2, HDAC2, ATR, PMS2, GEN1, MSH2, MSH6, BRIP1, or FAM175A will be assigned to Arm IV with single agent olaparib. NOTE: This study is now closed. 

Mobile Mindfulness Meditation Intervention to Improve Neuropathy in Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/132/mobile-mindfulness-meditation-intervention-to-improve-neuropathy-in-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts cancer-related neuropathy. We are asking people who have been diagnosed with cancer, have finished primary treatment and are experiencing neuropathy if they would like to use a mobile app for mindfulness meditation to see if it helps their neuropathy.  

Interested participants will be asked to follow the link for either anxiety OR neuropathy and to participate in only one of the studies, one time only. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Niraparib + Ipilimumab or Nivolumab in Pancreatic Cancer that Has Not Progressed After Platinum Chemotherapy (Parpvax)

https://www.facingourrisk.org/research-clinical-trials/study/136/niraparib-ipilimumab-or-nivolumab-in-pancreatic-cancer-that-has-not-progressed-after-platinum-chemotherapy-parpvax


The purpose of this study is to look at the effectiveness, safety, and anti-cancer activity of the drug Niraparib combined with one of two immunotherapy agents: Ipilimumab or Nivolumab on patients with locally advanced or metastatic pancreatic cancer.  Patients in this study must also have previously received Platinum-based chemotherapy without evidence of disease progression.  NOTE: This study is no longer enrolling patients. 

Parenting Adolescent-Aged Children While Managing a Parental Cancer Diagnosis – Share Your Story

https://www.facingourrisk.org/research-clinical-trials/study/130/parenting-adolescent-aged-children-while-managing-a-parental-cancer-diagnosis-share-your-story


The study explores how families faced with a parental cancer diagnosis communicate, or why they choose not to communicate, with their children about the cancer diagnosis, treatments, and other related topics. At least one family member (diagnosed parent or non-diagnosed parent) is asked to participate, but more than one member can sign up to be interviewed. NOTE: This study is no longer enrolling people. 

Mobile Mindfulness Meditation Intervention to Improve the Well-Being of Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/131/mobile-mindfulness-meditation-intervention-for-cancer-survivors


Aloha! The University of Hawai‘i Cancer Center is running a mobile app study to see how it impacts different areas of well-being in cancer survivors – namely, anxiety and cancer-related neuropathy. We are asking people who have been diagnosed with cancer and finished primary treatment if they would like to use a mobile app for mindfulness meditation to see if it impacts anxiety.  

Interested participants will be asked to follow the link for anxiety. Upon enrollment, you will randomly be assigned to begin using the mobile app either immediately or after eight weeks. You will be asked to complete online questionnaires about your well-being upon your initial enrollment, 8 weeks later, and 16 weeks later.

Nous-209 Genetic Vaccine for the Treatment of Microsatellite -High (MSI-H) Colorectal, Gastric and Gastro-esophageal junction Tumors

https://www.facingourrisk.org/research-clinical-trials/study/105/nous-209-genetic-vaccine-for-the-treatment-of-msi-h-colorectal-gastric-and-gastro-esophageal-junction-tumors


Treatment study for people with advanced colorectal, gastric and gastro-esophageal junction tumors

The goal of this cancer treatment study is to find the best dose and learn how safe and effective this cancer vaccine is for treating advanced colorectal, gastric and gastro-esophageal junction tumors that test positive for the biomarkers MSI-High or dMMR. Participants will receive the vaccine in combination with the immunotherapy drug Keytruda (pembrolizumab). 

A Study of Rucaparib Verses Physician's Choice of Therapy in Patients With Metastatic Castration-resistant Prostate Cancer and Homologous Recombination Gene Deficiency (TRITON3)

https://www.facingourrisk.org/research-clinical-trials/study/17/triton3-rucaparib-vs-physician-choice-for-castration-resistant-prostate-cancer


The purpose of Triton3 is to determine how patients with metastatic castration-resistant prostate cancer, and an inherited gene mutation or tumor genetic deficiency, respond to treatment with the PARP inhibitor rucaparib compared to treatment with physician's choice of abiraterone acetate, enzalutamide, or docetaxel. NOTE: This study is no longer enrolling patients. 

Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS)

https://www.facingourrisk.org/research-clinical-trials/study/108/prostate-cancer-genetic-risk-experience-and-support-study-progress


Prostate Cancer Genetic Risk, Experience, and Support Study (PROGRESS) is a national, patient-driven registry for any male who has undergone or is currently undergoing genetic testing for prostate cancer. Note: This study is no longer enrolling. 

 

A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment with Immune Checkpoint Inhibitors (QUILT-3.055)

https://www.facingourrisk.org/research-clinical-trials/study/106/combination-immunotherapies-in-patients-who-previously-received-immune-checkpoint-inhibitors-quilt-3055


Immune checkpoint inhibitors immunotherapy drugs that allow the immune system to find and destroy cancer cells.

This study will use a combination of immunotherapies in people who's cancer got worse after treatment with a PD-1 or PD-L1 immune checkpoint inhibitor. NOTE: This study is no longer recruiting.

Safety and Efficacy of Olaparib Combined with Agents Targeting DNA Damage Repair Compared to Olaparib Alone

https://www.facingourrisk.org/research-clinical-trials/study/104/olaparib-combined-with-agents-targeting-dna-damage-repair-compared-to-olaparib-alone


The purpose of this study is to assess the efficacy and safety of treatment with the PARP inhibitor, olaparib combined with the drug Ceralasertib compared with olaparib alone for patients with Triple-Negative Breast Cancer.

NOTE: This study is no longer enrolling patients. 

A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden

https://www.facingourrisk.org/research-clinical-trials/study/77/studying-a-combination-of-immunotherapies-and-biomarker-for-advanced-solid-tumors


This study is researching a combination of two immunotherapy drugs for advanced solid tumors that contain a tumor biomarker known as "High Tumor Mutation Burden" (TMB-H). The researchers are studying whether treatment  of these tumors with a combination of the drugs nivolumab plus ipilimumab is safe and effective compared with nivolumab alone. NOTE: This study is no longer enrolling.

A Study of Nivolumab in Selected Uterine Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/110/a-study-of-nivolumab-in-selected-uterine-cancer-patients


The purpose of this study is to test the effectiveness, safety, and tolerability of Nivolumab on patients with metastatic or recurrent uterine cancer. 

Nivolumab is a type of immunotherapy known as an immune checkpoint inhibitor. Immune checkpoint inhibitors are drugs that prevent cancer cells from switching off immune cells. This allows the immune system to find, unmask and destroy cancer cells.  NOTE: This study is no longer enrolling. 

GENetic Education Risk Assessment and TEsting Study (GENERATE)

https://www.facingourrisk.org/research-clinical-trials/study/69/generate


The goal of the GENERATE study is to increase the uptake of genetic testing among family members of pancreatic cancer patients who may carry a genetic mutation.

This study involves education about genetic testing, undergoing genetic testing for cancer risk (for those who choose to) and completion of a series of 4 sets of questionnaires. Note: This study is no longer enrolling patients.

 

A Study in Advanced Breast Cancer Patients with BRCA 1/2 Mutations Evaluating Olaparib alone or in Combination with Atezolizumab

https://www.facingourrisk.org/research-clinical-trials/study/66/parp-inhibitor-alone-or-plus-immunotherapy-for-advanced-brca-associated-breast-cancer


This is a study for women or men who have been diagnosed with advanced breast cancer with a BRCA 1/2 mutation. The goal of the study is to look at whether giving the PARP inhibitor olaparib in combination with the immunotherapy atezolizumab improves outcomes for patients compared to olaparib alone.  NOTE: This study is no longer enrolling people.

 

Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair

https://www.facingourrisk.org/research-clinical-trials/study/107/combination-chemotherapy-with-or-without-atezolizumab-in-treating-patients-with-stage-iii-colon-cancer-and-deficient-dna-mismatch-repair


This study is no longer enrolling people. 

PHACT Study: Population Health and Cancer Testing

https://www.facingourrisk.org/research-clinical-trials/study/75/phact-study


NOTE: The PHACT study is no longer recruiting patients. 

Pilot Study of Denosumab in BRCA1 or BRCA2 Mutation Carriers Scheduling Risk-Reducing Salpingo-Oophorectomy

https://www.facingourrisk.org/research-clinical-trials/study/74/denosumab-in-brca1-or-brca2-mutation-carriers-scheduling-risk-reducing-salpingo-oophorectomy


The purpose of this study is to evaluate the effects of denosumab on ovarian cancer risk markers among premenopausal women with a BRCA1 or BRCA2 mutation, who are scheduled to undergo risk-reducing surgery to remove their ovaries and fallopian tubes. UPDATE: THIS STUDY HAS BEEN DISCONTINUED.

A Study in Hereditary Breast and Ovarian Cancer Families to Provide Men With Up-To-Date Information About the Personal Importance of Genetic Testing (GEM)

https://www.facingourrisk.org/research-clinical-trials/study/65/genetic-education-for-men-gem-study


The Genetic Education for Men or GEM study, is a clinical trial evaluating educational tools for men from families in which a BRCA1/2 gene mutation has been identified. In order to identify untested men from BRCA1/2 families, we are seeking women who have received positive BRCA1/2 test results and have at least one untested male relative. NOTE: This study is no longer enrolling people. 

A Phase 2 Study of Nivolumab in Combination with Either Rucaparib, Docetaxel, or Enzalutamide in Men with Castration-resistant Metastatic Prostate Cancer (CheckMate-9KD)

https://www.facingourrisk.org/research-clinical-trials/study/64/checkmate-9kd-for-men-with-metastatic-prostate-cancer


CheckMate-9KD is a clinical research study for men with metastatic prostate cancer (which means cancer that has spread) that no longer responds to treatments that lower testosterone. The purpose of this study is to compare three different combination therapies, each containing a drug called nivolumab and another anti-cancer drug. All three combination therapies are considered investigational, which means that they are not currently approved to treat men with metastatic prostate cancer. The study doctors want to learn more about which therapy is most effective in treating metastatic prostate cancer. NOTE: This study is no longer enrolling. 

A Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy (ATHENA)

https://www.facingourrisk.org/research-clinical-trials/study/62/athena-rucaparib-and-nivolumab-for-maintenance-in-ovarian-cancer


ATHENA is a study for women who are newly diagnosed with ovarian cancer. The goal of ATHENA is to look at whether giving maintenance therapy with different agents improves outcomes for women who have completed front-line treatment. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Decision Navigation for Advanced Prostate Cancer Treatment Options Using mHealth

https://www.facingourrisk.org/research-clinical-trials/study/59/decision-navigation-for-advanced-prostate-cancer-treatment-options-using-mhealth


Men with advanced prostate cancer face difficult choices for treatment because of the nature of their disease and having limited options. This study will test the use of an innovative Registered Nurse-Community Patient Navigator team delivered interactive mHealth decision aid for patients with advanced prostate cancer to help facilitate informed shared decisions about anti-cancer treatment that affects their quality of life. NOTE: This study is no longer enrolling. 

Safety and Efficacy of Olaparib Alone Or in Combination with Medication Targeting DNA Damaging Repair for Metastatic Triple Negative Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/91/olaparib-plus-dna-damage-repair-targeted-therapy-for-metastatic-tnbc


The purpose of this study is to learn the safety and effectiveness of the PARP inhibitor, olaparib as a single drug therapy compared with olaparib in combination with the new agent AZD6738 in patients with metastatic Triple-Negative Breast Cancer (TNBC).  NOTE: This study is no longer enrolling people. 

Olive Oil for High Risk Breast Cancer Prevention

https://www.facingourrisk.org/research-clinical-trials/study/97/olive-oil-for-high-risk-breast-cancer-prevention


This study will evaluate the effect of hydroxytyrosol, a component of olive oil, on breast density in women who are at high risk for developing breast cancer. UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

 

Auricular Point Acupressure to Self-Manage Aromatase Inhibitor Musculoskeletal Symptoms in Breast Cancer Survivors

https://www.facingourrisk.org/research-clinical-trials/study/94/acupressure-to-self-manage-aromatase-inhibitor-musculoskeletal-symptoms-in-breast-cancer-survivors


Severe joint pain and muscle stiffness are common side effects of taking Aromatase Inhibitors.  Aromatase inhibitor musculoskeletal symptoms have a negative effect on a woman's physical function and quality of life. Auricular point acupressure uses stimulation applied to points on the ear without using needles. This study will look at and test auricular (ear) point acupressure to manage aromatase-inhibitor-caused joint pain and muscle stiffness in breast cancer survivors. 

Note: This study is no longer enrolling patients.

 

A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor (SEASTAR)

https://www.facingourrisk.org/research-clinical-trials/study/92/a-study-to-evaluate-rucaparib-in-combination-with-other-anticancer-agents-in-patients-with-a-solid-tumor-seastar


This study will look at how safe, effective and tolerable the oral PARP inhibitor Rucaparib is when used in combination with other anticancer agents in patients with advanced solid tumors, including triple-negative breast cancer, ovarian cancer or urothelial cancer. Note: This study has completed enrollment. 

Study of Safety and Effectiveness of Motiva® Breast Implants

https://www.facingourrisk.org/research-clinical-trials/study/80/study-of-safety-and-effectiveness-of-motiva-breast-implants


Note: This study is no longer enrolling. 

The Women Choosing Surgical Prevention (WISP) Trial

https://www.facingourrisk.org/research-clinical-trials/study/4/women-choosing-surgical-prevention-wisp-trial


The WISP Study is closed to enrollment. Stay tuned for updates from FORCE on study results or new studies for ovarian cancer prevention. 

 

A Study to Evaluate Rucaparib in Patients with Solid Tumors and with Deleterious Mutations in HRR Genes (LODESTAR)

https://www.facingourrisk.org/research-clinical-trials/study/88/a-study-to-evaluate-rucaparib-in-patients-with-solid-tumors-and-with-deleterious-mutations-in-hrr-genes


The LODESTAR study is evaluating the response of the PARP inhibitor rucaparib in people with advanced solid tumors (including breast, ovarian, pancreatic, prostate and other cancers) who have an inherited mutation or an acquired mutation in any of the following genes: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BARD1, BRIP1, FANCA, NBN, RAD51 or RAD51B.   NOTE: This study is no longer enrolling people.

A Non-Randomized Phase II Research Study of M6620 (VX-970) in Selected Solid Tumors to Inhibit the ATR Enzyme.

https://www.facingourrisk.org/research-clinical-trials/study/87/study-using-m6620-vx-970-an-atr-inhibitor-to-treat-solid-tumors


This clinical trial is studying how well M6620 works in treating patients with advanced solid tumors. M6620 is a drug designed to block the ATR enzyme. ATR repairs damaged DNA. In cancer, ATR may protect the cancer cells by helping them repair damage. Blocking ATR may keep cancers from repairing their damaged DNA; slowing the growth of, or killing cancer cells. The study will be recruiting people with different types of cancer, including people with advanced solid tumors and a BRCA1, BRCA2 or ATM mutation.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS.

A Study of IMMray™ PanCan-d Test for Early Detection of Pancreatic Cancer in High-risk Groups

https://www.facingourrisk.org/research-clinical-trials/study/83/immray-pancan-d-test-for-early-detection-of-pancreatic-cancer-in-high-risk-groups


This study will validate and evaluate the performance of the IMMray PanCan-d test for pancreatic cancer diagnosis in comparison to standard of care imaging currently used in pancreatic cancer disease surveillance by the research sites’ institutions. ENROLLMENT HAS CLOSED FOR THIS STUDY!

INTense Exercise foR surVivAL Among Men With Metastatic Castrate-Resistant Prostate Cancer (INTERVAL)

https://www.facingourrisk.org/research-clinical-trials/study/82/interval-intense-exercise-for-survival-in-men-with-metastatic-prostate-cancer


This study will determine if high intensity aerobic and resistance training (with supervised exercise) plus psychosocial support increases overall survival compared to psychosocial support alone (with self-directed exercise) in patients with metastatic castrate-resistant prostate cancer. NOTE: This study is no longer enrolling people. 

Patient-Driven Clinical Classification of Genetic VUS (Variants of Uncertain Significance)

https://www.facingourrisk.org/research-clinical-trials/study/28/find-my-variant


NOTE: This study is no longer enrolling. 

 

Making Genetic Testing Accessible (MAGENTA)

https://www.facingourrisk.org/research-clinical-trials/study/27/making-genetic-testing-accessible-magenta


The goal of this research study is to test the effects of online genetic education alone or in combination with telephone genetic counseling in order to compare the two methods and the stress a person feels about their risk of cancer.  NOTE: This study has closed for enrollment.

IMProving Executive function Study

https://www.facingourrisk.org/research-clinical-trials/study/22/impres-improving-memory-after-rrso


Dr. C. Neill Epperson and her research team at the Penn Center for Women's Behavioral Wellness are studying the effects of a stimulant medication called Vyvanse® on memory and attention in women who had surgery to remove their ovaries to lower their risk for ovarian cancer (risk-reducing salpingo-oophorectomy or RRSO). NOTE: The study offers travel reimbursements and hotel accommodations for those eligible to participate. 

NOTE: This study is no longer enrolling people. 

Olaparib as Adjuvant Treatment in Patients With Germline BRCA Mutated High Risk HER2 Negative Primary Breast Cancer. (OlympiA)

https://www.facingourrisk.org/research-clinical-trials/study/19/olympia-olaparib-adjuvant-therapy-for-brca-related-breast-cancer


The OlympiA trial is the first major study to test a targeted therapy for people with BRCA mutation-associated breast cancer in the adjuvant setting (after surgery) for people with earlier-stage (stage 2 or stage 3) cancers. The OlympiA trial has now completed enrollment. Interim results from OlympiA were presented at the 2021 ASCO Annual Symposium. 

Dose-Response of Aerobic Training in Post-Menopausal Women at High-Risk for Development of Breast Cancer

https://www.facingourrisk.org/research-clinical-trials/study/10/aerobic-training-in-post-menopausal-women-at-high-risk-for-breast-cancer


In this study, researchers wanted to determine the optimal amount of exercise needed to change certain factors associated with breast cancer risk for post-menopausal, high-risk women. 

NOTE:  THIS STUDY ENROLLMENT HAS CLOSED

Prospective Registry Of MultiPlex Testing (PROMPT)

https://www.facingourrisk.org/research-clinical-trials/study/50/prompt


PROMPT is an online research registry for people who have had genetic panel testing (also known as multiplex testing) — a newer form of genetic testing that looks for mutations in several different genes at once. All genes on the panels have been linked to an increased risk of cancer, but some risks are better known than others.

The goal of the PROMPT Registry is to follow people with mutations or variants in genes on these panels, so that patients, physicians, and researchers can more clearly understand these lesser-known risks.

Serum Folate in Patients Treated with Olaparib

https://www.facingourrisk.org/research-clinical-trials/study/99/serum-folate-in-patients-treated-with-olaparib


This is a study looking at folate deficiency (lack of folic acid in the blood) in patients who take the drug olaparib (Lynparza) to treat their advanced ovarian or breast cancer. The main goal of this study is to measure how often and when folate deficiency is most likely to occur; and to learn more about whether giving folic acid supplements (vitamins) will help delay or avoid deficiency in these patients. Folate deficiency can cause side effects and lead to reduction or stopping of treatment with olaparib.  NOTE: This study is no longer enrolling people.

Talazoparib Beyond BRCA (TBB) Trial

https://www.facingourrisk.org/research-clinical-trials/study/35/talazoparib-beyond-brca-tbb-trial


The goal of the study is to evaluate the anti-cancer activity of Talazoparib (a type of treatment known as a PARP inhibitor) in patients with advanced breast cancer with specific genetic mutations based on a blood, saliva, or tumor test. See the clinicaltrials.gov listing for additional information. NOTE: This study is no longer enrolling people.

ARIEL4: A Study of Rucaparib Versus Chemotherapy BRCA Mutant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients

https://www.facingourrisk.org/research-clinical-trials/study/38/ariel4-rucaparib-and-recurrent-ovarian-cancer


ARIEL4 is a treatment study for women with relapsed, high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a BRCA1 or BRCA2 mutation. ARIEL4 is designed to evaluate rucaparib against standard of care chemotherapy in women who have had at least two prior chemotherapy regimens.  UPDATE: THIS STUDY IS NO LONGER ENROLLING PATIENTS

Additional Results on Clinicaltrials.gov
1000 results

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer
NCT ID: NCT02610426 (https://clinicaltrials.gov/study/NCT02610426)

Optimizing Surgical Decisions in Young Adults With Breast Cancer
NCT ID: NCT06275126 (https://clinicaltrials.gov/study/NCT06275126)

Cancer Preventive Vaccine Nous-209 for Lynch Syndrome Patients
NCT ID: NCT05078866 (https://clinicaltrials.gov/study/NCT05078866)

Oncoplastic Partial Mastectomy With Intraoperative Radiation Therapy (IORT) in Early Stage Breast Cancer Patients With Prior History of Chest Wall Radiation.
NCT ID: NCT05289466 (https://clinicaltrials.gov/study/NCT05289466)

Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors
NCT ID: NCT06425926 (https://clinicaltrials.gov/study/NCT06425926)

Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
NCT ID: NCT05693766 (https://clinicaltrials.gov/study/NCT05693766)

Gastrointestinal Biomarkers in Tissue and Biological Fluid Samples From Colorectal Cancer Patients
NCT ID: NCT00899626 (https://clinicaltrials.gov/study/NCT00899626)

Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
NCT ID: NCT04812366 (https://clinicaltrials.gov/study/NCT04812366)

PRE-I-SPY Phase I/Ib Oncology Platform Program
NCT ID: NCT05868226 (https://clinicaltrials.gov/study/NCT05868226)

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
NCT ID: NCT04198766 (https://clinicaltrials.gov/study/NCT04198766)

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer
NCT ID: NCT05756166 (https://clinicaltrials.gov/study/NCT05756166)

Serial Circulating Tumor DNA (ctDNA) Monitoring During Adjuvant Capecitabine in Early Triple-negative Breast Cancer
NCT ID: NCT04768426 (https://clinicaltrials.gov/study/NCT04768426)

Gemcitabine, Cisplatin and Nab-Paclitaxel As Neoadjuvant Treatment for Patients with Resectable or Borderline Resectable Pancreatic Cancer
NCT ID: NCT06423326 (https://clinicaltrials.gov/study/NCT06423326)

Pharmacokinetic Study of Skeletal Muscle Area-based Paclitaxel Infusion in Patients With Breast Cancer
NCT ID: NCT05183126 (https://clinicaltrials.gov/study/NCT05183126)

Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
NCT ID: NCT05842057 (https://clinicaltrials.gov/study/NCT05842057)

Genetic Testing Decision Aid
NCT ID: NCT05470920 (https://clinicaltrials.gov/study/NCT05470920)

Ribociclib and Bicalutamide in AR+ TNBC
NCT ID: NCT03090165 (https://clinicaltrials.gov/study/NCT03090165)

A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
NCT ID: NCT05325866 (https://clinicaltrials.gov/study/NCT05325866)

Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma
NCT ID: NCT05209074 (https://clinicaltrials.gov/study/NCT05209074)

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer
NCT ID: NCT05679674 (https://clinicaltrials.gov/study/NCT05679674)

Prospective Breast Cancer Biospecimen Collection
NCT ID: NCT04074720 (https://clinicaltrials.gov/study/NCT04074720)

PRO1184 for Advanced Solid Tumors
NCT ID: NCT05579366 (https://clinicaltrials.gov/study/NCT05579366)

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
NCT ID: NCT03452774 (https://clinicaltrials.gov/study/NCT03452774)

Talazoparib Monotherapy in PALB2 Mutation Associated Advanced Breast Cancer
NCT ID: NCT04756765 (https://clinicaltrials.gov/study/NCT04756765)

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
NCT ID: NCT05691465 (https://clinicaltrials.gov/study/NCT05691465)

Exercise to Enhance Cardiovascular Health Among Black Prostate Cancer Patients With Androgen Deprivation Therapy
NCT ID: NCT05327465 (https://clinicaltrials.gov/study/NCT05327465)

Magnetic Resonance (MR) Imaging With Hyperpolarized Bicarbonate (13C) to Measure Tissue pH in Prostate Cancer
NCT ID: NCT05851365 (https://clinicaltrials.gov/study/NCT05851365)

A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors
NCT ID: NCT05268666 (https://clinicaltrials.gov/study/NCT05268666)

Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
NCT ID: NCT04703920 (https://clinicaltrials.gov/study/NCT04703920)

CV CARE: CardioVascular Care in PC Patients
NCT ID: NCT06202820 (https://clinicaltrials.gov/study/NCT06202820)

A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
NCT ID: NCT05568420 (https://clinicaltrials.gov/study/NCT05568420)

Breast Cancer Patient Engagement With Patient Reported Outcome Measure Survey
NCT ID: NCT03995082 (https://clinicaltrials.gov/study/NCT03995082)

FK-PC101 as Adjuvant Therapy for Men With High-Risk Prostate Cancer
NCT ID: NCT06636682 (https://clinicaltrials.gov/study/NCT06636682)

SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab
NCT ID: NCT03161431 (https://clinicaltrials.gov/study/NCT03161431)

Surveillance Colonoscopy in Older Adults: The SurvOlderAdults Study
NCT ID: NCT05994482 (https://clinicaltrials.gov/study/NCT05994482)

A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
NCT ID: NCT05123482 (https://clinicaltrials.gov/study/NCT05123482)

EUS Examination Using EndoSound Vision System vs. Standard Echoendoscope
NCT ID: NCT06340620 (https://clinicaltrials.gov/study/NCT06340620)

DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
NCT ID: NCT04567420 (https://clinicaltrials.gov/study/NCT04567420)

Performance of SGM-101 for the Delineation of Primary and Recurrent Tumor and Metastases in Patients Undergoing Surgery for Colorectal Cancer
NCT ID: NCT03659448 (https://clinicaltrials.gov/study/NCT03659448)

A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors
NCT ID: NCT06399757 (https://clinicaltrials.gov/study/NCT06399757)

A Study Called ARAMON to Learn to What Extent Does Study Treatment With Darolutamide Affects Testosterone Levels in Men With Prostate Cancer That Had Not Been Treated With Hormonal Therapy Compared to Treatment With Enzalutamide
NCT ID: NCT05526248 (https://clinicaltrials.gov/study/NCT05526248)

Tumor-Derived FGF19
NCT ID: NCT06068257 (https://clinicaltrials.gov/study/NCT06068257)

Neutrophil Extracellular Traps Formation in Breast Cancer Patients Taking Tamoxifen
NCT ID: NCT05056857 (https://clinicaltrials.gov/study/NCT05056857)

An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2)
NCT ID: NCT05952557 (https://clinicaltrials.gov/study/NCT05952557)

Peer Support For Young Adult Women With High Breast Cancer Risk
NCT ID: NCT04248257 (https://clinicaltrials.gov/study/NCT04248257)

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
NCT ID: NCT06249048 (https://clinicaltrials.gov/study/NCT06249048)

PSMA PET Response Guided SabR in High Risk Pca
NCT ID: NCT06044857 (https://clinicaltrials.gov/study/NCT06044857)

Genomic Services Research Program
NCT ID: NCT02595957 (https://clinicaltrials.gov/study/NCT02595957)

Evaluation of Prostate Specific Membrane Antigen Positron Emission Tomography-Computed Tomography in Active Surveillance for Prostate CancEr
NCT ID: NCT05948657 (https://clinicaltrials.gov/study/NCT05948657)

Avelumab or Hydroxychloroquine With or Without Palbociclib to Eliminate Dormant Breast Cancer
NCT ID: NCT04841148 (https://clinicaltrials.gov/study/NCT04841148)

Selinexor in Maintenance Therapy After Systemic Therapy for Participants with P53 Wild-Type, Advanced or Recurrent Endometrial Carcinoma
NCT ID: NCT05611931 (https://clinicaltrials.gov/study/NCT05611931)

Testing the Addition of Ipatasertib to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) for Stage III or IV Epithelial Ovarian Cancer
NCT ID: NCT05276973 (https://clinicaltrials.gov/study/NCT05276973)

CEM to Reduce Biopsy Rates for Less Than Highly Suspicious Breast Abnormalities: a Prospective Study
NCT ID: NCT05206331 (https://clinicaltrials.gov/study/NCT05206331)

A Study of BMS-986449 With and Without Nivolumab in Participants With Advanced Solid Tumors
NCT ID: NCT05888831 (https://clinicaltrials.gov/study/NCT05888831)

INCMGA00012 in Patients With Previously Treated Unresectable or Metastatic Adenosquamous Pancreatic or Ampullary Cancer
NCT ID: NCT04116073 (https://clinicaltrials.gov/study/NCT04116073)

GammaPod Registry and Quality of Life Nomogram
NCT ID: NCT03562273 (https://clinicaltrials.gov/study/NCT03562273)

Prostate Specific Membrane Antigen (PSMA) or (FACBC) PET/CT Site-Directed Therapy for Treatment of Prostate Cancer, Flu-BLAST-PC Study
NCT ID: NCT04175431 (https://clinicaltrials.gov/study/NCT04175431)

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer
NCT ID: NCT06471673 (https://clinicaltrials.gov/study/NCT06471673)

Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
NCT ID: NCT04573231 (https://clinicaltrials.gov/study/NCT04573231)

Adjuvant Curcumin to Assess Recurrence Free Survival in Patients Who Have Had a Radical Prostatectomy
NCT ID: NCT02064673 (https://clinicaltrials.gov/study/NCT02064673)

Stool Sample Collection Study
NCT ID: NCT06294873 (https://clinicaltrials.gov/study/NCT06294873)

Trial of Radiotherapy in Combination With TTI-101 in Patients With Borderline Resectable Pancreatic Cancer
NCT ID: NCT06141031 (https://clinicaltrials.gov/study/NCT06141031)

A Behavioral Intervention to Promote Primary Prevention and Uterine Preservation in Premenopausal Women With Obesity and Endometrial Hyperplasia
NCT ID: NCT05903131 (https://clinicaltrials.gov/study/NCT05903131)

Tart Cherry Juice as a Dietary Supplement for the Prevention of Paclitaxel-Induced Neuropathy
NCT ID: NCT06268665 (https://clinicaltrials.gov/study/NCT06268665)

The DETECT Study: Discovery and Evaluation of Testing for Endometrial and Ovarian Cancer in Tampons
NCT ID: NCT03538665 (https://clinicaltrials.gov/study/NCT03538665)

Prostate Active Surveillance Study
NCT ID: NCT00756665 (https://clinicaltrials.gov/study/NCT00756665)

Pre-operative SABR With and Without Caloric Restriction for Early Stage Breast Cancer
NCT ID: NCT04959474 (https://clinicaltrials.gov/study/NCT04959474)

A Phase I Dual Dose Escalation Study of Radiation and Nab-Paclitaxel in Patients With Unresectable and Borderline Resectable Pancreatic Cancer
NCT ID: NCT02207465 (https://clinicaltrials.gov/study/NCT02207465)

Manual Lymphatic Drainage Breast Massage in Breast Cancer Patients After Breast Conserving Surgery
NCT ID: NCT06297265 (https://clinicaltrials.gov/study/NCT06297265)

Maternal Cancer Diagnosis and Treatment During Pregnancy:a Database for Maternal, Fetal, and Neonatal Outcomes
NCT ID: NCT02749474 (https://clinicaltrials.gov/study/NCT02749474)

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
NCT ID: NCT04449874 (https://clinicaltrials.gov/study/NCT04449874)

Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer
NCT ID: NCT06437574 (https://clinicaltrials.gov/study/NCT06437574)

Study of Screening Brain MRIs in Stage IV Breast Cancer
NCT ID: NCT05115474 (https://clinicaltrials.gov/study/NCT05115474)

Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
NCT ID: NCT02918474 (https://clinicaltrials.gov/study/NCT02918474)

A Phase 1/2a Study of IMM-1-104 in Participants With Previously Treated, RAS-Mutant, Advanced or Metastatic Solid Tumors
NCT ID: NCT05585320 (https://clinicaltrials.gov/study/NCT05585320)

Phase 3 Study of RMC-6236 in Patients with Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT06625320 (https://clinicaltrials.gov/study/NCT06625320)

Impact of Topical Tranexamic Acid in Breast Reconstruction
NCT ID: NCT05807074 (https://clinicaltrials.gov/study/NCT05807074)

Collection of Specimens and Clinical Data for Patients With Recurrent or Metastatic Breast Cancer or Male Breast Cancer
NCT ID: NCT06217874 (https://clinicaltrials.gov/study/NCT06217874)

Tucatinib+Trastuzumab+Eribulin in HER2+ MBC
NCT ID: NCT05458674 (https://clinicaltrials.gov/study/NCT05458674)

Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery
NCT ID: NCT05111574 (https://clinicaltrials.gov/study/NCT05111574)

A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
NCT ID: NCT05361174 (https://clinicaltrials.gov/study/NCT05361174)

Developing an Internet-Delivered Sexual Health Program for Breast Cancer Survivors, SHINE Trial
NCT ID: NCT06216574 (https://clinicaltrials.gov/study/NCT06216574)

Hepatic Artery Chemotherapy for Patients With Localized Pancreas Cancer
NCT ID: NCT05634720 (https://clinicaltrials.gov/study/NCT05634720)

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors
NCT ID: NCT05902520 (https://clinicaltrials.gov/study/NCT05902520)

A Single-arm Phase II Trial of SAcituzumab Govitecan and Trastuzumab for HER2+ Metastatic Breast Cancer After Trastuzumab dEruxtEcaN (SATEEN)
NCT ID: NCT06100874 (https://clinicaltrials.gov/study/NCT06100874)

Safety of RAD301 in Healthy Human Volunteers and Patients With Pancreatic Cancer
NCT ID: NCT05799274 (https://clinicaltrials.gov/study/NCT05799274)

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer
NCT ID: NCT06253520 (https://clinicaltrials.gov/study/NCT06253520)

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
NCT ID: NCT06393374 (https://clinicaltrials.gov/study/NCT06393374)

Talking to Employers and Medical Staff About Breast Cancer Treatment and Your Job
NCT ID: NCT03572374 (https://clinicaltrials.gov/study/NCT03572374)

Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
NCT ID: NCT03866382 (https://clinicaltrials.gov/study/NCT03866382)

BOLD-100 in Combination with FOLFOX for the Treatment of Advanced Solid Tumours
NCT ID: NCT04421820 (https://clinicaltrials.gov/study/NCT04421820)

Psychosexual Educational Partners Program (PEPP)
NCT ID: NCT06253182 (https://clinicaltrials.gov/study/NCT06253182)

Study of Avutometinib (VS-6766) +Defactinib With Gemcitabine and Nab-paclitaxel in Patients With Pancreatic Cancer
NCT ID: NCT05669482 (https://clinicaltrials.gov/study/NCT05669482)

Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer
NCT ID: NCT05563220 (https://clinicaltrials.gov/study/NCT05563220)

Turkey Tail Mushroom for Treating Post-Menopausal Women with HER2-Negative ER-Positive Breast Cancer Undergoing Surgery
NCT ID: NCT06450873 (https://clinicaltrials.gov/study/NCT06450873)

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)
NCT ID: NCT04896073 (https://clinicaltrials.gov/study/NCT04896073)

Trial of Pre-operative Neratinib and Endocrine Therapy With Trastuzumab in ER-Positive, HER-2 Positive Breast Cancers
NCT ID: NCT04886531 (https://clinicaltrials.gov/study/NCT04886531)

Breaking Through the Brain Fog: An Online Research Study
NCT ID: NCT05444231 (https://clinicaltrials.gov/study/NCT05444231)

Focused Ultrasound and Gemcitabine in Breast Cancer
NCT ID: NCT04796220 (https://clinicaltrials.gov/study/NCT04796220)

Acolbifene Versus Low Dose Tamoxifen for the Prevention of Breast Cancer in Premenopausal Women at High Risk for Development of Breast Cancer
NCT ID: NCT05941520 (https://clinicaltrials.gov/study/NCT05941520)

Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
NCT ID: NCT05631574 (https://clinicaltrials.gov/study/NCT05631574)

ZEN-3694, Enzalutamide, and Pembrolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04471974 (https://clinicaltrials.gov/study/NCT04471974)

A Dose Escalation Study of HBI-2438 in Patients With Solid Tumors Harboring KRAS G12C Mutation
NCT ID: NCT05485974 (https://clinicaltrials.gov/study/NCT05485974)

Optimizing a mHealth Physical Activity Intervention With Mindful Awareness Lessons in Breast Cancer Survivors
NCT ID: NCT05931874 (https://clinicaltrials.gov/study/NCT05931874)

A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
NCT ID: NCT06312176 (https://clinicaltrials.gov/study/NCT06312176)

Diagnosing and Treating Low Blood Sugar Levels
NCT ID: NCT00001276 (https://clinicaltrials.gov/study/NCT00001276)

PReclude Infection EVEnts With No Prophylaxis Transperineal Biopsy 2
NCT ID: NCT04815876 (https://clinicaltrials.gov/study/NCT04815876)

Developing and Evaluating Culturally Relevant Interventions to Improve Breast Cancer Screening
NCT ID: NCT05665660 (https://clinicaltrials.gov/study/NCT05665660)

First in Human Phase 1 Study of AG01 Anti-Progranulin/GP88 Antibody in Advanced Solid Tumor Malignancies
NCT ID: NCT05627960 (https://clinicaltrials.gov/study/NCT05627960)

SafeHeal Diverting Ileostomy Pivotal Study
NCT ID: NCT06152276 (https://clinicaltrials.gov/study/NCT06152276)

Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
NCT ID: NCT05983276 (https://clinicaltrials.gov/study/NCT05983276)

T-reg Function Changes: a Novel Immune Regulatory Effect Underlying Benefit of Statin Use on Lethal Prostate Cancer
NCT ID: NCT05586360 (https://clinicaltrials.gov/study/NCT05586360)

A Phase 1 Trial of ZN-A-1041 Enteric Capsules or Combination in Patients With HER2-Positive Advanced Solid Tumors
NCT ID: NCT05593094 (https://clinicaltrials.gov/study/NCT05593094)

A Study to Prevent and Improve Sexual Health Concerns for People With Breast Cancer
NCT ID: NCT05910294 (https://clinicaltrials.gov/study/NCT05910294)

A Study of Intra-operative Imaging in Women With Ovarian Cancer
NCT ID: NCT04878094 (https://clinicaltrials.gov/study/NCT04878094)

PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer
NCT ID: NCT04329494 (https://clinicaltrials.gov/study/NCT04329494)

Comparing Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS-HIPEC) Using Mitomycin-C Versus Melphalan for Colorectal Peritoneal Carcinomatosis
NCT ID: NCT03073694 (https://clinicaltrials.gov/study/NCT03073694)

Telephone-Based Intervention in Increasing Adherence to Adjuvant Hormonal Therapy in Patients With Breast Cancer
NCT ID: NCT02400060 (https://clinicaltrials.gov/study/NCT02400060)

Long-Term Prospective Registry in Prostate Cancer Patients From Diverse Urology Practice Settings Following Prolaris® Testing
NCT ID: NCT04404894 (https://clinicaltrials.gov/study/NCT04404894)

A Neoadjuvant Study of Tislelizumab and SX-682 for Resectable Pancreas Cancer
NCT ID: NCT05604560 (https://clinicaltrials.gov/study/NCT05604560)

Experimental PET Imaging Scans Before Cancer Surgery to Study the Amount of PET Tracer Accumulated in Normal and Cancer Tissues
NCT ID: NCT04147494 (https://clinicaltrials.gov/study/NCT04147494)

A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
NCT ID: NCT06179160 (https://clinicaltrials.gov/study/NCT06179160)

Dose-Escalation Study of Cabozantinib in Combination With Lutetium-177 (177Lu)-PSMA-617 in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT05613894 (https://clinicaltrials.gov/study/NCT05613894)

Single Cell Immune and Non-immune Correlates of Response to Neoadjuvant Abemaciclib
NCT ID: NCT04614194 (https://clinicaltrials.gov/study/NCT04614194)

Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
NCT ID: NCT05040360 (https://clinicaltrials.gov/study/NCT05040360)

Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
NCT ID: NCT06239194 (https://clinicaltrials.gov/study/NCT06239194)

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types
NCT ID: NCT05000294 (https://clinicaltrials.gov/study/NCT05000294)

A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05150691 (https://clinicaltrials.gov/study/NCT05150691)

MRI Screening in Men at High Risk of Developing Prostate Cancer
NCT ID: NCT05608694 (https://clinicaltrials.gov/study/NCT05608694)

Study of a Rapid Triadic Communication Intention Elicitation Intervention to Improve Supportive Oncology Care Delivery
NCT ID: NCT05995860 (https://clinicaltrials.gov/study/NCT05995860)

Outcomes of Focal Ablation for Prostate Cancer
NCT ID: NCT05478694 (https://clinicaltrials.gov/study/NCT05478694)

CALM: Managing Distress in Malignant Brain Cancer
NCT ID: NCT06180460 (https://clinicaltrials.gov/study/NCT06180460)

Association of Plant-based Diet and Gut Microbiome Signature with Response to Neoadjuvant Therapy in Pancreatic Ductal Adenocarcinoma
NCT ID: NCT06595160 (https://clinicaltrials.gov/study/NCT06595160)

Diagnostic Strategies, Risk Assessment and Progression of Pancreatic Cysts
NCT ID: NCT04473794 (https://clinicaltrials.gov/study/NCT04473794)

Data Collection for the Assessment of Acute and Late Normal Tissue in Patients Treated with Proton Therapy
NCT ID: NCT00991094 (https://clinicaltrials.gov/study/NCT00991094)

Topical Dermaprazole for Radiation Dermatitis in Breast Cancer and Head and Neck Cancer Patients (TOPAZ)
NCT ID: NCT05269160 (https://clinicaltrials.gov/study/NCT05269160)

CyberKnife Dose Escalation Prostate Cancer Trial
NCT ID: NCT03822494 (https://clinicaltrials.gov/study/NCT03822494)

An Enhanced Vaginal Dilator to Reduce Radiation-Induced Vaginal Stenosis
NCT ID: NCT03876860 (https://clinicaltrials.gov/study/NCT03876860)

Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
NCT ID: NCT04697576 (https://clinicaltrials.gov/study/NCT04697576)

4:3 Intermittent Fasting Intervention in Adults With Breast Cancer and Overweight or Obesity
NCT ID: NCT06399276 (https://clinicaltrials.gov/study/NCT06399276)

Role of Diet on the Microbiome of the Digestive System
NCT ID: NCT04666727 (https://clinicaltrials.gov/study/NCT04666727)

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer
NCT ID: NCT05722327 (https://clinicaltrials.gov/study/NCT05722327)

F-Tryptophan PET/CT in Human Cancers
NCT ID: NCT05556473 (https://clinicaltrials.gov/study/NCT05556473)

A Study in Participants With Advanced Cancers Associated With Expression of DLL3 (MK-6070-001/HPN328-4001)
NCT ID: NCT04471727 (https://clinicaltrials.gov/study/NCT04471727)

PSMA-PET Imaging for Detecting Early Metastatic Prostate Cancer in Men w/ High Decipher Test Scores
NCT ID: NCT03495427 (https://clinicaltrials.gov/study/NCT03495427)

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
NCT ID: NCT04294927 (https://clinicaltrials.gov/study/NCT04294927)

A Study of Blood Pressure Control During Cancer Treatment
NCT ID: NCT06023576 (https://clinicaltrials.gov/study/NCT06023576)

Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
NCT ID: NCT03861676 (https://clinicaltrials.gov/study/NCT03861676)

Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
NCT ID: NCT04808427 (https://clinicaltrials.gov/study/NCT04808427)

Breast Elasticity Imaging During Neoadjuvant Chemotherapy
NCT ID: NCT04824027 (https://clinicaltrials.gov/study/NCT04824027)

Epidemiological Study to Monitor Study Participants With Resected Stage II (High Risk) or Stage III Colorectal Cancer for Circulating Tumor DNA Before, During and After Their Treatment With Adjuvant Chemotherapy
NCT ID: NCT04813627 (https://clinicaltrials.gov/study/NCT04813627)

Marker Driven Selection of Patients for Prostate Biopsy and Management
NCT ID: NCT04240327 (https://clinicaltrials.gov/study/NCT04240327)

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer (Sub-Study A)
NCT ID: NCT05548127 (https://clinicaltrials.gov/study/NCT05548127)

Registry of Patients Undergoing Cryoablation for Early Stage Breast Cancer
NCT ID: NCT06387173 (https://clinicaltrials.gov/study/NCT06387173)

A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer
NCT ID: NCT04709276 (https://clinicaltrials.gov/study/NCT04709276)

Bright White Light Therapy in Reducing Cancer-Related Fatigue and Depression in Advanced Prostate Cancer Patients Undergoing Treatment With ADT Combination Therapy
NCT ID: NCT05869682 (https://clinicaltrials.gov/study/NCT05869682)

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas
NCT ID: NCT02451982 (https://clinicaltrials.gov/study/NCT02451982)

Brain Health in Breast Cancer Survivors
NCT ID: NCT04297020 (https://clinicaltrials.gov/study/NCT04297020)

Collecting Tissue Samples for Future Research From Women Undergoing Surgery for Breast Cancer
NCT ID: NCT00898131 (https://clinicaltrials.gov/study/NCT00898131)

The Effect of Acupuncture on Cancer-Related Cognitive Difficulties
NCT ID: NCT04837820 (https://clinicaltrials.gov/study/NCT04837820)

Evaluation of Endoscopic Ultrasound-Guided Radiofrequency Ablation for the Management of Pancreatic Tumors, ERASE Study
NCT ID: NCT05961982 (https://clinicaltrials.gov/study/NCT05961982)

Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
NCT ID: NCT05828082 (https://clinicaltrials.gov/study/NCT05828082)

Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
NCT ID: NCT05806931 (https://clinicaltrials.gov/study/NCT05806931)

Testing a New Imaging Agent to Identify Cancer
NCT ID: NCT04692831 (https://clinicaltrials.gov/study/NCT04692831)

Role of TXA in Patients Undergoing Breast Free Flap Reconstruction
NCT ID: NCT06428682 (https://clinicaltrials.gov/study/NCT06428682)

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors
NCT ID: NCT06188520 (https://clinicaltrials.gov/study/NCT06188520)

A Multi-Center, Prospective, Observational Study of Patients Being Treated With ORGOVYX
NCT ID: NCT05467176 (https://clinicaltrials.gov/study/NCT05467176)

Prospective Collection of Samples to Enable the Development of Natera Screening Assay for Early Cancer Detection
NCT ID: NCT06620627 (https://clinicaltrials.gov/study/NCT06620627)

Comparing Supplemental Topical Agents for the Treatment of Acute Radiation Dermatitis in Patients With Breast Cancer
NCT ID: NCT05340673 (https://clinicaltrials.gov/study/NCT05340673)

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy
NCT ID: NCT05477576 (https://clinicaltrials.gov/study/NCT05477576)

Breast Mesh Used in Two-staged Breast Reconstruction
NCT ID: NCT04967976 (https://clinicaltrials.gov/study/NCT04967976)

TRANBERG® Transperineal MR/US Fusion Laser--Induced Thermal Therapy for Men With Prostate Cancer
NCT ID: NCT05698576 (https://clinicaltrials.gov/study/NCT05698576)

A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors
NCT ID: NCT05812027 (https://clinicaltrials.gov/study/NCT05812027)

Breast Cancer Pre-habilitation and Prospective Surveillance to Prevent, Detect, and Optimize Physical and Function
NCT ID: NCT06081127 (https://clinicaltrials.gov/study/NCT06081127)

Choosing Ovarian Preservation or Removal Before Surgery for Endometrial Cancer
NCT ID: NCT04569773 (https://clinicaltrials.gov/study/NCT04569773)

Pembrolizumab and Carboplatin for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04387227 (https://clinicaltrials.gov/study/NCT04387227)

Intraoperative Use of ClearEdge Device in Breast Conserving Surgery
NCT ID: NCT05456373 (https://clinicaltrials.gov/study/NCT05456373)

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC
NCT ID: NCT04701476 (https://clinicaltrials.gov/study/NCT04701476)

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma
NCT ID: NCT06508827 (https://clinicaltrials.gov/study/NCT06508827)

REJOIN Trial for Older Breast Cancer Survivors
NCT ID: NCT03955627 (https://clinicaltrials.gov/study/NCT03955627)

A Study of CPI-0209 in Patients With Advanced Solid Tumors and Lymphomas
NCT ID: NCT04104776 (https://clinicaltrials.gov/study/NCT04104776)

ASk Questions in GYnecologic Oncology (ASQ-GYO)
NCT ID: NCT06339827 (https://clinicaltrials.gov/study/NCT06339827)

Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma
NCT ID: NCT04375527 (https://clinicaltrials.gov/study/NCT04375527)

Comprehensive Outcomes for After Cancer Health
NCT ID: NCT05349227 (https://clinicaltrials.gov/study/NCT05349227)

A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
NCT ID: NCT05208762 (https://clinicaltrials.gov/study/NCT05208762)

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors
NCT ID: NCT05389462 (https://clinicaltrials.gov/study/NCT05389462)

Abiraterone and Prednisone or Darolutamide for the Treatment of Advanced Prostate Cancer
NCT ID: NCT06173362 (https://clinicaltrials.gov/study/NCT06173362)

A Study of Tobemstomig + Nab-Paclitaxel Compared With Pembrolizumab + Nab-Paclitaxel in Participants With Previously Untreated, PD-L1-Positive, Locally-Advanced Unresectable or Metastatic Triple-Negative Breast Cancer
NCT ID: NCT05852691 (https://clinicaltrials.gov/study/NCT05852691)

A Study of Zolbetuximab With Chemotherapy in Adults With Pancreatic Cancer
NCT ID: NCT06396091 (https://clinicaltrials.gov/study/NCT06396091)

KK-LC-1 TCR-T Cell Therapy for Gastric, Breast, Cervical, and Lung Cancer
NCT ID: NCT05483491 (https://clinicaltrials.gov/study/NCT05483491)

Study of INKmune in Patients With mCRPC (CaRe Prostate)
NCT ID: NCT06056791 (https://clinicaltrials.gov/study/NCT06056791)

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy
NCT ID: NCT05747794 (https://clinicaltrials.gov/study/NCT05747794)

Enfortumab Vedotin As Monotherapy in Patients with Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04754191 (https://clinicaltrials.gov/study/NCT04754191)

Opioid-Sparing Effects of Nurse-Delivered Hypnosis During Breast Cancer Surgery
NCT ID: NCT05766891 (https://clinicaltrials.gov/study/NCT05766891)

Testing the Safety of the Anti-Cancer Drugs Durvalumab and Olaparib During Radiation Therapy for Locally Advanced Unresectable Pancreatic Cancer
NCT ID: NCT05411094 (https://clinicaltrials.gov/study/NCT05411094)

A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
NCT ID: NCT06447662 (https://clinicaltrials.gov/study/NCT06447662)

A RAndomizeD Intervention for Cardiovascular and Lifestyle Risk Factors in Prostate Cancer Patients
NCT ID: NCT03127631 (https://clinicaltrials.gov/study/NCT03127631)

The Role of MicroRNA in the Diagnosis, Prognosis and Response to Treatment in Pancreatic Cancer
NCT ID: NCT04406831 (https://clinicaltrials.gov/study/NCT04406831)

Genetic Predisposition Testing Program for Pancreatic Neuroendocrine Neoplasms
NCT ID: NCT05746182 (https://clinicaltrials.gov/study/NCT05746182)

Surgical Excision vs Neoadjuvant Radiotherapy+Delayed Surgical Excision of Ductal Carcinoma
NCT ID: NCT03909282 (https://clinicaltrials.gov/study/NCT03909282)

Functional Precision Oncology to Predict, Prevent, and Treat Early Metastatic Recurrence of TNBC
NCT ID: NCT05464082 (https://clinicaltrials.gov/study/NCT05464082)

Androgen Receptor Directed Therapy on Cognitive Function in Patients Treated With Darolutamide or Enzalutamide
NCT ID: NCT04335682 (https://clinicaltrials.gov/study/NCT04335682)

Ultrahypofractionation and Normal Tissue Toxicity
NCT ID: NCT05912231 (https://clinicaltrials.gov/study/NCT05912231)

Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors
NCT ID: NCT04771520 (https://clinicaltrials.gov/study/NCT04771520)

Pancreatic Cancer Screening for At-risk Individuals
NCT ID: NCT05006131 (https://clinicaltrials.gov/study/NCT05006131)

Study of IK-595 in RAS- or RAF-altered Advanced Tumors
NCT ID: NCT06270082 (https://clinicaltrials.gov/study/NCT06270082)

Breast Margin Study: Routine Cavity Shave Margins Vs. Selective Margins Using Savi Scout®
NCT ID: NCT05825482 (https://clinicaltrials.gov/study/NCT05825482)

Salud en Mis Manos - Breast and Cervical Cancer Prevention and Early Detection - Expansion 2
NCT ID: NCT06082882 (https://clinicaltrials.gov/study/NCT06082882)

Prospective Evaluation of Targeted Axillary Dissection (TAD)
NCT ID: NCT04998682 (https://clinicaltrials.gov/study/NCT04998682)

A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors
NCT ID: NCT05653882 (https://clinicaltrials.gov/study/NCT05653882)

A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
NCT ID: NCT06099782 (https://clinicaltrials.gov/study/NCT06099782)

Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
NCT ID: NCT05856773 (https://clinicaltrials.gov/study/NCT05856773)

Study of AZD9574 as Monotherapy and in Combination With Anti-cancer Agents in Participants With Advanced Solid Malignancies
NCT ID: NCT05417594 (https://clinicaltrials.gov/study/NCT05417594)

A Study to Compare the Effectiveness of Two Types of Ultrasound Technologies in Women Who Have Had Breast Cancer
NCT ID: NCT05408260 (https://clinicaltrials.gov/study/NCT05408260)

Anti-inflammatory Drugs and Serum Prostate-Specific Antigen Test
NCT ID: NCT05629494 (https://clinicaltrials.gov/study/NCT05629494)

MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer
NCT ID: NCT05076760 (https://clinicaltrials.gov/study/NCT05076760)

Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer
NCT ID: NCT04134260 (https://clinicaltrials.gov/study/NCT04134260)

Contrast Enhanced Endoscopic Ultrasound in Pancreas Lesions
NCT ID: NCT04324294 (https://clinicaltrials.gov/study/NCT04324294)

Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer
NCT ID: NCT06253494 (https://clinicaltrials.gov/study/NCT06253494)

Collection of Blood in Studying Metabolites in Patients With Prostate Cancer
NCT ID: NCT03485794 (https://clinicaltrials.gov/study/NCT03485794)

Bariatric Education for Women With Obesity and Endometrial Cancer
NCT ID: NCT05396794 (https://clinicaltrials.gov/study/NCT05396794)

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations
NCT ID: NCT04550494 (https://clinicaltrials.gov/study/NCT04550494)

Discontinuation of Maintenance HER-2 Directed Therapy in Long-Term Survivors of Metastatic HER-2 Positive Breast Cancer
NCT ID: NCT05959291 (https://clinicaltrials.gov/study/NCT05959291)

Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
NCT ID: NCT05092373 (https://clinicaltrials.gov/study/NCT05092373)

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer
NCT ID: NCT05319873 (https://clinicaltrials.gov/study/NCT05319873)

Genetic Testing in African Americans
NCT ID: NCT05591131 (https://clinicaltrials.gov/study/NCT05591131)

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06318273 (https://clinicaltrials.gov/study/NCT06318273)

Sensory Restoration After DIEP Flap Neurotization
NCT ID: NCT04533373 (https://clinicaltrials.gov/study/NCT04533373)

A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2
NCT ID: NCT06003231 (https://clinicaltrials.gov/study/NCT06003231)

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab
NCT ID: NCT05029882 (https://clinicaltrials.gov/study/NCT05029882)

Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
NCT ID: NCT06106282 (https://clinicaltrials.gov/study/NCT06106282)

Trial of Neoadjuvant and Adjuvant Nivolumab and BMS-813160 With or Without GVAX for Locally Advanced Pancreatic Ductal Adenocarcinomas.
NCT ID: NCT03767582 (https://clinicaltrials.gov/study/NCT03767582)

The Purpose of This Study is to Determine the Frequency of Colorectal Cancer in Male and Female Endurance Athletes Between the Ages of 35 and 50
NCT ID: NCT05419531 (https://clinicaltrials.gov/study/NCT05419531)

A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Subjects With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression
NCT ID: NCT05736731 (https://clinicaltrials.gov/study/NCT05736731)

Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
NCT ID: NCT05803382 (https://clinicaltrials.gov/study/NCT05803382)

A Study of TAK-186 (Also Known as MVC-101) in Adults With Advanced or Metastatic Cancer
NCT ID: NCT04844073 (https://clinicaltrials.gov/study/NCT04844073)

Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)
NCT ID: NCT02861573 (https://clinicaltrials.gov/study/NCT02861573)

Study of an eHealth Delivery Alternative for Cancer Genetic Testing for Hereditary Predisposition in Metastatic Cancer Patients
NCT ID: NCT04353973 (https://clinicaltrials.gov/study/NCT04353973)

Open-Label Study to Evaluate the Safety, Tolerability, PK, and Efficacy of INX-315 in Patients With Advanced Cancer
NCT ID: NCT05735080 (https://clinicaltrials.gov/study/NCT05735080)

Shared Decision-making and Colorectal Cancer Screening
NCT ID: NCT04748380 (https://clinicaltrials.gov/study/NCT04748380)

With Love, Grandma ("Con Cariño, Abuelita") Pilot Study
NCT ID: NCT05721976 (https://clinicaltrials.gov/study/NCT05721976)

A Phase I/II Trial of Vemurafenib and Metformin to Melanoma Patients
NCT ID: NCT01638676 (https://clinicaltrials.gov/study/NCT01638676)

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer
NCT ID: NCT05020860 (https://clinicaltrials.gov/study/NCT05020860)

At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients with Advanced Cancer
NCT ID: NCT05969860 (https://clinicaltrials.gov/study/NCT05969860)

64Cu-SAR-BBN and 67CU SAR-BBN for Identification and Treatment of Gastrin Releasing Peptide Receptor (GRPR)-Expressing Metastatic Castrate Resistant Prostate Cancer in Patients Who Are Ineligible for Therapy With 177Lu-PSMA-617 (COMBAT)
NCT ID: NCT05633160 (https://clinicaltrials.gov/study/NCT05633160)

Men Moving Forward: A Lifestyle Program for African-American Prostate Cancer Survivors
NCT ID: NCT03971591 (https://clinicaltrials.gov/study/NCT03971591)

KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
NCT ID: NCT06411691 (https://clinicaltrials.gov/study/NCT06411691)

A Study of the Use of the Medtronic Pump and Codman Catheter to Give Chemotherapy to Patients With Colorectal Carcinoma or Cholangiocarcinoma
NCT ID: NCT04668976 (https://clinicaltrials.gov/study/NCT04668976)

INCMGA00012 and Pelareorep for the Treatment of Metastatic Triple Negative Breast Cancer, IRENE Study
NCT ID: NCT04445844 (https://clinicaltrials.gov/study/NCT04445844)

Radiation Therapy and IRreversible Electroporation for Intermediate Risk Prostate Cancer (RTIRE)
NCT ID: NCT05345444 (https://clinicaltrials.gov/study/NCT05345444)

A Registry Study of Breast Microseed Treatment
NCT ID: NCT02701244 (https://clinicaltrials.gov/study/NCT02701244)

Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
NCT ID: NCT04956640 (https://clinicaltrials.gov/study/NCT04956640)

Development of Patient Derived Xenografts (PDX) in Patients With Breast Cancer
NCT ID: NCT04703244 (https://clinicaltrials.gov/study/NCT04703244)

Adoptive T Cell Immunotherapy for Advanced Melanoma Using Engineered Lymphocytes
NCT ID: NCT02870244 (https://clinicaltrials.gov/study/NCT02870244)

SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
NCT ID: NCT04599140 (https://clinicaltrials.gov/study/NCT04599140)

Feasibility of the LUM Imaging System for Detection of Gastrointestinal Cancers
NCT ID: NCT02584244 (https://clinicaltrials.gov/study/NCT02584244)

A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.
NCT ID: NCT06022029 (https://clinicaltrials.gov/study/NCT06022029)

alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells
NCT ID: NCT03692429 (https://clinicaltrials.gov/study/NCT03692429)

Infusion of Autologous T Cells Engineered to Target FSH Receptor in Recurrent Ovarian Cancer
NCT ID: NCT05316129 (https://clinicaltrials.gov/study/NCT05316129)

A Phase II Trial of PD-L1 Therapy Combined with Anti-VEGF Therapy in Unresectable or Metastatic Melanoma
NCT ID: NCT04356729 (https://clinicaltrials.gov/study/NCT04356729)

Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT ID: NCT05919329 (https://clinicaltrials.gov/study/NCT05919329)

Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
NCT ID: NCT05367440 (https://clinicaltrials.gov/study/NCT05367440)

Rectal Spacers in Prostate Cancer Patients Undergoing Radiation Therapy
NCT ID: NCT06599476 (https://clinicaltrials.gov/study/NCT06599476)

Eye Plaque Brachytherapy for Ocular Melanoma
NCT ID: NCT06432660 (https://clinicaltrials.gov/study/NCT06432660)

A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma
NCT ID: NCT06594991 (https://clinicaltrials.gov/study/NCT06594991)

A Study of CBX 12 in Subjects With Platinum Resistant or Refractory Ovarian Cancer
NCT ID: NCT06315491 (https://clinicaltrials.gov/study/NCT06315491)

Trial to Compare MRI-guided Precision Prone Irradiation (PPI) Versus CT-guided Breast Irradiation
NCT ID: NCT05731791 (https://clinicaltrials.gov/study/NCT05731791)

Saruparib (AZD5305) vs Placebo in Men With Metastatic Castration-Sensitive Prostate Cancer Receiving Physician's Choice New Hormonal Agents
NCT ID: NCT06120491 (https://clinicaltrials.gov/study/NCT06120491)

Ribociclib And Endocrine Treatment of Physician's Choice for Locoregional Recurrent, Resected Hormone Receptor Positive HER2 Negative Breast Cancer
NCT ID: NCT05467891 (https://clinicaltrials.gov/study/NCT05467891)

High Dose Omeprazole in Patients With Pancreatic Cancer
NCT ID: NCT04930991 (https://clinicaltrials.gov/study/NCT04930991)

A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
NCT ID: NCT04903873 (https://clinicaltrials.gov/study/NCT04903873)

UroLift System With SAbR for Prostate Cancer and BPH
NCT ID: NCT05311527 (https://clinicaltrials.gov/study/NCT05311527)

Associations Between Chemotherapy-Induced Nausea in Patients With Genitourinary, Sarcoma or Melanoma Cancers and Changes in Gut Microbiome: Potential for Precision Therapeutics
NCT ID: NCT05819827 (https://clinicaltrials.gov/study/NCT05819827)

Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer
NCT ID: NCT05034627 (https://clinicaltrials.gov/study/NCT05034627)

Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection
NCT ID: NCT05413850 (https://clinicaltrials.gov/study/NCT05413850)

A Study to Evaluate ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Unresectable or Metastatic Melanoma
NCT ID: NCT06054555 (https://clinicaltrials.gov/study/NCT06054555)

Clinical Trial of Green Tea Catechins in Men on Active Surveillance
NCT ID: NCT04300855 (https://clinicaltrials.gov/study/NCT04300855)

A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)
NCT ID: NCT06136650 (https://clinicaltrials.gov/study/NCT06136650)

EMBRACE: Exercising Together
NCT ID: NCT06049355 (https://clinicaltrials.gov/study/NCT06049355)

Study to Evaluate LB-LR1109 for the Treatment of Solid Tumors
NCT ID: NCT06332755 (https://clinicaltrials.gov/study/NCT06332755)

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations
NCT ID: NCT05907304 (https://clinicaltrials.gov/study/NCT05907304)

Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
NCT ID: NCT03543969 (https://clinicaltrials.gov/study/NCT03543969)

Familial Investigations of Childhood Cancer Predisposition
NCT ID: NCT03050268 (https://clinicaltrials.gov/study/NCT03050268)

Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
NCT ID: NCT05308901 (https://clinicaltrials.gov/study/NCT05308901)

Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma
NCT ID: NCT06121180 (https://clinicaltrials.gov/study/NCT06121180)

Physical Function During ARSI Treatment
NCT ID: NCT05612880 (https://clinicaltrials.gov/study/NCT05612880)

FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
NCT ID: NCT06244004 (https://clinicaltrials.gov/study/NCT06244004)

Fasting Mimicking Diet in Chemotherapy of Gynecologic Malignancies
NCT ID: NCT06376604 (https://clinicaltrials.gov/study/NCT06376604)

Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer
NCT ID: NCT01050504 (https://clinicaltrials.gov/study/NCT01050504)

Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
NCT ID: NCT00899301 (https://clinicaltrials.gov/study/NCT00899301)

Early Onset Colorectal Cancer Detection
NCT ID: NCT06342401 (https://clinicaltrials.gov/study/NCT06342401)

PRO1107 in Patients With Advanced Solid Tumors
NCT ID: NCT06171789 (https://clinicaltrials.gov/study/NCT06171789)

Effects of Tirzepatide on Blood, Imaging and Breast Tissue Biomarkers
NCT ID: NCT06485089 (https://clinicaltrials.gov/study/NCT06485089)

Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
NCT ID: NCT05143229 (https://clinicaltrials.gov/study/NCT05143229)

Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors
NCT ID: NCT05896189 (https://clinicaltrials.gov/study/NCT05896189)

International Registry for Men With Advanced Prostate Cancer (IRONMAN)
NCT ID: NCT03151629 (https://clinicaltrials.gov/study/NCT03151629)

Interstitial Assessment of Architectural Heterogeneity in Prostate Cancer Using a Fine Needle Photoacoustic Probe
NCT ID: NCT05965180 (https://clinicaltrials.gov/study/NCT05965180)

Digital Tomosynthesis Mammography and Digital Mammography in Screening Patients for Breast Cancer
NCT ID: NCT03233191 (https://clinicaltrials.gov/study/NCT03233191)

A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery
NCT ID: NCT05608291 (https://clinicaltrials.gov/study/NCT05608291)

Evaluation of CyberKnife Stereotactic Radiotherapy in Prostate Cancer
NCT ID: NCT02016248 (https://clinicaltrials.gov/study/NCT02016248)

Contrast-enhanced Spectral Mammography (CESM) Breast Cancer Screening
NCT ID: NCT04904757 (https://clinicaltrials.gov/study/NCT04904757)

Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
NCT ID: NCT00830557 (https://clinicaltrials.gov/study/NCT00830557)

Postmarketing Prospective Study of Melanoma Patients Treated With IMLYGIC® to Characterize Risk of Herpetic Infection
NCT ID: NCT02910557 (https://clinicaltrials.gov/study/NCT02910557)

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies
NCT ID: NCT04678648 (https://clinicaltrials.gov/study/NCT04678648)

Dual BET and CBP/p300 Inhibitor in Patients With Targeted Advanced Solid Tumors and Hematological Malignancies
NCT ID: NCT05488548 (https://clinicaltrials.gov/study/NCT05488548)

MIRAI-MRI: Comparing Screening MRI for Patients at High Risk for Breast Cancer Identified by Mirai and Tyrer-Cuzick
NCT ID: NCT05968157 (https://clinicaltrials.gov/study/NCT05968157)

Study of RP1 Monotherapy and RP1 in Combination With Nivolumab
NCT ID: NCT03767348 (https://clinicaltrials.gov/study/NCT03767348)

A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
NCT ID: NCT02632448 (https://clinicaltrials.gov/study/NCT02632448)

Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib in Combination With Trastuzumab Deruxtecan or With Trastuzumab Emtansine and to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
NCT ID: NCT06324357 (https://clinicaltrials.gov/study/NCT06324357)

The Effect of IBD Flares on Serum PSA
NCT ID: NCT03558048 (https://clinicaltrials.gov/study/NCT03558048)

Feasibility Study: IGNITE-TX (Identifying Individuals for Genetic Testing & Treatment) Intervention
NCT ID: NCT05677048 (https://clinicaltrials.gov/study/NCT05677048)

Jump: MR Simulation For Radiation Therapy Master Protocol
NCT ID: NCT04545957 (https://clinicaltrials.gov/study/NCT04545957)

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
NCT ID: NCT06586957 (https://clinicaltrials.gov/study/NCT06586957)

MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
NCT ID: NCT06483048 (https://clinicaltrials.gov/study/NCT06483048)

A Study Assessing KB707 for the Treatment of Advanced Solid Tumor Malignancies Affecting the Lungs
NCT ID: NCT06228326 (https://clinicaltrials.gov/study/NCT06228326)

Vapocoolant Analgesia for Breast Lymphoscintigraphy
NCT ID: NCT05744557 (https://clinicaltrials.gov/study/NCT05744557)

A Study Comparing Cancer Imaging Approaches in People With Lobular Breast Cancer
NCT ID: NCT06557148 (https://clinicaltrials.gov/study/NCT06557148)

Survivorship Care for Women Living With Ovarian Cancer: (POSTCARE-O)
NCT ID: NCT05752448 (https://clinicaltrials.gov/study/NCT05752448)

Using Radiogenomics to Predict Malignant Potential of Intraductal Papillary Mucinous Neoplasms of the Pancreas
NCT ID: NCT04275557 (https://clinicaltrials.gov/study/NCT04275557)

Monitoring Response to Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Using High-speed MR Spectroscopic Imaging
NCT ID: NCT03568448 (https://clinicaltrials.gov/study/NCT03568448)

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer
NCT ID: NCT05501548 (https://clinicaltrials.gov/study/NCT05501548)

Impact of Aromatase Inhibitor Therapy on Glucose Homeostasis and Diabetes Risk
NCT ID: NCT06557057 (https://clinicaltrials.gov/study/NCT06557057)

The Impact of Low Pressure Pneumo in RARP II
NCT ID: NCT04394676 (https://clinicaltrials.gov/study/NCT04394676)

Immunological Effects of Vitamin D Replacement Among Black/African American Prostate Cancer Patients
NCT ID: NCT05045066 (https://clinicaltrials.gov/study/NCT05045066)

A Study of a Selective T Cell Receptor (TCR) Targeting, Bifunctional Antibody-fusion Molecule STAR0602 in Participants with Advanced Solid Tumors
NCT ID: NCT05592626 (https://clinicaltrials.gov/study/NCT05592626)

Concurrent WOKVAC Vaccination, Chemotherapy, and HER2-Targeted Monoclonal Antibody Therapy Before Surgery for the Treatment of Patients With Breast Cancer
NCT ID: NCT04329065 (https://clinicaltrials.gov/study/NCT04329065)

Stereotactic Body Radiation Therapy Plus Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy for Treatment of Metastatic, Recurrent Hormone-Sensitive Prostate Cancer, DIVINE Trial
NCT ID: NCT06378866 (https://clinicaltrials.gov/study/NCT06378866)

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer
NCT ID: NCT06549465 (https://clinicaltrials.gov/study/NCT06549465)

Study Assessing QBS72S for Treating Brain Metastases
NCT ID: NCT05305365 (https://clinicaltrials.gov/study/NCT05305365)

Trial of Curcumin to Prevent Progression of Low-risk Prostate Cancer Under Active Surveillance
NCT ID: NCT03769766 (https://clinicaltrials.gov/study/NCT03769766)

A Study of BTX-A51 in People With Advanced Solid Tumor and Breast Cancer
NCT ID: NCT04872166 (https://clinicaltrials.gov/study/NCT04872166)

Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
NCT ID: NCT04609566 (https://clinicaltrials.gov/study/NCT04609566)

Improving Colonoscopy Surveillance for Patients with High Risk Colon Polyps
NCT ID: NCT06376565 (https://clinicaltrials.gov/study/NCT06376565)

Metabolomics and Genetic Diagnosing Pancreatic Neuroendocrine Tumors in MEN1 Patients
NCT ID: NCT03048266 (https://clinicaltrials.gov/study/NCT03048266)

Transgender and Gender-Diverse Breast Cancer Screening Pilot
NCT ID: NCT06383026 (https://clinicaltrials.gov/study/NCT06383026)

ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors
NCT ID: NCT04319757 (https://clinicaltrials.gov/study/NCT04319757)

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer
NCT ID: NCT06026657 (https://clinicaltrials.gov/study/NCT06026657)

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
NCT ID: NCT06065748 (https://clinicaltrials.gov/study/NCT06065748)

A Pilot Study Evaluating the Effect of 2D Antiscatter Grids on CBCT Image Quality
NCT ID: NCT04565457 (https://clinicaltrials.gov/study/NCT04565457)

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
NCT ID: NCT04673448 (https://clinicaltrials.gov/study/NCT04673448)

A Study Evaluating the Integrative Medicine at Home (IM@HOME) Program in People With Cancer
NCT ID: NCT05053230 (https://clinicaltrials.gov/study/NCT05053230)

ProAgio in Previously Treated Advanced Pancreatic Cancer and Other Solid Tumor Malignancies
NCT ID: NCT05085548 (https://clinicaltrials.gov/study/NCT05085548)

Bupivacaine vs Placebo for Unilateral Mastectomy Surgical Site Post-operative Pain Control
NCT ID: NCT03351348 (https://clinicaltrials.gov/study/NCT03351348)

ABemacicliB or Abemaciclib and HydroxYchloroquine to Target Minimal Residual Disease in Breast Cancer
NCT ID: NCT04523857 (https://clinicaltrials.gov/study/NCT04523857)

Proteomics and Radiomics Research of Breast Cancer Markers in Tissue, Interstitial Fluid and Serum
NCT ID: NCT01042548 (https://clinicaltrials.gov/study/NCT01042548)

Fluorescence Image Guided Surgery Followed by Intraoperative Photodynamic Therapy for Improving Local Tumor Control in Patients With Locally Advanced or Recurrent Colorectal Cancer
NCT ID: NCT06307548 (https://clinicaltrials.gov/study/NCT06307548)

Multiparametric MRI in Evaluating Cancer Stage and Helping Treatment Planning in Patients With Prostate Cancer
NCT ID: NCT03697148 (https://clinicaltrials.gov/study/NCT03697148)

STOP-HER2: Stopping Trastuzumab in HER2+ MBC
NCT ID: NCT05721248 (https://clinicaltrials.gov/study/NCT05721248)

[18F] F-GLN by PET/CT in Breast Cancer
NCT ID: NCT03863457 (https://clinicaltrials.gov/study/NCT03863457)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)
NCT ID: NCT05461430 (https://clinicaltrials.gov/study/NCT05461430)

A Trial to Find Out if REGN5678 is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metastatic Castration-Resistant Prostate Cancer and Other Tumors
NCT ID: NCT03972657 (https://clinicaltrials.gov/study/NCT03972657)

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery
NCT ID: NCT02884648 (https://clinicaltrials.gov/study/NCT02884648)

Single Arm Trial of Tumor-Treating Fields in Combination With Nivolumab and Ipilimumab in Metastatic Uveal Melanoma
NCT ID: NCT05004025 (https://clinicaltrials.gov/study/NCT05004025)

Blood-Based Colorectal Cancer (CRC) Screening Implementation Into Clinical Practice Highlands
NCT ID: NCT06119425 (https://clinicaltrials.gov/study/NCT06119425)

Immunotherapy in High-risk Ductal Carcinoma in Situ (DCIS)
NCT ID: NCT02872025 (https://clinicaltrials.gov/study/NCT02872025)

Phase Ib Trial of the KRASG12C Inhibitor Adagrasib (MRTX849) in KRAS G12C Mutant Metastatic Pancreatic Cancer Patients
NCT ID: NCT05634525 (https://clinicaltrials.gov/study/NCT05634525)

A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation
NCT ID: NCT06385925 (https://clinicaltrials.gov/study/NCT06385925)

Debunking the Frailty-sarcopenIa-ADT Axis in mEtastatic Prostate canceR With multiComponent Exercise: The FIERCE Trial
NCT ID: NCT06040125 (https://clinicaltrials.gov/study/NCT06040125)

A Feasibility Study Evaluating a Role for Maintenance Therapy in Patients With Biochemically Progressive Castration Sensitive Prostate Cancer on Intermittent Androgen Deprivation Therapy
NCT ID: NCT06044025 (https://clinicaltrials.gov/study/NCT06044025)

Claudin 18.2-Targeted Chimeric Antigen Receptor T-cells in Subjects With Unresectable, Locally Advanced, or Metastatic Gastric, Gastroesophageal Junction (GEJ), Esophageal, or Pancreatic Adenocarcinoma
NCT ID: NCT05539430 (https://clinicaltrials.gov/study/NCT05539430)

RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy
NCT ID: NCT03524430 (https://clinicaltrials.gov/study/NCT03524430)

Study of STP938 in Advanced Solid Tumours
NCT ID: NCT06297525 (https://clinicaltrials.gov/study/NCT06297525)

Medical Cannabis in Patients With Advanced Pancreatic Cancer
NCT ID: NCT06605430 (https://clinicaltrials.gov/study/NCT06605430)

A Study of Navicixizumab Monotherapy or in Combination in Patients With Select Advanced Solid Tumors
NCT ID: NCT05453825 (https://clinicaltrials.gov/study/NCT05453825)

Magnetic Resonance Imaging (MRI) With Hyperpolarized Pyruvate (13C) as Diagnostic Tool in Advanced Prostate Cancer
NCT ID: NCT04346225 (https://clinicaltrials.gov/study/NCT04346225)

Blood Markers of Early Pancreas Cancer
NCT ID: NCT03568630 (https://clinicaltrials.gov/study/NCT03568630)

High Dose IL-2 in Combination With Anti-PD-1 to Overcome Anti-PD-1 Resistance in Metastatic Melanoma and Renal Cell Carcinoma
NCT ID: NCT03991130 (https://clinicaltrials.gov/study/NCT03991130)

A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents
NCT ID: NCT06090266 (https://clinicaltrials.gov/study/NCT06090266)

Clonal Hematopoiesis in Ovarian Cancer Survivors and Risk of Secondary Blood Cancers, CHANCES Study
NCT ID: NCT06295965 (https://clinicaltrials.gov/study/NCT06295965)

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer
NCT ID: NCT05800665 (https://clinicaltrials.gov/study/NCT05800665)

A Phase 1b Study of WU-NK-101 in Combination With Cetuximab
NCT ID: NCT05674526 (https://clinicaltrials.gov/study/NCT05674526)

Resistance Exercise and Creatine in Colorectal Cancer
NCT ID: NCT06420726 (https://clinicaltrials.gov/study/NCT06420726)

First in Human Study of TORL-2-307-ADC in Participants With Advanced Cancer
NCT ID: NCT05156866 (https://clinicaltrials.gov/study/NCT05156866)

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC
NCT ID: NCT04140526 (https://clinicaltrials.gov/study/NCT04140526)

Impact of Protect Your Colon™ on CRC Screening
NCT ID: NCT05929820 (https://clinicaltrials.gov/study/NCT05929820)

Stereotactic Adaptive Radiation Therapy of Borderline Resectable Pancreatic Cancer an Individualized Approach
NCT ID: NCT05764720 (https://clinicaltrials.gov/study/NCT05764720)

Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
NCT ID: NCT03203525 (https://clinicaltrials.gov/study/NCT03203525)

A Study of an Alternative Treatment Approach (Preoperative Radiotherapy, Then Mastectomy, Then Immediate Reconstruction Surgery) in People With T4 Breast Cancer
NCT ID: NCT05412225 (https://clinicaltrials.gov/study/NCT05412225)

Online Dietary and Resistance Training to Improve Physical Function in Older Cancer Survivors, E-PROOF Trial
NCT ID: NCT06016725 (https://clinicaltrials.gov/study/NCT06016725)

A Study of [225Ac]-FPI-2059 in Adult Participants With Solid Tumours
NCT ID: NCT05605522 (https://clinicaltrials.gov/study/NCT05605522)

Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET
NCT ID: NCT05722925 (https://clinicaltrials.gov/study/NCT05722925)

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
NCT ID: NCT05400122 (https://clinicaltrials.gov/study/NCT05400122)

Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
NCT ID: NCT05283330 (https://clinicaltrials.gov/study/NCT05283330)

Disposable Perfusion Phantom for Accurate DCE (Dynamic Contrast Enhanced)-MRI Measurement of Pancreatic Cancer Therapy Response
NCT ID: NCT04588025 (https://clinicaltrials.gov/study/NCT04588025)

Obtaining Solid Tumor Tissue From People Having Biopsy or Surgery for Certain Types of Cancer
NCT ID: NCT01915225 (https://clinicaltrials.gov/study/NCT01915225)

Safety, Tolerability, Pharmacokinetics, Radiation Dosimetry, and PET Imaging Properties of 89Zr-labeled hNd2 (NMK89) in Patients With Pancreatic Cancer
NCT ID: NCT06129422 (https://clinicaltrials.gov/study/NCT06129422)

Study of INCB123667 in Subjects With Advanced Solid Tumors
NCT ID: NCT05238922 (https://clinicaltrials.gov/study/NCT05238922)

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial
NCT ID: NCT06022822 (https://clinicaltrials.gov/study/NCT06022822)

Early Detection of Breast Cancer in Women With Suspicious Mammograms
NCT ID: NCT03147430 (https://clinicaltrials.gov/study/NCT03147430)

Microwave Ablation or Wedge Resection for the Treatment of Lung, Sarcoma and Colorectal Lesions, ALLUME Study
NCT ID: NCT04430725 (https://clinicaltrials.gov/study/NCT04430725)

Standard Systemic Therapy With or Without Definitive Treatment in Treating Participants With Metastatic Prostate Cancer
NCT ID: NCT03678025 (https://clinicaltrials.gov/study/NCT03678025)

Prostate Resection After Microwave Ablation (PRAMA)
NCT ID: NCT06128525 (https://clinicaltrials.gov/study/NCT06128525)

Feasibility Trial of Tele-IPT and Tele-Pharmacotherapy for Patients With Depression and Non-Metastatic Breast Cancer
NCT ID: NCT04973930 (https://clinicaltrials.gov/study/NCT04973930)

SABER Study for Selected Early Stage Breast Cancer
NCT ID: NCT04360330 (https://clinicaltrials.gov/study/NCT04360330)

Immunotherapy for Third Line Metastatic Colorectal Cancer
NCT ID: NCT04444622 (https://clinicaltrials.gov/study/NCT04444622)

A Study to Evaluate Similarity of ABP 206 Compared With OPDIVO® (Nivolumab) in Subjects With Resected Melanoma
NCT ID: NCT05907122 (https://clinicaltrials.gov/study/NCT05907122)

FHIR-Enhanced RealRisks to Improve Accuracy of Breast Cancer Risk Assessments
NCT ID: NCT05810025 (https://clinicaltrials.gov/study/NCT05810025)

Study of 3-Day Partial Breast Radiation Therapy in Women With Breast Cancer
NCT ID: NCT04084730 (https://clinicaltrials.gov/study/NCT04084730)

A Study to Learn About the Study Medicine Called PF-07799544 in People With Advanced Solid Tumors
NCT ID: NCT05538130 (https://clinicaltrials.gov/study/NCT05538130)

Study to Evaluate Sacituzumab Govitecan in Combination With Talazoparib in Patients With Metastatic Breast Cancer.
NCT ID: NCT04039230 (https://clinicaltrials.gov/study/NCT04039230)

Positron Emission Tomography Using 64Cu-SAR-bisPSMA in Participants With High-risk Prostate Cancer Prior to Radical Prostatectomy
NCT ID: NCT06056830 (https://clinicaltrials.gov/study/NCT06056830)

Geriatric Care Survivorship Intervention for Improving the Overall Health of Older Adults With Stage I-III Breast Cancer Who Have Completed Curative Treatment
NCT ID: NCT05928325 (https://clinicaltrials.gov/study/NCT05928325)

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast Cancer
NCT ID: NCT05746325 (https://clinicaltrials.gov/study/NCT05746325)

The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors
NCT ID: NCT05037825 (https://clinicaltrials.gov/study/NCT05037825)

LymphBridge: Surgical Evaluation for Breast Cancer-Associated Lymphedema (BioBridge)
NCT ID: NCT04606030 (https://clinicaltrials.gov/study/NCT04606030)

Endocrine Therapy Fulvestrant & Palbociclib or Aromatase Inhibitor Therapy in Treating Older Patients With Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
NCT ID: NCT02760030 (https://clinicaltrials.gov/study/NCT02760030)

HER2-CAR T Cells in Treating Patients With Recurrent Brain or Leptomeningeal Metastases
NCT ID: NCT03696030 (https://clinicaltrials.gov/study/NCT03696030)

Reishi Mushroom Extract for Fatigue And/or Arthralgias/myalgias in Patients with Breast Cancer on Aromatase Inhibitors
NCT ID: NCT06028022 (https://clinicaltrials.gov/study/NCT06028022)

Follow-Up Study of Subjects Previously Enrolled in Poxviral Vector Gene Transfer Studies
NCT ID: NCT00451022 (https://clinicaltrials.gov/study/NCT00451022)

TACTIVE-U: A Study to Learn About the Study Medicine (Vepdegestrant) When Given With Other Medicines in People With Advanced or Metastatic Breast Cancer. (Sub-Study C)
NCT ID: NCT06125522 (https://clinicaltrials.gov/study/NCT06125522)

Safety and Preliminary Effectiveness of BNT327, an Investigational Therapy for Breast Cancer, When Given in Combination With Chemotherapy
NCT ID: NCT06449222 (https://clinicaltrials.gov/study/NCT06449222)

Understanding and Addressing Disparities in Cancer Therapy Induced Inflammation and Associated Endothelial Dysfunction
NCT ID: NCT05223322 (https://clinicaltrials.gov/study/NCT05223322)

Exosome-based Detection of Molecular Residual Disease in Stage II-III Colorectal Cancer.
NCT ID: NCT06654622 (https://clinicaltrials.gov/study/NCT06654622)

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
NCT ID: NCT05051722 (https://clinicaltrials.gov/study/NCT05051722)

DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Metastatic Breast Cancer Patients
NCT ID: NCT06388122 (https://clinicaltrials.gov/study/NCT06388122)

Developing a Test for the Detection of Ovarian Cancer
NCT ID: NCT04794322 (https://clinicaltrials.gov/study/NCT04794322)

Oral EPI-7386 in Patients With Castration-Resistant Prostate Cancer
NCT ID: NCT04421222 (https://clinicaltrials.gov/study/NCT04421222)

Nutrition and Exercise Interventions in Reducing Androgen Deprivation Therapy-Induced Obese Frailty in Prostate Cancer Survivors
NCT ID: NCT03880422 (https://clinicaltrials.gov/study/NCT03880422)

Evaluation of the Bexa Breast Examination
NCT ID: NCT06643767 (https://clinicaltrials.gov/study/NCT06643767)

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
NCT ID: NCT05554367 (https://clinicaltrials.gov/study/NCT05554367)

Resilience and Equity in Aging, Cancer, and Health (REACH)
NCT ID: NCT04674267 (https://clinicaltrials.gov/study/NCT04674267)

A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
NCT ID: NCT06346067 (https://clinicaltrials.gov/study/NCT06346067)

Metformin and Nightly Fasting in Women With Early Breast Cancer
NCT ID: NCT05023967 (https://clinicaltrials.gov/study/NCT05023967)

Hepatic Artery Infusional Floxuridine to Treat Pancreatic Cancer Liver Metastases
NCT ID: NCT03856658 (https://clinicaltrials.gov/study/NCT03856658)

TAS102 in Combination With NAL-IRI in Advanced GI Cancers
NCT ID: NCT03368963 (https://clinicaltrials.gov/study/NCT03368963)

Remote Exercise and Nutritional Prehabilitation for Pancreatic Cancer
NCT ID: NCT06423963 (https://clinicaltrials.gov/study/NCT06423963)

MRI-guided Transurethral Urethral Ultrasound Ablation for the Treatment of Intermediate Grade Prostate Cancer
NCT ID: NCT05438563 (https://clinicaltrials.gov/study/NCT05438563)

Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma Patients
NCT ID: NCT06250335 (https://clinicaltrials.gov/study/NCT06250335)

Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT ID: NCT06132958 (https://clinicaltrials.gov/study/NCT06132958)

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer
NCT ID: NCT05455658 (https://clinicaltrials.gov/study/NCT05455658)

Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT ID: NCT02307058 (https://clinicaltrials.gov/study/NCT02307058)

A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
NCT ID: NCT02960022 (https://clinicaltrials.gov/study/NCT02960022)

Quantitative Microvasculature Imaging for Breast Cancer Detection and Monitoring
NCT ID: NCT04799535 (https://clinicaltrials.gov/study/NCT04799535)

The Genomic Medicine at VA Study
NCT ID: NCT04331535 (https://clinicaltrials.gov/study/NCT04331535)

Tumor Microenvironment Analysis of Prostate Cancer Metastasis
NCT ID: NCT05304858 (https://clinicaltrials.gov/study/NCT05304858)

A Prospective Study to Evaluate Continuous Positive Airway Pressure Devices to Reduce Pulmonary Dose
NCT ID: NCT05142358 (https://clinicaltrials.gov/study/NCT05142358)

MBC Physical Activity Study
NCT ID: NCT06500858 (https://clinicaltrials.gov/study/NCT06500858)

African Cancer Genome: GMD
NCT ID: NCT05754658 (https://clinicaltrials.gov/study/NCT05754658)

Lymphedema Surveillance Study
NCT ID: NCT02743858 (https://clinicaltrials.gov/study/NCT02743858)

Evaluation of Vaginal Microbiome as a Biomarker for the Improvement of Vaginal Health in Women With Breast Cancer, ARISE Study
NCT ID: NCT05946668 (https://clinicaltrials.gov/study/NCT05946668)

Feasibility of the LUM Imaging System for Peritoneal Surface Malignancies
NCT ID: NCT03834272 (https://clinicaltrials.gov/study/NCT03834272)

A Study of SGN-B7H4V in Advanced Solid Tumors
NCT ID: NCT05194072 (https://clinicaltrials.gov/study/NCT05194072)

A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian Cancer
NCT ID: NCT06394804 (https://clinicaltrials.gov/study/NCT06394804)

THRIVE Study: Positive Affect Training for Endocrine Therapy Medication Adherence
NCT ID: NCT06388304 (https://clinicaltrials.gov/study/NCT06388304)

Phase II Study of REPotrectinib With or Without Fulvestrant in Patients With Hormone Receptor-positive Human Epidermal Growth Factor 2-negative Metastatic Invasive LObular Carcinoma Who Received a Prior Endocrine Therapy in Combination With Cyclin-dependent Kinase 4 and 6 Inhibitor (REPLOT Trial)
NCT ID: NCT06408168 (https://clinicaltrials.gov/study/NCT06408168)

Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial Cancer
NCT ID: NCT05139368 (https://clinicaltrials.gov/study/NCT05139368)

Abbreviate or FAST Breast MRI for Supplemental Breast Cancer Screening for Black Women at Average Risk and Dense Breasts
NCT ID: NCT04854304 (https://clinicaltrials.gov/study/NCT04854304)

Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
NCT ID: NCT05691504 (https://clinicaltrials.gov/study/NCT05691504)

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC
NCT ID: NCT04265872 (https://clinicaltrials.gov/study/NCT04265872)

Biopsy After Radioembolization to Identify Changes in Tumor Cells From the Radiation
NCT ID: NCT04668872 (https://clinicaltrials.gov/study/NCT04668872)

Neoadjuvant Folfirinox Combined With Pembrolizumab Followed by Surgery for Patients With Resectable Pancreatic Cancer
NCT ID: NCT05132504 (https://clinicaltrials.gov/study/NCT05132504)

Phase I/II Study of the Anti-Programmed Death Ligand-1 Durvalumab Antibody (MEDI4736) in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Can...
NCT ID: NCT02484404 (https://clinicaltrials.gov/study/NCT02484404)

Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known Homologous Recombination Deficiency
NCT ID: NCT06120972 (https://clinicaltrials.gov/study/NCT06120972)

Hyperpolarized Carbon 13-Based Metabolic Imaging to Detect Radiation-Induced Cardiotoxicity
NCT ID: NCT04044872 (https://clinicaltrials.gov/study/NCT04044872)

The Differential Impact of Proton Beam Irradiation Versus Conventional Radiation on Organs-at-risk in Stage II-III Breast Cancer Patients
NCT ID: NCT03270072 (https://clinicaltrials.gov/study/NCT03270072)

A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
NCT ID: NCT05094804 (https://clinicaltrials.gov/study/NCT05094804)

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer
NCT ID: NCT02977468 (https://clinicaltrials.gov/study/NCT02977468)

A Study of LY4170156 in Participants With Selected Advanced Solid Tumors
NCT ID: NCT06400472 (https://clinicaltrials.gov/study/NCT06400472)

(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer
NCT ID: NCT05607004 (https://clinicaltrials.gov/study/NCT05607004)

A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain
NCT ID: NCT05892068 (https://clinicaltrials.gov/study/NCT05892068)

Minimal Residual Disease Assessment in Patients with Colorectal Cancer, the MiRDA-C Study
NCT ID: NCT04739072 (https://clinicaltrials.gov/study/NCT04739072)

Mechanisms, Predictors, and Social Determinants of Cardiotoxicity in Prostate Cancer
NCT ID: NCT05096338 (https://clinicaltrials.gov/study/NCT05096338)

Collection of Information to Better Understand Young Onset Colorectal Cancer
NCT ID: NCT04489238 (https://clinicaltrials.gov/study/NCT04489238)

The Effects of Two Exercise Interventions on Breast Cancer Patients Undergoing Cardiotoxic Chemotherapies
NCT ID: NCT05786014 (https://clinicaltrials.gov/study/NCT05786014)

Exploring Cultural Acceptability of Community Breast Cancer Risk Assessment Among Hispanic Women in Maricopa County
NCT ID: NCT06112795 (https://clinicaltrials.gov/study/NCT06112795)

Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.
NCT ID: NCT05831995 (https://clinicaltrials.gov/study/NCT05831995)

Real-Time Feedback (RTFB) to Improve Colonoscopy
NCT ID: NCT05241210 (https://clinicaltrials.gov/study/NCT05241210)

Intervening on Women's Health for Rural Young Breast Cancer Survivors
NCT ID: NCT05414812 (https://clinicaltrials.gov/study/NCT05414812)

Susan G. Komen's ShareForCures
NCT ID: NCT05654246 (https://clinicaltrials.gov/study/NCT05654246)

Pilot Study of Pancreatic Cancer Screening
NCT ID: NCT05058846 (https://clinicaltrials.gov/study/NCT05058846)

Portable Scalp Cooling System (PSCS) to Prevent Hair Loss for Breast Cancer Patients (Cooler Heads)
NCT ID: NCT06215469 (https://clinicaltrials.gov/study/NCT06215469)

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy
NCT ID: NCT05245812 (https://clinicaltrials.gov/study/NCT05245812)

Trial Assessing Light Intensity Exercise on the Health of Older Breast Cancer Survivors
NCT ID: NCT04965246 (https://clinicaltrials.gov/study/NCT04965246)

Washington University Participant Engagement and Cancer Genomic Sequencing Center (WU-PE-CGS)
NCT ID: NCT06340646 (https://clinicaltrials.gov/study/NCT06340646)

Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients with Prostate Cancer, HEATWAVE Trial
NCT ID: NCT06067269 (https://clinicaltrials.gov/study/NCT06067269)

Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction
NCT ID: NCT02927912 (https://clinicaltrials.gov/study/NCT02927912)

Changes in Reproductive and Sexual Health in People With Early Onset Colorectal Cancer
NCT ID: NCT04812912 (https://clinicaltrials.gov/study/NCT04812912)

Physical Therapy for Men Undergoing Prostatectomy
NCT ID: NCT02558946 (https://clinicaltrials.gov/study/NCT02558946)

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer
NCT ID: NCT05217446 (https://clinicaltrials.gov/study/NCT05217446)

Association Between Health Care Provider (HCP)-Assessed ECOG Performance Status (PS) and Overall Survival, and Objectively Measure of Physical Activity (PA) Levels in Advance-cancer Patients"
NCT ID: NCT01365169 (https://clinicaltrials.gov/study/NCT01365169)

Using MRI to Identify Areas to Receive Lower Doses of Radiation Treatment in Men With Prostate Cancerdose Mapping to Preserve Quality of Life
NCT ID: NCT06171269 (https://clinicaltrials.gov/study/NCT06171269)

Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study
NCT ID: NCT05568472 (https://clinicaltrials.gov/study/NCT05568472)

ProAgio in Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT06182072 (https://clinicaltrials.gov/study/NCT06182072)

ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)
NCT ID: NCT04829604 (https://clinicaltrials.gov/study/NCT04829604)

Megestrol Acetate Compared With Megestrol Acetate and Metformin to Prevent Endometrial Cancer
NCT ID: NCT04576104 (https://clinicaltrials.gov/study/NCT04576104)

Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
NCT ID: NCT04514692 (https://clinicaltrials.gov/study/NCT04514692)

Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
NCT ID: NCT04106492 (https://clinicaltrials.gov/study/NCT04106492)

Enhancing Skin Appearance and Quality of Life in Breast Cancer Survivors on Aromatase Inhibitor Therapy
NCT ID: NCT06401889 (https://clinicaltrials.gov/study/NCT06401889)

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors
NCT ID: NCT05887492 (https://clinicaltrials.gov/study/NCT05887492)

Phase I Trial Testing the Safety and Tolerability of Chemoradiation Followed by Chemotherapy + Dostarlimab for Stage IIIC, Node Positive, Endometrial Cancer
NCT ID: NCT05819892 (https://clinicaltrials.gov/study/NCT05819892)

A Conversational Agent (Cecebot) to Improve Insomnia in Stage I-III Breast Cancer Survivors
NCT ID: NCT06392789 (https://clinicaltrials.gov/study/NCT06392789)

Phase 1 Dose Escalation Study for VIP236 in Patients With Advanced Cancer
NCT ID: NCT05712889 (https://clinicaltrials.gov/study/NCT05712889)

PET Dynamics to Response-Adapted Neoadjuvant Therapy in TNBC
NCT ID: NCT06245889 (https://clinicaltrials.gov/study/NCT06245889)

A Multicenter Cancer Biospecimen Collection Study
NCT ID: NCT04510129 (https://clinicaltrials.gov/study/NCT04510129)

Study of Autologous Tumor-Infiltrating Lymphocytes in Pediatric, Adolescent, and Young Adult Participants
NCT ID: NCT06566092 (https://clinicaltrials.gov/study/NCT06566092)

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer
NCT ID: NCT06538389 (https://clinicaltrials.gov/study/NCT06538389)

A Beta-only IL-2 ImmunoTherapY Study
NCT ID: NCT05086692 (https://clinicaltrials.gov/study/NCT05086692)

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
NCT ID: NCT04840589 (https://clinicaltrials.gov/study/NCT04840589)

Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C Melanoma Patients
NCT ID: NCT03567889 (https://clinicaltrials.gov/study/NCT03567889)

IMPACT Trial: Intervention to iMProve AdherenCe Equitably
NCT ID: NCT05496829 (https://clinicaltrials.gov/study/NCT05496829)

Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate Cancer
NCT ID: NCT04109729 (https://clinicaltrials.gov/study/NCT04109729)

Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
NCT ID: NCT01441089 (https://clinicaltrials.gov/study/NCT01441089)

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC)
NCT ID: NCT06085729 (https://clinicaltrials.gov/study/NCT06085729)

The Cancer of the Pancreas Screening-5 CAPS5)Study
NCT ID: NCT02000089 (https://clinicaltrials.gov/study/NCT02000089)

Statin Therapy to Reduce Progression in Women With Platinum Sensitive Ovarian Cancer
NCT ID: NCT04457089 (https://clinicaltrials.gov/study/NCT04457089)

Evaluation of the Acceptability, Appropriateness, and Feasibility/Usability of a Metastatic Breast-cancer Specific Prognostic Calculator Among Clinicians
NCT ID: NCT05440929 (https://clinicaltrials.gov/study/NCT05440929)

A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors
NCT ID: NCT06157892 (https://clinicaltrials.gov/study/NCT06157892)

Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid Tumors
NCT ID: NCT03682289 (https://clinicaltrials.gov/study/NCT03682289)

UNC Pleural Fluid Registry
NCT ID: NCT05620329 (https://clinicaltrials.gov/study/NCT05620329)

Real-Time Assessment Of Breast Cancer Lumpectomy Specimen Margins With Nonlinear Microscopy
NCT ID: NCT02926729 (https://clinicaltrials.gov/study/NCT02926729)

A Study of Enzalutamide Plus the Glucocorticoid Receptor Antagonist Relacorilant Versus Placebo for Patients With High-risk Localized Prostate Cancer
NCT ID: NCT05726292 (https://clinicaltrials.gov/study/NCT05726292)

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Endometrial Cancer.
NCT ID: NCT06481592 (https://clinicaltrials.gov/study/NCT06481592)

Phase II Trial of Carboplatin +/- Tocilizumab for Metastatic Triple Negative and ER-low Breast Cancers
NCT ID: NCT05846789 (https://clinicaltrials.gov/study/NCT05846789)

A Phase 2 Study of PCS6422 with Capecitabine in Patients with Advanced or Metastatic Breast Cancer
NCT ID: NCT06568692 (https://clinicaltrials.gov/study/NCT06568692)

Trametinib and Hydroxychloroquine in Treating Patients With Pancreatic Cancer
NCT ID: NCT03825289 (https://clinicaltrials.gov/study/NCT03825289)

Assoc. of Genomic Polymorphisms With Cancer Cachexia in Subjects With Panc Adenocarcinoma
NCT ID: NCT05376592 (https://clinicaltrials.gov/study/NCT05376592)

Preliminary Evaluation of Screening for Pancreatic Cancer in Patients With Inherited Genetic Risk
NCT ID: NCT02478892 (https://clinicaltrials.gov/study/NCT02478892)

Quality of Life in Patients With Clinically Localized Prostate Cancer Treated With Radiosurgery
NCT ID: NCT01766492 (https://clinicaltrials.gov/study/NCT01766492)

Psychoeducation for Uveal Melanoma
NCT ID: NCT06075589 (https://clinicaltrials.gov/study/NCT06075589)

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
NCT ID: NCT01954992 (https://clinicaltrials.gov/study/NCT01954992)

Neratinib + Valproate in Advanced Solid Tumors, w/Expansion Cohort in Ras-Mutated Ca
NCT ID: NCT03919292 (https://clinicaltrials.gov/study/NCT03919292)

Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
NCT ID: NCT05914792 (https://clinicaltrials.gov/study/NCT05914792)

A Phase 1/2 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway
NCT ID: NCT05578092 (https://clinicaltrials.gov/study/NCT05578092)

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
NCT ID: NCT04609592 (https://clinicaltrials.gov/study/NCT04609592)

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ
NCT ID: NCT04722692 (https://clinicaltrials.gov/study/NCT04722692)

Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer
NCT ID: NCT03734692 (https://clinicaltrials.gov/study/NCT03734692)

A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
NCT ID: NCT06095089 (https://clinicaltrials.gov/study/NCT06095089)

Adjuvant Monotherapy With Endocrine Therapy or Accelerated Partial Breast Irradiation Following Lumpectomy for Low Risk Breast Cancer Patients Over 65 (CAMERAN)
NCT ID: NCT05472792 (https://clinicaltrials.gov/study/NCT05472792)

IIT2023-09-Chung-UpfrontTAD: Upfront TAD/SNB in Patients With Breast Cancer With Nodal Metastases
NCT ID: NCT06092892 (https://clinicaltrials.gov/study/NCT06092892)

MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma
NCT ID: NCT05655312 (https://clinicaltrials.gov/study/NCT05655312)

Adaptive Radiation Therapy (ART) Stereotactic Ablative Body Radiotherapy (SABR) for Primary Localized Prostate Cancer
NCT ID: NCT06325046 (https://clinicaltrials.gov/study/NCT06325046)

Time Restricted Eating During Chemotherapy for Breast Cancer
NCT ID: NCT05259410 (https://clinicaltrials.gov/study/NCT05259410)

Accurate, Rapid and Inexpensive MRI Protocol for Breast Cancer Screening
NCT ID: NCT04877912 (https://clinicaltrials.gov/study/NCT04877912)

A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
NCT ID: NCT06079346 (https://clinicaltrials.gov/study/NCT06079346)

Diagnostic Performance of Non-Endorectal Coil Multiparametric Magnetic Resonance Imaging of Prostate with Flexible AIR Coil (DoNEMAC Study)
NCT ID: NCT05043012 (https://clinicaltrials.gov/study/NCT05043012)

Phase 1 Clinical Trial of Lenvatinib, Pembrolizumab and Hypofractionated Pelvic Radiation Therapy for pMMR Recurrent/Unresectable Endometrial Carcinoma
NCT ID: NCT05603910 (https://clinicaltrials.gov/study/NCT05603910)

Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
NCT ID: NCT02912312 (https://clinicaltrials.gov/study/NCT02912312)

Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
NCT ID: NCT03821246 (https://clinicaltrials.gov/study/NCT03821246)

Novel Lung Imaging in Adults Undergoing Radiation Therapy to Assess for Radiation Pneumonitis
NCT ID: NCT02735746 (https://clinicaltrials.gov/study/NCT02735746)

GU-01: Glycyrrhizin in Prostate Cancer
NCT ID: NCT06378346 (https://clinicaltrials.gov/study/NCT06378346)

Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
NCT ID: NCT06072612 (https://clinicaltrials.gov/study/NCT06072612)

Pembrolizumab and Lenvatinib in Clear Cell Ovarian Cancer
NCT ID: NCT05296512 (https://clinicaltrials.gov/study/NCT05296512)

Using Aspirin to Improve Immunological Features of Ovarian Tumors
NCT ID: NCT05080946 (https://clinicaltrials.gov/study/NCT05080946)

Lesion Composition and Quantitative Imaging Analysis on Breast Cancer Diagnosis
NCT ID: NCT05369546 (https://clinicaltrials.gov/study/NCT05369546)

High-dose Brachytherapy Boost With Stereostatic Body Radiation Therapy to Intermediate or Higher Risk Prostate Cancer
NCT ID: NCT05754580 (https://clinicaltrials.gov/study/NCT05754580)

Phase 1, Safety and Tolerability Study of XmAb®541 in Advanced Solid Tumors
NCT ID: NCT06276491 (https://clinicaltrials.gov/study/NCT06276491)

A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma
NCT ID: NCT05077280 (https://clinicaltrials.gov/study/NCT05077280)

TH1902 in Patients With Advanced Solid Tumors
NCT ID: NCT04706962 (https://clinicaltrials.gov/study/NCT04706962)

Blood and Stool Sample Collection in Subjects with a Diagnosis of Colorectal Cancer or Colorectal Lesion: Act Fast
NCT ID: NCT03789162 (https://clinicaltrials.gov/study/NCT03789162)

Phase II Study to Evaluate Modified Folfirinox and Stereotactic Body Radiation Therapy in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT ID: NCT03991962 (https://clinicaltrials.gov/study/NCT03991962)

A Prospective Natural History Study in Uveal Melanoma
NCT ID: NCT04588662 (https://clinicaltrials.gov/study/NCT04588662)

Study of Pembrolizumab With or Without Defactinib Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma
NCT ID: NCT03727880 (https://clinicaltrials.gov/study/NCT03727880)

Infusion System for Hepatic Cancer
NCT ID: NCT04684862 (https://clinicaltrials.gov/study/NCT04684862)

A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
NCT ID: NCT04873362 (https://clinicaltrials.gov/study/NCT04873362)

Prospective Evaluation of Pencil Beam Scanning Proton Therapy for Previously Irradiated Tumors
NCT ID: NCT05313191 (https://clinicaltrials.gov/study/NCT05313191)

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
NCT ID: NCT05688280 (https://clinicaltrials.gov/study/NCT05688280)

VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
NCT ID: NCT06264180 (https://clinicaltrials.gov/study/NCT06264180)

A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
NCT ID: NCT05646862 (https://clinicaltrials.gov/study/NCT05646862)

Biospecimen Collection to Identify Gene Mutations for High Risk Pancreatic Cancer in Pediatric Patients, INSPPIRE 2 Study
NCT ID: NCT06651580 (https://clinicaltrials.gov/study/NCT06651580)

Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination With the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients With Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors
NCT ID: NCT03065062 (https://clinicaltrials.gov/study/NCT03065062)

Neoadjuvant TIL- and Response-Adapted Chemoimmunotherapy for TNBC
NCT ID: NCT05645380 (https://clinicaltrials.gov/study/NCT05645380)

Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer
NCT ID: NCT04337580 (https://clinicaltrials.gov/study/NCT04337580)

The Effect of Hand Exercises on Upper Limb Volume, Quality of Life, and Hand Function in Breast Cancer Survivors
NCT ID: NCT05983380 (https://clinicaltrials.gov/study/NCT05983380)

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy
NCT ID: NCT05710380 (https://clinicaltrials.gov/study/NCT05710380)

A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
NCT ID: NCT06435429 (https://clinicaltrials.gov/study/NCT06435429)

Pancrelipase in People With Pancreatic Ductal Adenocarcinoma (PDAC)
NCT ID: NCT05642962 (https://clinicaltrials.gov/study/NCT05642962)

Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
NCT ID: NCT05272462 (https://clinicaltrials.gov/study/NCT05272462)

Prevention of Heart Failure Induced by Doxorubicin with Early Administration of Dexrazoxane
NCT ID: NCT03930680 (https://clinicaltrials.gov/study/NCT03930680)

A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
NCT ID: NCT05544929 (https://clinicaltrials.gov/study/NCT05544929)

Personalized Self-Management Training Compared to Standardized Self-Management Training in Colorectal Cancer Patients.
NCT ID: NCT05984589 (https://clinicaltrials.gov/study/NCT05984589)

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer
NCT ID: NCT03368729 (https://clinicaltrials.gov/study/NCT03368729)

ExoLuminate Study for Early Detection of Pancreatic Cancer
NCT ID: NCT05625529 (https://clinicaltrials.gov/study/NCT05625529)

Aim 3, Optimizing CRC Screening in Patients With Diabetes in Safety-net Primary Care Settings
NCT ID: NCT05785780 (https://clinicaltrials.gov/study/NCT05785780)

TrAstuzumab Cardiomyopathy Therapeutic Intervention With Carvedilol
NCT ID: NCT03879629 (https://clinicaltrials.gov/study/NCT03879629)

Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma
NCT ID: NCT06194929 (https://clinicaltrials.gov/study/NCT06194929)

Ultrasound Imaging and Spectroscopy as Early Indicators of Locally-Advanced Breast Cancer Response
NCT ID: NCT04134780 (https://clinicaltrials.gov/study/NCT04134780)

A Study of DF6002 Alone and in Combination With Nivolumab
NCT ID: NCT04423029 (https://clinicaltrials.gov/study/NCT04423029)

APL-2 and Pembrolizumab Versus APL-2, Pembrolizumab and Bevacizumab Versus Bevacizumab Alone for the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer and Malignant Effusion
NCT ID: NCT04919629 (https://clinicaltrials.gov/study/NCT04919629)

ARX517 in Subjects With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04662580 (https://clinicaltrials.gov/study/NCT04662580)

Cryoablation as a Minimally Invasive Alternative to Surgery for Managing Ductal Carcinoma In Situ
NCT ID: NCT05218044 (https://clinicaltrials.gov/study/NCT05218044)

IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients
NCT ID: NCT04562129 (https://clinicaltrials.gov/study/NCT04562129)

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Patients With Advanced Solid Tumors
NCT ID: NCT05932862 (https://clinicaltrials.gov/study/NCT05932862)

Study of CB307 in Patients With Advanced and/or Metastatic PSMA-positive Tumours.
NCT ID: NCT04839991 (https://clinicaltrials.gov/study/NCT04839991)

Trial of EP0057, a Nanoparticle Camptothecin With Olaparib in People With Relapsed/Refractory Small Cell Lung Cancer
NCT ID: NCT02769962 (https://clinicaltrials.gov/study/NCT02769962)

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
NCT ID: NCT05691491 (https://clinicaltrials.gov/study/NCT05691491)

A Study of 68Gallium PSMA-PET/CT Scans in People With Bladder Cancer or Skin Cancer
NCT ID: NCT05562791 (https://clinicaltrials.gov/study/NCT05562791)

Quantitative MRI Assessment of Breast Cancer Therapy Response
NCT ID: NCT05704062 (https://clinicaltrials.gov/study/NCT05704062)

Use of the CA 125 Algorithm for the Early Detection of Ovarian Cancer in Low Risk Women
NCT ID: NCT00539162 (https://clinicaltrials.gov/study/NCT00539162)

Improving Genetic Counseling for BRCA+ Mothers
NCT ID: NCT04258280 (https://clinicaltrials.gov/study/NCT04258280)

Cancer Coaching and Remote Education for Self-Empowerment (CARES) Study
NCT ID: NCT06323291 (https://clinicaltrials.gov/study/NCT06323291)

Study BT8009-100 in Subjects With Nectin-4 Expressing Advanced Malignancies
NCT ID: NCT04561362 (https://clinicaltrials.gov/study/NCT04561362)

Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
NCT ID: NCT03704662 (https://clinicaltrials.gov/study/NCT03704662)

TRADE: Dose Escalation Tolerability of Abemaciclib in HR+ HER2- Early Stage Breast Cancer
NCT ID: NCT06001762 (https://clinicaltrials.gov/study/NCT06001762)

Water Vapor Ablation for Localized Intermediate Risk Prostate Cancer
NCT ID: NCT05683691 (https://clinicaltrials.gov/study/NCT05683691)

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer
NCT ID: NCT05304962 (https://clinicaltrials.gov/study/NCT05304962)

A Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) Guided by Magnetic Resonance Imaging (MRI) in People With Liver Metastasis From Colorectal Cancer
NCT ID: NCT06130280 (https://clinicaltrials.gov/study/NCT06130280)

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma
NCT ID: NCT05568680 (https://clinicaltrials.gov/study/NCT05568680)

Study of RAS(ON) Inhibitors in Patients With Gastrointestinal Solid Tumors
NCT ID: NCT06445062 (https://clinicaltrials.gov/study/NCT06445062)

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer
NCT ID: NCT05896839 (https://clinicaltrials.gov/study/NCT05896839)

Cell Therapy (STEAP1 CART) With Enzalutamide for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT06236139 (https://clinicaltrials.gov/study/NCT06236139)

ArtemiCoffee in Patients With Rising PSA
NCT ID: NCT05478239 (https://clinicaltrials.gov/study/NCT05478239)

Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
NCT ID: NCT03716739 (https://clinicaltrials.gov/study/NCT03716739)

Gedatolisib Plus Fulvestrant With or Without Palbociclib vs Standard-of-Care for the Treatment of Patients With Advanced or Metastatic HR+/HER2- Breast Cancer (VIKTORIA-1)
NCT ID: NCT05501886 (https://clinicaltrials.gov/study/NCT05501886)

Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
NCT ID: NCT04511039 (https://clinicaltrials.gov/study/NCT04511039)

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer
NCT ID: NCT02610439 (https://clinicaltrials.gov/study/NCT02610439)

Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk
NCT ID: NCT05174286 (https://clinicaltrials.gov/study/NCT05174286)

GammaPod Dose Escalation Radiation for Early Stage Breast Cancer
NCT ID: NCT04234386 (https://clinicaltrials.gov/study/NCT04234386)

Clinical Trial of SOT102 Antibody Drug Conjugate in Patients With Advanced Gastric and Pancreatic Adenocarcinoma
NCT ID: NCT05525286 (https://clinicaltrials.gov/study/NCT05525286)

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT ID: NCT05832086 (https://clinicaltrials.gov/study/NCT05832086)

Longitudinal Sexual and Reproductive Health Study of Women With Breast Cancer and Lymphoma
NCT ID: NCT01788839 (https://clinicaltrials.gov/study/NCT01788839)

Frequency and Clinical Phenotype of BAP1 Hereditary Predisposition Syndrome
NCT ID: NCT04792463 (https://clinicaltrials.gov/study/NCT04792463)

Prostate Cancer Upgrading Reference Set
NCT ID: NCT02189486 (https://clinicaltrials.gov/study/NCT02189486)

Double-blind Randomized Controlled Trial Comparing Suvorexant 20 mg to Placebo for Treatment of Insomnia in Cancer Survivors
NCT ID: NCT06162663 (https://clinicaltrials.gov/study/NCT06162663)

Accuracy of 18F-rhPSMA-7.3 PET/ MRI for Prediction of Lymph Node Metastasis in Localized High-Risk Prostate Cancer
NCT ID: NCT06389786 (https://clinicaltrials.gov/study/NCT06389786)

Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors
NCT ID: NCT03385486 (https://clinicaltrials.gov/study/NCT03385486)

Gemcitabine, Nab-paclitaxel, Durvalumab, and Oleclumab Before Surgery for the Treatment of in Resectable/Borderline Resectable Primary Pancreatic Cancer
NCT ID: NCT04940286 (https://clinicaltrials.gov/study/NCT04940286)

Precision-Based Genomics in Prostate Cancer
NCT ID: NCT04706663 (https://clinicaltrials.gov/study/NCT04706663)

Study of DCC-3084 in Participants with Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway
NCT ID: NCT06287463 (https://clinicaltrials.gov/study/NCT06287463)

Exercise for Tumor Suppressive Impact in Black Men With Prostate Cancer on Active Surveillance: The REMOVE Trial
NCT ID: NCT05918263 (https://clinicaltrials.gov/study/NCT05918263)

GENOCARE: A Prospective, Randomized Clinical Trial of Genotype-Guided Dosing Versus Usual Care
NCT ID: NCT05391126 (https://clinicaltrials.gov/study/NCT05391126)

Microbiome and Association With Implant Infections
NCT ID: NCT05020574 (https://clinicaltrials.gov/study/NCT05020574)

Novel RNA-nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy
NCT ID: NCT05264974 (https://clinicaltrials.gov/study/NCT05264974)

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018
NCT ID: NCT04590326 (https://clinicaltrials.gov/study/NCT04590326)

First in Human Study of TORL-3-600 in Participants With Advanced Cancer
NCT ID: NCT05948826 (https://clinicaltrials.gov/study/NCT05948826)

Reinvigorating TNBC Response to Immunotherapy With Combination Myeloid Inhibition and Radiation
NCT ID: NCT05491226 (https://clinicaltrials.gov/study/NCT05491226)

A Study of NX-1607 in Adults With Advanced Malignancies
NCT ID: NCT05107674 (https://clinicaltrials.gov/study/NCT05107674)

Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
NCT ID: NCT05267626 (https://clinicaltrials.gov/study/NCT05267626)

Transrectal Ultrasound Robot-Assisted Prostate Biopsy
NCT ID: NCT02871726 (https://clinicaltrials.gov/study/NCT02871726)

COAST Therapy in Advanced Solid Tumors and Prostate Cancer
NCT ID: NCT05036226 (https://clinicaltrials.gov/study/NCT05036226)

Trial of 225Ac-DOTATATE (RYZ101) Alone and with Pembrolizumab in Subjects with ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs
NCT ID: NCT06590857 (https://clinicaltrials.gov/study/NCT06590857)

In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
NCT ID: NCT04616248 (https://clinicaltrials.gov/study/NCT04616248)

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1
NCT ID: NCT05870748 (https://clinicaltrials.gov/study/NCT05870748)

Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
NCT ID: NCT04991948 (https://clinicaltrials.gov/study/NCT04991948)

Anti-CEACAM5 ADC M9140 in Advanced Solid Tumors (PROCEADE-CRC-01)
NCT ID: NCT05464030 (https://clinicaltrials.gov/study/NCT05464030)

Pre-op Pembro + Radiation Therapy in Breast Cancer (P-RAD)
NCT ID: NCT04443348 (https://clinicaltrials.gov/study/NCT04443348)

A Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
NCT ID: NCT04707248 (https://clinicaltrials.gov/study/NCT04707248)

Study of Effect of Azeliragon in Patients Refractory to Prior Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT05766748 (https://clinicaltrials.gov/study/NCT05766748)

Study of TROP2 CAR Engineered IL15-transduced Cord Blood-derived NK Cells Delivered Intraperitoneally for the Management of Platinum Resistant Ovarian Cancer, Mesonephric-like Adenocarcinoma, and Pancreatic Cancer
NCT ID: NCT05922930 (https://clinicaltrials.gov/study/NCT05922930)

Weight Loss Interventions to Reduce Cancer Progression in Prostate Cancer Patients Under Active Surveillance
NCT ID: NCT05764330 (https://clinicaltrials.gov/study/NCT05764330)

Active Surveillance SNEP Assay Registry Trial for Prostate Cancer
NCT ID: NCT04052048 (https://clinicaltrials.gov/study/NCT04052048)

Study to Assess Colonic Microbiota Changes in Response to Energy Drink Consumption
NCT ID: NCT06137248 (https://clinicaltrials.gov/study/NCT06137248)

Support Through Remote Observation and Nutrition Guidance Program (STRONG-PCS)
NCT ID: NCT06001268 (https://clinicaltrials.gov/study/NCT06001268)

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)
NCT ID: NCT02993068 (https://clinicaltrials.gov/study/NCT02993068)

Phase I/IIa Study of AZD5335 as Monotherapy and Combination Therapy in Participants With Solid Tumors
NCT ID: NCT05797168 (https://clinicaltrials.gov/study/NCT05797168)

Exercise Post-Diagnosis of Breast Cancer
NCT ID: NCT04013568 (https://clinicaltrials.gov/study/NCT04013568)

A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors
NCT ID: NCT03611868 (https://clinicaltrials.gov/study/NCT03611868)

Phase I Study of Autologous CAR T-Cells Targeting the B7-H3 Antigen in Recurrent Epithelial Ovarian
NCT ID: NCT04670068 (https://clinicaltrials.gov/study/NCT04670068)

A Study of Pembrolizumab and Cryoablation in People with Breast Cancer
NCT ID: NCT06246968 (https://clinicaltrials.gov/study/NCT06246968)

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
NCT ID: NCT05692596 (https://clinicaltrials.gov/study/NCT05692596)

T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial
NCT ID: NCT04457596 (https://clinicaltrials.gov/study/NCT04457596)

A Study of ACR-368 in Ovarian Carcinoma, Endometrial Adenocarcinoma, and Urothelial Carcinoma
NCT ID: NCT05548296 (https://clinicaltrials.gov/study/NCT05548296)

A Study of Sacituzumab Govitecan (IMMU-132) in Endometrial Carcinoma
NCT ID: NCT04251416 (https://clinicaltrials.gov/study/NCT04251416)

Two Fraction Prostate SBRT With DIL SIB
NCT ID: NCT05864196 (https://clinicaltrials.gov/study/NCT05864196)

Evaluation of Talazoparib, a PARP Inhibitor, in Patients With Somatic BRCA Mutant Metastatic Breast Cancer: Genotyping Based Clinical Trial
NCT ID: NCT03990896 (https://clinicaltrials.gov/study/NCT03990896)

A Study to Find a Suitable Dose of ASP4396 in Adults With Solid Tumors
NCT ID: NCT06364696 (https://clinicaltrials.gov/study/NCT06364696)

Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
NCT ID: NCT03819296 (https://clinicaltrials.gov/study/NCT03819296)

Collection of Blood From Patients With Cancer
NCT ID: NCT00034216 (https://clinicaltrials.gov/study/NCT00034216)

Breast Cancer Survivor Educational Intervention
NCT ID: NCT05700396 (https://clinicaltrials.gov/study/NCT05700396)

PRISM: Pre-Operative Radiotherapy and Immunotherapy for Sinonasal Melanoma
NCT ID: NCT05546827 (https://clinicaltrials.gov/study/NCT05546827)

Pilot Comparing ctDNA IDV vs. SPV Sample in Pts Undergoing Biopsies for Hepatobiliary and Pancreatic Cancers
NCT ID: NCT05497531 (https://clinicaltrials.gov/study/NCT05497531)

FPI-2265 (225Ac-PSMA-I&T) for Patients With PSMA-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC)
NCT ID: NCT06402331 (https://clinicaltrials.gov/study/NCT06402331)

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831 (https://clinicaltrials.gov/study/NCT05797831)

A Phase 1/2 Study of [225Ac]-FPI-1434 Injection
NCT ID: NCT03746431 (https://clinicaltrials.gov/study/NCT03746431)

Comparing Two Methods to Follow Patients With Pancreatic Cysts
NCT ID: NCT04239573 (https://clinicaltrials.gov/study/NCT04239573)

Pembrolizumab Combined With Bevacizumab With or Without Agonist Anti-CD40 CDX-1140 for the Treatment of Patients With Recurrent Ovarian Cancer
NCT ID: NCT05231122 (https://clinicaltrials.gov/study/NCT05231122)

Phase 2A Pilot C3 Trial of Recurrent/Refractory Metastatic Advanced Pancreatic Cancer
NCT ID: NCT06030622 (https://clinicaltrials.gov/study/NCT06030622)

Evaluating the Effects of an Exercise Intervention on the Gut Microbiota in Stage II-III Colorectal Cancer Survivors
NCT ID: NCT05930496 (https://clinicaltrials.gov/study/NCT05930496)

Onvansertib + Paclitaxel in TNBC
NCT ID: NCT05383196 (https://clinicaltrials.gov/study/NCT05383196)

Cone Beam Breast CT for Breast Cancer Screening
NCT ID: NCT05036096 (https://clinicaltrials.gov/study/NCT05036096)

LOAd703 Oncolytic Virus Therapy for Pancreatic Cancer
NCT ID: NCT02705196 (https://clinicaltrials.gov/study/NCT02705196)

Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring
NCT ID: NCT05054296 (https://clinicaltrials.gov/study/NCT05054296)

A Study of XMT-1660 in Participants With Solid Tumors
NCT ID: NCT05377996 (https://clinicaltrials.gov/study/NCT05377996)

Evaluation of Xaluritamig in High-Risk, Biochemically Recurrent, Non-metastatic Castrate-sensitive Prostate Cancer
NCT ID: NCT06555796 (https://clinicaltrials.gov/study/NCT06555796)

Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy
NCT ID: NCT04997096 (https://clinicaltrials.gov/study/NCT04997096)

Lifestyle Intervention for the Reduction of Breast Cancer Risk in Normal Weight Women
NCT ID: NCT04267796 (https://clinicaltrials.gov/study/NCT04267796)

Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
NCT ID: NCT05462496 (https://clinicaltrials.gov/study/NCT05462496)

A Study of Mesothelin-Targeted CAR T-Cell Therapy in People With Esophagogastric Cancer
NCT ID: NCT06623396 (https://clinicaltrials.gov/study/NCT06623396)

A Study of MGC018 in Combination With MGD019 in Participants With Advanced Solid Tumors
NCT ID: NCT05293496 (https://clinicaltrials.gov/study/NCT05293496)

Prospective Screening for Pancreatic Ductal Adenocarcinoma in High-Risk Individuals
NCT ID: NCT06122896 (https://clinicaltrials.gov/study/NCT06122896)

Physical Rehabilitation Evaluation and Optimal Physical Therapy (PRE-OPT)
NCT ID: NCT04225572 (https://clinicaltrials.gov/study/NCT04225572)

EGF-Depleting Therapy CIMAvax-EGF in Combination With Standard Therapy for RAS- and BRAF Wild-Type Metastatic Colorectal Cancer
NCT ID: NCT06011772 (https://clinicaltrials.gov/study/NCT06011772)

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors
NCT ID: NCT05563272 (https://clinicaltrials.gov/study/NCT05563272)

A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
NCT ID: NCT02332668 (https://clinicaltrials.gov/study/NCT02332668)

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer
NCT ID: NCT04691804 (https://clinicaltrials.gov/study/NCT04691804)

Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
NCT ID: NCT05498272 (https://clinicaltrials.gov/study/NCT05498272)

A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies
NCT ID: NCT04104672 (https://clinicaltrials.gov/study/NCT04104672)

Tissue Procurement and Natural History Study of Patients With Malignant Mesothelioma
NCT ID: NCT01950572 (https://clinicaltrials.gov/study/NCT01950572)

Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
NCT ID: NCT05352672 (https://clinicaltrials.gov/study/NCT05352672)

Molecular Basis for Variations in Hereditary Colorectal Cancer Syndromes
NCT ID: NCT02863172 (https://clinicaltrials.gov/study/NCT02863172)

Telemedicine Use in Preoperative Counseling for Endometrial Cancer Survivors
NCT ID: NCT05712668 (https://clinicaltrials.gov/study/NCT05712668)

JAB-2485 Activity in Adult Patients With Advanced Solid Tumors
NCT ID: NCT05490472 (https://clinicaltrials.gov/study/NCT05490472)

Patient Decision-making About Precision Oncology in Veterans With Advanced Prostate Cancer
NCT ID: NCT05396872 (https://clinicaltrials.gov/study/NCT05396872)

Adaptive Approach to Neoadjuvant Therapy to Maximize Resection Rates for Pancreatic Adenocarcinoma
NCT ID: NCT04594772 (https://clinicaltrials.gov/study/NCT04594772)

Prospective Observational Exploratory Clinical Study to Determine the Assay Cut-Off for the RadTox Test in Prostate Cancer Patients to Predict Gastrointestinal Radiation Toxicity Using Circulating Cell Free DNA Directly From Plasma
NCT ID: NCT04580667 (https://clinicaltrials.gov/study/NCT04580667)

Study of REGN4018 Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers
NCT ID: NCT03564340 (https://clinicaltrials.gov/study/NCT03564340)

Molecular Analyses to Predict Pathways of Endocrine Resistance Following Short Term Neoadjuvant Endocrine Treatment in Patients with Hormone Receptor-Positive HER2-negative Breast Cancer
NCT ID: NCT06361940 (https://clinicaltrials.gov/study/NCT06361940)

Preoperative Irradiation for Stage I Breast Cancer
NCT ID: NCT05464667 (https://clinicaltrials.gov/study/NCT05464667)

Ultra-Hypofractionated vs. Hypofractionated Radiation for Node-Positive Breast Cancer
NCT ID: NCT06559540 (https://clinicaltrials.gov/study/NCT06559540)

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
NCT ID: NCT05372640 (https://clinicaltrials.gov/study/NCT05372640)

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer
NCT ID: NCT05130840 (https://clinicaltrials.gov/study/NCT05130840)

Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
NCT ID: NCT04902040 (https://clinicaltrials.gov/study/NCT04902040)

Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158)
NCT ID: NCT02628067 (https://clinicaltrials.gov/study/NCT02628067)

Cancer Genetic Testing in Ethnic Populations
NCT ID: NCT04475640 (https://clinicaltrials.gov/study/NCT04475640)

Early Detection of Advanced Adenomas and Colorectal Cancer
NCT ID: NCT06342440 (https://clinicaltrials.gov/study/NCT06342440)

Intra-Operative Radiation Registry
NCT ID: NCT04994067 (https://clinicaltrials.gov/study/NCT04994067)

Association Between Changes in the Gut Microbiome and Chemotherapy-Induced Nausea in Stage I-III Breast Cancer
NCT ID: NCT05417867 (https://clinicaltrials.gov/study/NCT05417867)

Time Restricted Eating (TRE) Among Endometrial Cancer Patients
NCT ID: NCT04783467 (https://clinicaltrials.gov/study/NCT04783467)

Zafirlukast in Treatment of Marker Relapsed Ovarian Cancer
NCT ID: NCT04339140 (https://clinicaltrials.gov/study/NCT04339140)

Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
NCT ID: NCT04879940 (https://clinicaltrials.gov/study/NCT04879940)

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
NCT ID: NCT05537740 (https://clinicaltrials.gov/study/NCT05537740)

Exercise to ReGain Stamina and Energy (The EXERGISE Study)
NCT ID: NCT05684367 (https://clinicaltrials.gov/study/NCT05684367)

Well-Being and Health-Related Quality of Life in Melanoma Patients During COVID-19 Pandemic
NCT ID: NCT04474301 (https://clinicaltrials.gov/study/NCT04474301)

Choices About Genetic Testing And Learning Your Risk With Smart Technology
NCT ID: NCT06184867 (https://clinicaltrials.gov/study/NCT06184867)

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
NCT ID: NCT05032040 (https://clinicaltrials.gov/study/NCT05032040)

A Study of ARV-766 Given by Mouth in Men With Metastatic Prostate Cancer
NCT ID: NCT05067140 (https://clinicaltrials.gov/study/NCT05067140)

Bevacizumab and/or Niraparib in Patients With Recurrent Endometrial and/or Ovarian Cancer With ARID1A Mutation
NCT ID: NCT05523440 (https://clinicaltrials.gov/study/NCT05523440)

Golf Recreational Exercise for Enhanced Survivorship in Prostate Cancer Survivors
NCT ID: NCT06500169 (https://clinicaltrials.gov/study/NCT06500169)

Evaluation of a Mixed Meal Test for Diagnosis and Characterization and Type 3c Diabetes Mellitus Secondary to Pancreatic Cancer and Chronic Pancreatitis (DETECT)
NCT ID: NCT03460769 (https://clinicaltrials.gov/study/NCT03460769)

Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer
NCT ID: NCT05318469 (https://clinicaltrials.gov/study/NCT05318469)

Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
NCT ID: NCT05239546 (https://clinicaltrials.gov/study/NCT05239546)

Palliadelic Treatment to Reduce Psychological Distress in Persons With Inoperable Pancreatobiliary Cancer
NCT ID: NCT05220046 (https://clinicaltrials.gov/study/NCT05220046)

A Study of Oral 7HP349 (Alintegimod) in Combination with Ipilimumab Followed by Nivolumab Monotherapy
NCT ID: NCT06362369 (https://clinicaltrials.gov/study/NCT06362369)

Pancreatic Cancer Genetics
NCT ID: NCT01102569 (https://clinicaltrials.gov/study/NCT01102569)

Multimodal Machine Learning Characterization of Solid Tumors
NCT ID: NCT04687969 (https://clinicaltrials.gov/study/NCT04687969)

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
NCT ID: NCT06465069 (https://clinicaltrials.gov/study/NCT06465069)

Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
NCT ID: NCT05534646 (https://clinicaltrials.gov/study/NCT05534646)

Effectiveness of the SpaceOAR Vue System in Subjects With Prostate Cancer Being Treated With Stereotactic Body Radiotherapy
NCT ID: NCT04905069 (https://clinicaltrials.gov/study/NCT04905069)

A Video Intervention to Improve Patient Understanding of Tumor Genomic Testing in Patients With Metastatic Cancer
NCT ID: NCT05215769 (https://clinicaltrials.gov/study/NCT05215769)

Locally ablatiVe therApy in oLigO-pRogressive sOlid tUmorS (VALOROUS)
NCT ID: NCT06103669 (https://clinicaltrials.gov/study/NCT06103669)

Leflunomide in Previously Treated Metastatic Triple Negative Cancers
NCT ID: NCT03709446 (https://clinicaltrials.gov/study/NCT03709446)

Comparing Single vs Multiple Dose Radiation for Cancer Patients With Brain Metastasis and Receiving Immunotherapy
NCT ID: NCT05703269 (https://clinicaltrials.gov/study/NCT05703269)

Study of PF-07248144 in Advanced or Metastatic Solid Tumors
NCT ID: NCT04606446 (https://clinicaltrials.gov/study/NCT04606446)

Dose-Reduced Docetaxel With Cyclophosphamide for the Treatment of Vulnerable Older Women With Stage I-III HER2 Negative Breast Cancer, the DOROTHY Trial
NCT ID: NCT06042569 (https://clinicaltrials.gov/study/NCT06042569)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT ID: NCT05334069 (https://clinicaltrials.gov/study/NCT05334069)

My Best GI Eating Study
NCT ID: NCT05396846 (https://clinicaltrials.gov/study/NCT05396846)

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT ID: NCT04354246 (https://clinicaltrials.gov/study/NCT04354246)

Olaparib in Combination With Either Durvalumab, Selumetinib, or Capivasertib or Ceralasertib Alone in Treating Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03801369 (https://clinicaltrials.gov/study/NCT03801369)

First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer
NCT ID: NCT06239467 (https://clinicaltrials.gov/study/NCT06239467)

Pancreatic Cancer Detection Consortium
NCT ID: NCT06388967 (https://clinicaltrials.gov/study/NCT06388967)

Cardiac Rehabilitation to Improve Breast Cancer Outcomes
NCT ID: NCT05867667 (https://clinicaltrials.gov/study/NCT05867667)

Generation of Heart Muscle Cells From Blood or Skin Cells of Breast Cancer Patients
NCT ID: NCT02772367 (https://clinicaltrials.gov/study/NCT02772367)

A Study of Radiation Therapy to Treat Solid Tumor Cancer That Has Spread to Soft Tissue
NCT ID: NCT05837767 (https://clinicaltrials.gov/study/NCT05837767)

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer
NCT ID: NCT04090567 (https://clinicaltrials.gov/study/NCT04090567)

Imaging of Primary or Recurrent Breast Cancer With 18F-FluorThanatrace PET/CT
NCT ID: NCT03846167 (https://clinicaltrials.gov/study/NCT03846167)

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer
NCT ID: NCT03606967 (https://clinicaltrials.gov/study/NCT03606967)

TmPSMA-02 in mCRPC
NCT ID: NCT06046040 (https://clinicaltrials.gov/study/NCT06046040)

TeleHealth Resistance Exercise Intervention to Preserve Dose Intensity and Vitality in Elder Breast Cancer Patients
NCT ID: NCT05535192 (https://clinicaltrials.gov/study/NCT05535192)

A Study to Evaluate the Intratumoral Influenza Vaccine Administration in Patients With Breast Cancer
NCT ID: NCT06229392 (https://clinicaltrials.gov/study/NCT06229392)

Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
NCT ID: NCT04007744 (https://clinicaltrials.gov/study/NCT04007744)

Outcomes and Cosmesis With Whole Breast Irradiation and Boost
NCT ID: NCT06295744 (https://clinicaltrials.gov/study/NCT06295744)

A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
NCT ID: NCT03899792 (https://clinicaltrials.gov/study/NCT03899792)

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
NCT ID: NCT05059444 (https://clinicaltrials.gov/study/NCT05059444)

Project: Every Child for Younger Patients With Cancer
NCT ID: NCT02402244 (https://clinicaltrials.gov/study/NCT02402244)

Phase II Investigation of Pembrolizumab in Combination With Bevacizumab and Oral Cyclophosphamide in Patients With High Grade Ovarian Cancer and Surgically Documented Minimal Residual Disease After Frontline Therapy
NCT ID: NCT06083844 (https://clinicaltrials.gov/study/NCT06083844)

FTT PET/CT in Metastatic Prostate Cancer
NCT ID: NCT05242744 (https://clinicaltrials.gov/study/NCT05242744)

Cabozantinib in Patients With Metastatic Castrate Resistant Prostate Cancer (mCRPC)
NCT ID: NCT04631744 (https://clinicaltrials.gov/study/NCT04631744)

LiSWT for Nerve Sparing Radical Prostatectomy ED
NCT ID: NCT05877144 (https://clinicaltrials.gov/study/NCT05877144)

Towards Understanding Between ADT Treatment, Circadian Rhythm, and Physiological Responsiveness
NCT ID: NCT05968144 (https://clinicaltrials.gov/study/NCT05968144)

Trial Evaluating Feasibility and Quality of Life of Second Look Laparoscopy With Hyperthermic Intraperitoneal Chemotherapy
NCT ID: NCT04415944 (https://clinicaltrials.gov/study/NCT04415944)

[Lu-177]Ludotadipep in Castration-resistant Prostate Cancer(CRPC): Investigation of Drug and Application
NCT ID: NCT05458544 (https://clinicaltrials.gov/study/NCT05458544)

Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
NCT ID: NCT04282044 (https://clinicaltrials.gov/study/NCT04282044)

Curcumin and Piperine in Patients on Surveillance for Monoclonal Gammopathy, Smoldering Myeloma or Prostate Cancer
NCT ID: NCT04731844 (https://clinicaltrials.gov/study/NCT04731844)

Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma.
NCT ID: NCT05727904 (https://clinicaltrials.gov/study/NCT05727904)

64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)
NCT ID: NCT04868604 (https://clinicaltrials.gov/study/NCT04868604)

A Study to Evaluate the Safety, Pharmacokinetics, and Activity of RO7502175 as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT05581004 (https://clinicaltrials.gov/study/NCT05581004)

Optimization of Prostate Biopsy - Micro-Ultrasound Versus MRI
NCT ID: NCT05220501 (https://clinicaltrials.gov/study/NCT05220501)

Hypo-fractionated Radiation Therapy With or Without Androgen Suppression for Intermediate Risk Prostate Cancer
NCT ID: NCT01492972 (https://clinicaltrials.gov/study/NCT01492972)

Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
NCT ID: NCT02021604 (https://clinicaltrials.gov/study/NCT02021604)

Improving Survival for Metastatic Lobular Breast Cancer (PLUMB Registry)
NCT ID: NCT05964504 (https://clinicaltrials.gov/study/NCT05964504)

A Prospective Study of Plasma Genotyping as a Noninvasive Biomarker for Genotype-directed Cancer Care
NCT ID: NCT02279004 (https://clinicaltrials.gov/study/NCT02279004)

Pilot Window of Opportunity Trial (POET)
NCT ID: NCT06129604 (https://clinicaltrials.gov/study/NCT06129604)

Study of 18F-FFNP Breast PET/MRI
NCT ID: NCT06086704 (https://clinicaltrials.gov/study/NCT06086704)

Cancer Experience Registry (CER) for Cancer Patients and Caregivers
NCT ID: NCT02333604 (https://clinicaltrials.gov/study/NCT02333604)

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
NCT ID: NCT05112601 (https://clinicaltrials.gov/study/NCT05112601)

A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1).
NCT ID: NCT05578872 (https://clinicaltrials.gov/study/NCT05578872)

Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
NCT ID: NCT04644068 (https://clinicaltrials.gov/study/NCT04644068)

Researching the Effect of Exercise on Cancer
NCT ID: NCT04589468 (https://clinicaltrials.gov/study/NCT04589468)

Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
NCT ID: NCT05751668 (https://clinicaltrials.gov/study/NCT05751668)

Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer
NCT ID: NCT03860272 (https://clinicaltrials.gov/study/NCT03860272)

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
NCT ID: NCT04657068 (https://clinicaltrials.gov/study/NCT04657068)

Identifying Underserved Individuals inTexas With Hereditary Cancer Risk Using Mobile Mammography Units and Telegenetics.
NCT ID: NCT05649072 (https://clinicaltrials.gov/study/NCT05649072)

Study of HRO761 Alone or in Combination in Cancer Patients With Specific DNA Alterations Called Microsatellite Instability or Mismatch Repair Deficiency.
NCT ID: NCT05838768 (https://clinicaltrials.gov/study/NCT05838768)

Assessing How Normal Variations in CT Scanning Affects Its Interpretation
NCT ID: NCT03038568 (https://clinicaltrials.gov/study/NCT03038568)

Pilot Study of (MR) Imaging With Pyruvate (13C) to Detect High Grade Prostate Cancer
NCT ID: NCT02526368 (https://clinicaltrials.gov/study/NCT02526368)

A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas
NCT ID: NCT05415072 (https://clinicaltrials.gov/study/NCT05415072)

Study of Autologous CAR-T Cells Targeting B7-H3 in TNBC iC9-CAR.B7-H3 T Cells
NCT ID: NCT06347068 (https://clinicaltrials.gov/study/NCT06347068)

A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
NCT ID: NCT06469281 (https://clinicaltrials.gov/study/NCT06469281)

The Effect of Diet and Exercise on ImmuNotherapy and the Microbiome (EDEN)
NCT ID: NCT04866810 (https://clinicaltrials.gov/study/NCT04866810)

Medical Imaging and Thermal Treatment for Breast Tumors Using Harmonic Motion Imaging (HMI)
NCT ID: NCT05219695 (https://clinicaltrials.gov/study/NCT05219695)

PET Scan Study to Detect Prostate Cancer in Patients with Early PSA Recurrence
NCT ID: NCT06617481 (https://clinicaltrials.gov/study/NCT06617481)

Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT06149481 (https://clinicaltrials.gov/study/NCT06149481)

A Study of Short-Course Radiation Therapy With Chemotherapy in People With Endometrial Cancer
NCT ID: NCT05691010 (https://clinicaltrials.gov/study/NCT05691010)

Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer
NCT ID: NCT05739981 (https://clinicaltrials.gov/study/NCT05739981)

The SUGAR Study: (SBRT and Ultrashort GnRH Antagonist-Relugolix) for Clinicogenomic Unfavorable Intermediate Risk Prostate Cancer
NCT ID: NCT06111781 (https://clinicaltrials.gov/study/NCT06111781)

Primary Breast Oligoprogressive Sites Treated With Radiotherapy to Obviate the Need to Change Systemic Therapy (BOSS)
NCT ID: NCT06055881 (https://clinicaltrials.gov/study/NCT06055881)

A QoL Intervention for Young African American Breast Cancer Survivors
NCT ID: NCT05452681 (https://clinicaltrials.gov/study/NCT05452681)

Reducing Metabolic Dysregulation in Obese Latina Breast Cancer Survivors Using Physical Activity
NCT ID: NCT04717050 (https://clinicaltrials.gov/study/NCT04717050)

Identification of Metabolic Phenotypes Associated With Melanoma Metastasis
NCT ID: NCT06400550 (https://clinicaltrials.gov/study/NCT06400550)

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
NCT ID: NCT04585750 (https://clinicaltrials.gov/study/NCT04585750)

Feasibility Study of Oral Ketamine Versus Placebo for the Treatment of Anxiety in Patients with Pancreatic Cancer
NCT ID: NCT05086250 (https://clinicaltrials.gov/study/NCT05086250)

A Phase II Study of Futibatinib and Pembrolizumab in Metastatic Microsatellite Stable Endometrial Carcinoma
NCT ID: NCT05036681 (https://clinicaltrials.gov/study/NCT05036681)

An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
NCT ID: NCT03897881 (https://clinicaltrials.gov/study/NCT03897881)

Converting HR+ Breast Cancer Into an Individualized Vaccine
NCT ID: NCT03804944 (https://clinicaltrials.gov/study/NCT03804944)

Mindfulness in Endometrial and Cervical Cancer
NCT ID: NCT04512144 (https://clinicaltrials.gov/study/NCT04512144)

CAR T Cell Immunotherapy for Pancreatic Cancer
NCT ID: NCT03323944 (https://clinicaltrials.gov/study/NCT03323944)

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
NCT ID: NCT05912244 (https://clinicaltrials.gov/study/NCT05912244)

Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer
NCT ID: NCT04787744 (https://clinicaltrials.gov/study/NCT04787744)

A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
NCT ID: NCT05864144 (https://clinicaltrials.gov/study/NCT05864144)

Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors
NCT ID: NCT05511844 (https://clinicaltrials.gov/study/NCT05511844)

A Study to Evaluate the Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension in Triple Negative Breast Cancer Patients
NCT ID: NCT03671044 (https://clinicaltrials.gov/study/NCT03671044)

Contrast Enhanced Spectral Mammography for the Evaluation of Pathologic Nipple Discharge
NCT ID: NCT05056844 (https://clinicaltrials.gov/study/NCT05056844)

Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast
NCT ID: NCT04009044 (https://clinicaltrials.gov/study/NCT04009044)

Exercise Timing in Breast Cancer Patients
NCT ID: NCT05821244 (https://clinicaltrials.gov/study/NCT05821244)

A Tissue Collection Study in Patients Who Respond to Immune Checkpoint Inhibitors to Identify Targets of Tumor-Reactive T Cells.
NCT ID: NCT05230186 (https://clinicaltrials.gov/study/NCT05230186)

Platform Study of Immunotherapy Combinations in Colorectal Cancer Liver Metastases
NCT ID: NCT06300463 (https://clinicaltrials.gov/study/NCT06300463)

Couple-Based Mindfulness Intervention for Metastatic Colorectal Cancer
NCT ID: NCT05840263 (https://clinicaltrials.gov/study/NCT05840263)

Adaptive Stereotactic Body Radiation Therapy to the Prostate and Pelvic Nodes With Simultaneous Integrated Boost to the MR-detected Nodule for Patients With High-risk and Unfavorable Intermediate-risk Prostate Cancer
NCT ID: NCT05628363 (https://clinicaltrials.gov/study/NCT05628363)

Evaluation of Lasofoxifene Combined with Abemaciclib Compared with Fulvestrant Combined with Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer with an ESR1 Mutation
NCT ID: NCT05696626 (https://clinicaltrials.gov/study/NCT05696626)

Prehabilitation for Stage IIIC-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients
NCT ID: NCT05047926 (https://clinicaltrials.gov/study/NCT05047926)

Use of Serial Plasma NGS as a New Efficacy Metric to Guide Immunotherapy Treatment Discontinuation
NCT ID: NCT06146920 (https://clinicaltrials.gov/study/NCT06146920)

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 Patients
NCT ID: NCT03745326 (https://clinicaltrials.gov/study/NCT03745326)

Phase 1/2 Study to Evaluate EP0062 in Patients With Relapsed Locally Advanced or Metastatic Androgen Receptor Positive (AR+)/HER2-/ER+ Breast Cancer
NCT ID: NCT05573126 (https://clinicaltrials.gov/study/NCT05573126)

Perioperative Gemcitabine, Cisplatin, and Pembrolizumab in Potentially Resectable Biliary Tract Cancers
NCT ID: NCT06001658 (https://clinicaltrials.gov/study/NCT06001658)

Evaluating Mechanical Properties of Post-Mastectomy Skin Flaps to Estimate Reconstruction Risks, the EMPOWER Study
NCT ID: NCT06584396 (https://clinicaltrials.gov/study/NCT06584396)

Prediction of Neoadjuvant Chemotherapy Response Using Contrast-Enhanced Ultrasound in Patients With Locally Advanced Breast Cancer
NCT ID: NCT04715958 (https://clinicaltrials.gov/study/NCT04715958)

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors
NCT ID: NCT04751396 (https://clinicaltrials.gov/study/NCT04751396)

Stage II/III Colorectal Cancer Recurrence
NCT ID: NCT06314958 (https://clinicaltrials.gov/study/NCT06314958)

Study of Belzutifan (MK-6482) Plus Fulvestrant for ER+/HER2- Metastatic Breast Cancer (MK-6482-029/LITESPARK-029)
NCT ID: NCT06428396 (https://clinicaltrials.gov/study/NCT06428396)

Protocol for Women at Increased Risk of Developing Breast Cancer
NCT ID: NCT00291096 (https://clinicaltrials.gov/study/NCT00291096)

A Phase II Study Evaluating an Organ Preservation Strategy Using Immune Checkpoint Blockade for Participants With Primary Colorectal or Gastroesophageal Cancer
NCT ID: NCT06410534 (https://clinicaltrials.gov/study/NCT06410534)

Pulmonary Suffusion in Controlling Minimal Residual Disease in Patients With Sarcoma or Colorectal Metastases
NCT ID: NCT03965234 (https://clinicaltrials.gov/study/NCT03965234)

Brain and Pelvic Floor Muscle Activity of Patients Who Had or Are Undergoing Robot-Assisted Radical Prostatectomy
NCT ID: NCT04646434 (https://clinicaltrials.gov/study/NCT04646434)

A Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer
NCT ID: NCT04898634 (https://clinicaltrials.gov/study/NCT04898634)

Tumor Genomic Pre-test Counseling Tool for Black or African-American Men With Prostate Cancer
NCT ID: NCT06171139 (https://clinicaltrials.gov/study/NCT06171139)

Robotic vs. Open NSM for Early Stage Breast Cancer
NCT ID: NCT05720039 (https://clinicaltrials.gov/study/NCT05720039)

Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
NCT ID: NCT04633239 (https://clinicaltrials.gov/study/NCT04633239)

Nivolumab and Ipilimumab and Radiation Therapy in MSS and MSI High Colorectal and Pancreatic Cancer
NCT ID: NCT03104439 (https://clinicaltrials.gov/study/NCT03104439)

Johns Hopkins Breast Cancer Program Longitudinal Repository
NCT ID: NCT01937039 (https://clinicaltrials.gov/study/NCT01937039)

Role of rhPSMA-7.3 PET/CT Imaging in Men With High-Risk Prostate Cancer Following Conventional Imaging and Associated Changes in Medical Management
NCT ID: NCT05799248 (https://clinicaltrials.gov/study/NCT05799248)

7T MRI Scan for the Early Detection of Melanoma Brain Metastases
NCT ID: NCT04941430 (https://clinicaltrials.gov/study/NCT04941430)

Immune Response Activation for the Treatment of Unresectable Metastatic Colorectal Cancer or CEA Positive Metastatic Breast Cancer
NCT ID: NCT06130826 (https://clinicaltrials.gov/study/NCT06130826)

Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
NCT ID: NCT04990726 (https://clinicaltrials.gov/study/NCT04990726)

Testing the Addition of Total Ablative Therapy to Usual Systemic Therapy Treatment for Limited Metastatic Colorectal Cancer, The ERASur Study
NCT ID: NCT05673148 (https://clinicaltrials.gov/study/NCT05673148)

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy
NCT ID: NCT05990426 (https://clinicaltrials.gov/study/NCT05990426)

Study of Stereotactic Radiosurgery With Olaparib Followed by Durvalumab and Physician's Choice Systemic Therapy in Subjects With Breast Cancer Brain Metastases
NCT ID: NCT04711824 (https://clinicaltrials.gov/study/NCT04711824)

Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)
NCT ID: NCT06136624 (https://clinicaltrials.gov/study/NCT06136624)

Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
NCT ID: NCT06075524 (https://clinicaltrials.gov/study/NCT06075524)

Ablative Therapy in the Management of Prostate Cancer
NCT ID: NCT03492424 (https://clinicaltrials.gov/study/NCT03492424)

A Study of GV20-0251 Monotherapy and GV20-0251 in Combination with Pembrolizumab in Participants with Solid Tumor Malignancies
NCT ID: NCT05669430 (https://clinicaltrials.gov/study/NCT05669430)

A Study of U3-1402 (Patritumab Deruxtecan) in Subjects With Metastatic Breast Cancer
NCT ID: NCT04699630 (https://clinicaltrials.gov/study/NCT04699630)

Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer
NCT ID: NCT05877430 (https://clinicaltrials.gov/study/NCT05877430)

Computed Tomography in Diagnosing Patients With Pancreatic or Hepatobiliary Cancer
NCT ID: NCT02361320 (https://clinicaltrials.gov/study/NCT02361320)

AOH1996 for the Treatment of Refractory Solid Tumors
NCT ID: NCT05227326 (https://clinicaltrials.gov/study/NCT05227326)

Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT ID: NCT05879926 (https://clinicaltrials.gov/study/NCT05879926)

Regorafenib Combined With Fulvestrant in Recurrent Low-Grade Serous Ovarian Cancer
NCT ID: NCT05113368 (https://clinicaltrials.gov/study/NCT05113368)

Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer
NCT ID: NCT04648904 (https://clinicaltrials.gov/study/NCT04648904)

BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
NCT ID: NCT04891068 (https://clinicaltrials.gov/study/NCT04891068)

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer
NCT ID: NCT05929768 (https://clinicaltrials.gov/study/NCT05929768)

Study of Oral MRT-2359 in Selected Cancer Patients
NCT ID: NCT05546268 (https://clinicaltrials.gov/study/NCT05546268)

Phase II Trial of Trilaciclib, Pembrolizumab, Gemcitabine and Carboplatin in Metastatic Triple-Negative Breast Cancer
NCT ID: NCT06027268 (https://clinicaltrials.gov/study/NCT06027268)

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors
NCT ID: NCT05039801 (https://clinicaltrials.gov/study/NCT05039801)

Couples' QOL in Metastatic Breast Cancer
NCT ID: NCT05636943 (https://clinicaltrials.gov/study/NCT05636943)

Utilizing Continuous Glucose Monitoring to Characterize and Manage Hyperglycemia in Patients Initiating Alpelisib
NCT ID: NCT06083038 (https://clinicaltrials.gov/study/NCT06083038)

Preserving Fertility After Colorectal Cancer Study
NCT ID: NCT05239338 (https://clinicaltrials.gov/study/NCT05239338)

CEND-1 in Combination With Neoadjuvant FOLFIRINOX With or Without Panitumumab
NCT ID: NCT05121038 (https://clinicaltrials.gov/study/NCT05121038)

Panitumumab-IRDye800 in Patients With Pancreatic Cancer Undergoing Surgery
NCT ID: NCT03384238 (https://clinicaltrials.gov/study/NCT03384238)

Therapeutic Effect of Cytoreductive Radical Prostatectomy in Men With Newly Diagnosed Metastatic Prostate Cancer
NCT ID: NCT03456843 (https://clinicaltrials.gov/study/NCT03456843)

Randomized Trial of Five or Two MRI-Guided Adaptive Radiotherapy Treatments for Prostate Cancer
NCT ID: NCT04984343 (https://clinicaltrials.gov/study/NCT04984343)

Determine the Utility of Liquid Biopsies and Tumor Molecular Profiling in Predicting Recurrence in High-Risk Endometrial Cancers
NCT ID: NCT05049538 (https://clinicaltrials.gov/study/NCT05049538)

Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment Prostate Cancer
NCT ID: NCT06369610 (https://clinicaltrials.gov/study/NCT06369610)

A Study of Focal Salvage High-Dose-Rate Brachytherapy for Prostate Gland Only Recurrence
NCT ID: NCT04645810 (https://clinicaltrials.gov/study/NCT04645810)

PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer
NCT ID: NCT06074510 (https://clinicaltrials.gov/study/NCT06074510)

Prospective Analysis of EnVisio Spatial Intelligence for Soft Tissue Localization and Guided Surgical Excision
NCT ID: NCT06572410 (https://clinicaltrials.gov/study/NCT06572410)

Sexual Health in Breast Cancer Patients
NCT ID: NCT05138510 (https://clinicaltrials.gov/study/NCT05138510)

Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma or Hormone Receptor Positive Her2 Negative Metastatic Refractory Breast Cancer
NCT ID: NCT05098210 (https://clinicaltrials.gov/study/NCT05098210)

Prospective Randomized Study of Accelerated Radiation Therapy (PRART)
NCT ID: NCT04175210 (https://clinicaltrials.gov/study/NCT04175210)

1911GCCC: Galeterone or Galeterone With Gemcitabine for Patients With Metastatic Pancreatic Adenocarcinoma
NCT ID: NCT04098081 (https://clinicaltrials.gov/study/NCT04098081)

KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors
NCT ID: NCT06026410 (https://clinicaltrials.gov/study/NCT06026410)

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine
NCT ID: NCT03854110 (https://clinicaltrials.gov/study/NCT03854110)

Assessing the Immunogenicity of PING-hHER3FL
NCT ID: NCT03832855 (https://clinicaltrials.gov/study/NCT03832855)

Hepatic Artery Infusion Pump Chemotherapy With Floxuridine and Dexamethasone in Combination With Systemic Chemotherapy for Patients With Colorectal Cancer Metastatic to the Liver
NCT ID: NCT03366155 (https://clinicaltrials.gov/study/NCT03366155)

Niraparib + Dostarlimab in BRCA Mutated Breast Cancer
NCT ID: NCT04584255 (https://clinicaltrials.gov/study/NCT04584255)

Hypofractionated Accelerated Pelvic Nodal Radiotherapy (GCC 2048)
NCT ID: NCT04486755 (https://clinicaltrials.gov/study/NCT04486755)

ETHAN - ET for Male BC
NCT ID: NCT05501704 (https://clinicaltrials.gov/study/NCT05501704)

DS8201a and Pembrolizumab in Participants With Locally Advanced/Metastatic Breast or Non-Small Cell Lung Cancer
NCT ID: NCT04042701 (https://clinicaltrials.gov/study/NCT04042701)

Clinical Trial of Approaches to Prostate Cancer Surgery
NCT ID: NCT05155501 (https://clinicaltrials.gov/study/NCT05155501)

War on Melanoma™ Public Health & Education Campaign
NCT ID: NCT04611568 (https://clinicaltrials.gov/study/NCT04611568)

Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
NCT ID: NCT06228768 (https://clinicaltrials.gov/study/NCT06228768)

The Safety and Pharmacokinetics Preliminary Efficacy of IMP7068 in Patients With Advanced Solid Tumors
NCT ID: NCT04768868 (https://clinicaltrials.gov/study/NCT04768868)

A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in Women Post Menopause
NCT ID: NCT06465368 (https://clinicaltrials.gov/study/NCT06465368)

A Study of Metastatic Gastrointestinal Cancers Treated With Tumor Infiltrating Lymphocytes in Which the Gene Encoding the Intracellular Immune Checkpoint CISH Is Inhibited Using CRISPR Genetic Engineering
NCT ID: NCT04426669 (https://clinicaltrials.gov/study/NCT04426669)

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.
NCT ID: NCT05230810 (https://clinicaltrials.gov/study/NCT05230810)

The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
NCT ID: NCT04541381 (https://clinicaltrials.gov/study/NCT04541381)

Biomarker Monitoring of Prostate Cancer Patients With RSI MRI (ProsRSI)
NCT ID: NCT04349501 (https://clinicaltrials.gov/study/NCT04349501)

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy
NCT ID: NCT01834001 (https://clinicaltrials.gov/study/NCT01834001)

A Study of Multiparametric MRI and pHLIP® ICG in Breast Cancer Imaging During Surgery
NCT ID: NCT05130801 (https://clinicaltrials.gov/study/NCT05130801)

National Cancer Institute "Cancer Moonshot Biobank"
NCT ID: NCT04314401 (https://clinicaltrials.gov/study/NCT04314401)

TRUDI: TDXD+Durva in HER2+/low IBC
NCT ID: NCT05795101 (https://clinicaltrials.gov/study/NCT05795101)

A Study to Learn About the Study Medicine Called PF-07799933 in People With Advanced Solid Tumors With BRAF Alterations.
NCT ID: NCT05355701 (https://clinicaltrials.gov/study/NCT05355701)

Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer
NCT ID: NCT05705401 (https://clinicaltrials.gov/study/NCT05705401)

Contrast-Enhanced Mammography for the Evaluation of Mammographic Microcalcifications
NCT ID: NCT05046301 (https://clinicaltrials.gov/study/NCT05046301)

Proglumide and Chemotherapy for Metastatic Pancreatic Cancer
NCT ID: NCT05827055 (https://clinicaltrials.gov/study/NCT05827055)

Trial of Neoadjuvant Enoblituzumab vs SOC in Men With High-Risk Localized Prostate Cancer
NCT ID: NCT06014255 (https://clinicaltrials.gov/study/NCT06014255)

Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
NCT ID: NCT06016855 (https://clinicaltrials.gov/study/NCT06016855)

Adaptive Symptom Self-Management Immunotherapy Study
NCT ID: NCT05715255 (https://clinicaltrials.gov/study/NCT05715255)

Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
NCT ID: NCT04273555 (https://clinicaltrials.gov/study/NCT04273555)

Testing Longer Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients With Cancer That Has Spread to the Brain
NCT ID: NCT06500455 (https://clinicaltrials.gov/study/NCT06500455)

The Breast Cancer Survivors and Partners Online Research Together (SUPORT) Project
NCT ID: NCT05676255 (https://clinicaltrials.gov/study/NCT05676255)

The Utility and Feasibility of Mt-sDNA as a Surveillance Procedure in Colorectal Cancer Survivors
NCT ID: NCT04624555 (https://clinicaltrials.gov/study/NCT04624555)

A Study to Determine the Preferred Dose of the Drug, Lisinopril, for Preventing Urinary Toxicity Following Radiotherapy for Prostate Cancer
NCT ID: NCT05530655 (https://clinicaltrials.gov/study/NCT05530655)

A Study of BMS-986484 Alone and Combination Therapy in Participants With Advanced Solid Tumors
NCT ID: NCT06544655 (https://clinicaltrials.gov/study/NCT06544655)

NeoTAILOR: ABiomarker-directed Approach to Guide Neoadjuvant Therapy for Patients With Stage II/III ER-positive, HER2-negative Breast Cancer
NCT ID: NCT05837455 (https://clinicaltrials.gov/study/NCT05837455)

Phase 3 Study to Evaluate the Efficacy and Safety of HER2/neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/neu Positive Subjects
NCT ID: NCT05232916 (https://clinicaltrials.gov/study/NCT05232916)

A Study of Sovilnesib in Subjects with Ovarian Cancer
NCT ID: NCT06084416 (https://clinicaltrials.gov/study/NCT06084416)

A Trial to Find Out if REGN4336 is Safe and How Well it Works Alone and in Combination With Cemiplimab or REGN5678 for Adult Participants With Advanced Prostate Cancer
NCT ID: NCT05125016 (https://clinicaltrials.gov/study/NCT05125016)

A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma
NCT ID: NCT06246916 (https://clinicaltrials.gov/study/NCT06246916)

A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors
NCT ID: NCT06208124 (https://clinicaltrials.gov/study/NCT06208124)

Axitinib and Nivolumab for the Treatment of Mucosal Melanoma
NCT ID: NCT05384496 (https://clinicaltrials.gov/study/NCT05384496)

This Study is Evaluating a New Radiation Treatment Technique for Patients Who Have Had Prostate Cancer, Undergone Surgery for Cancer, and Then Have Evidence That Their Prostate Cancer Has Returned.
NCT ID: NCT05946824 (https://clinicaltrials.gov/study/NCT05946824)

Long-Term Follow-Up in Women With Early Breast Cancer Three Years of More Post Primary Treatment
NCT ID: NCT05926024 (https://clinicaltrials.gov/study/NCT05926024)

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer
NCT ID: NCT06551116 (https://clinicaltrials.gov/study/NCT06551116)

EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
NCT ID: NCT05715216 (https://clinicaltrials.gov/study/NCT05715216)

Opening the Conversation Study
NCT ID: NCT04806724 (https://clinicaltrials.gov/study/NCT04806724)

A Study of Effect of Megakaryocytes and Platelets in Breast Cancer
NCT ID: NCT06011824 (https://clinicaltrials.gov/study/NCT06011824)

Myeloid-Derived Suppressor Cell Function in Breast Cancer Patients
NCT ID: NCT04022616 (https://clinicaltrials.gov/study/NCT04022616)

ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in Recurrent and/or Refractory Solid Tumors
NCT ID: NCT03686124 (https://clinicaltrials.gov/study/NCT03686124)

Metabolic Impact of Prospective Controlled Mediterranean Type Diets on Prostate Cancer
NCT ID: NCT05590624 (https://clinicaltrials.gov/study/NCT05590624)

A Diagnostic Test to Evaluate Cancer Risk Before Surgery in Women With an Ovarian Mass
NCT ID: NCT06566716 (https://clinicaltrials.gov/study/NCT06566716)

Study of EO-3021 in Adult Patients With Solid Tumors Likely to Express CLDN18.2
NCT ID: NCT05980416 (https://clinicaltrials.gov/study/NCT05980416)

Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)
NCT ID: NCT04568616 (https://clinicaltrials.gov/study/NCT04568616)

What Women Want: Real Time Results During Screening Mammography in the Era of Patient-Experience Driven Care
NCT ID: NCT04794816 (https://clinicaltrials.gov/study/NCT04794816)

64Cu-LNTH-1363S in Patients with Sarcoma or Gastrointestinal Tract Cancer
NCT ID: NCT06298916 (https://clinicaltrials.gov/study/NCT06298916)

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc
NCT ID: NCT05351424 (https://clinicaltrials.gov/study/NCT05351424)

International PPB/DICER1 Registry
NCT ID: NCT03382158 (https://clinicaltrials.gov/study/NCT03382158)

Study to Determine the Safety, Tolerability, Pharmacokinetics and Recommended Phase 2 Dose (RP2D) of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Participants With Locally Advanced or Metastatic Solid Tumors
NCT ID: NCT03821935 (https://clinicaltrials.gov/study/NCT03821935)

Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
NCT ID: NCT04074135 (https://clinicaltrials.gov/study/NCT04074135)

M9466 as Single Agent or in Combination With Tuvusertib in Advanced Solid Tumors (DDRiver 501)
NCT ID: NCT06421935 (https://clinicaltrials.gov/study/NCT06421935)

Dietary Intervention in Patients With a History of Melanoma
NCT ID: NCT03950635 (https://clinicaltrials.gov/study/NCT03950635)

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC
NCT ID: NCT03439735 (https://clinicaltrials.gov/study/NCT03439735)

Serial MRI Scans During Radiation Therapy
NCT ID: NCT04188535 (https://clinicaltrials.gov/study/NCT04188535)

Neoadjuvant SGLT2 Inhibition in High-Risk Localized Prostate Cancer
NCT ID: NCT04887935 (https://clinicaltrials.gov/study/NCT04887935)

Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity
NCT ID: NCT06542835 (https://clinicaltrials.gov/study/NCT06542835)

Individualized Response Assessment to Heated Intraperitoneal Chemotherapy (HIPEC) for the Treatment of Peritoneal Carcinomatosis From Ovarian, Colorectal, Appendiceal, or Peritoneal Mesothelioma Histologies
NCT ID: NCT04847063 (https://clinicaltrials.gov/study/NCT04847063)

Capivasertib + CDK4/6i + Fulvestrant for Advanced/Metastatic HR+/HER2- Breast Cancer (CAPItello-292)
NCT ID: NCT04862663 (https://clinicaltrials.gov/study/NCT04862663)

Minimally Invasive Surgery After Neoadjuvant Chemotherapy for the Treatment of Stage IIIC-IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer, LANCE Trial
NCT ID: NCT04575935 (https://clinicaltrials.gov/study/NCT04575935)

A Study of DSP107 Alone and in Combination with Atezolizumab for Patients with Advanced Solid Tumors
NCT ID: NCT04440735 (https://clinicaltrials.gov/study/NCT04440735)

Pembrolizumab in Combination With Olaparib in Advanced BRCA-mutated or HDR-defect Breast Cancer
NCT ID: NCT03025035 (https://clinicaltrials.gov/study/NCT03025035)

Living WELL: A Web-Based Program for Ovarian Cancer Survivors
NCT ID: NCT04533763 (https://clinicaltrials.gov/study/NCT04533763)

Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
NCT ID: NCT05998135 (https://clinicaltrials.gov/study/NCT05998135)

FOLFOX and Bevacizumab in Combination With Botensilimab and Balstilimab (3B-FOLFOX) for the Treatment of Microsatellite Stable (MSS) Metastatic Colorectal Cancer
NCT ID: NCT05627635 (https://clinicaltrials.gov/study/NCT05627635)

Utility of Biparametric MRI (Magnetic Resonance Imaging) as a Screening Tool for Prostate Cancer in a High-Risk Cohort
NCT ID: NCT05384535 (https://clinicaltrials.gov/study/NCT05384535)

11C-YJH08 PET Imaging for Detection of Glucocorticoid Receptor Expression
NCT ID: NCT04927663 (https://clinicaltrials.gov/study/NCT04927663)

A Study to Investigate LYL845 in Adults With Solid Tumors
NCT ID: NCT05573035 (https://clinicaltrials.gov/study/NCT05573035)

Breast Cancer Resiliency Through Exercise Program (B-REP)
NCT ID: NCT06100263 (https://clinicaltrials.gov/study/NCT06100263)

Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
NCT ID: NCT04158635 (https://clinicaltrials.gov/study/NCT04158635)

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
NCT ID: NCT03526835 (https://clinicaltrials.gov/study/NCT03526835)

Ulixertinib/Palbociclib in Patients With Advanced Pancreatic and Other Solid Tumors
NCT ID: NCT03454035 (https://clinicaltrials.gov/study/NCT03454035)

A Study of PF-08046049/SGN-BB228 in Advanced Melanoma and Other Solid Tumors
NCT ID: NCT05571839 (https://clinicaltrials.gov/study/NCT05571839)

Contrast-Enhanced Ultrasound Scan for the Estimation of Tissue Pressure in Patients With Breast Cancer
NCT ID: NCT04721886 (https://clinicaltrials.gov/study/NCT04721886)

Prostate Cancer Diagnosis by Multiparametric Ultrasound (Wholemount)
NCT ID: NCT05336786 (https://clinicaltrials.gov/study/NCT05336786)

Targeted Alpha Particle Radiotherapy for Metastatic Uveal Melanoma
NCT ID: NCT05496686 (https://clinicaltrials.gov/study/NCT05496686)

Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
NCT ID: NCT03987386 (https://clinicaltrials.gov/study/NCT03987386)

Biologically Optimized Infusion Schedule of Gemcitabine and Nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer
NCT ID: NCT04115163 (https://clinicaltrials.gov/study/NCT04115163)

Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC
NCT ID: NCT06193486 (https://clinicaltrials.gov/study/NCT06193486)

All-extremity Exercise During Breast Cancer Chemotherapy
NCT ID: NCT04914663 (https://clinicaltrials.gov/study/NCT04914663)

Evaluation of PET Probe [68Ga]CBP8 in the Detection of Radiation Induced Tissue Injury
NCT ID: NCT04485286 (https://clinicaltrials.gov/study/NCT04485286)

A Phase 1/2 Study to Evaluate CHM-2101, an Autologous Cadherin 17 Chimeric Antigen Receptor (CAR) T Cell Therapy
NCT ID: NCT06055439 (https://clinicaltrials.gov/study/NCT06055439)

Endocrine Treatment Alone for Elderly Patients With Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score
NCT ID: NCT02476786 (https://clinicaltrials.gov/study/NCT02476786)

EO2 Oxygen Delivery To Study Success Rate of Surgically Closed Wounds
NCT ID: NCT03960463 (https://clinicaltrials.gov/study/NCT03960463)

Pilot Study to Determine Pro-Inflammatory Cytokine Kinetics During Immune Checkpoint Inhibitor Therapy
NCT ID: NCT05707286 (https://clinicaltrials.gov/study/NCT05707286)

Intraperitoneal FT536 in Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer
NCT ID: NCT06342986 (https://clinicaltrials.gov/study/NCT06342986)

Evaluation of the Impact of Empty Versus Full Bladder in Patients With Prostate Cancer, RELIEF Trial
NCT ID: NCT06037863 (https://clinicaltrials.gov/study/NCT06037863)

A Prospective, Multi-center, Observational Study for Signal-C Test Evaluation
NCT ID: NCT06059963 (https://clinicaltrials.gov/study/NCT06059963)

LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
NCT ID: NCT05900986 (https://clinicaltrials.gov/study/NCT05900986)

A Study of PT217 in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study)
NCT ID: NCT05652686 (https://clinicaltrials.gov/study/NCT05652686)

NM32-2668 in Adult Patients With Selected Advanced Solid Tumors
NCT ID: NCT06299163 (https://clinicaltrials.gov/study/NCT06299163)

Talazoparib With Androgen Deprivation Therapy and Abiraterone for the Treatment of Castration Sensitive Prostate Cancer
NCT ID: NCT04734730 (https://clinicaltrials.gov/study/NCT04734730)

A Study of Nivolumab, Nivolumab Plus Ipilimumab, or Investigator's Choice Chemotherapy for the Treatment of Participants With Deficient Mismatch Repair (dMMR)/Microsatellite Instability High (MSI-H) Metastatic Colorectal Cancer (mCRC)
NCT ID: NCT04008030 (https://clinicaltrials.gov/study/NCT04008030)

Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer
NCT ID: NCT05553522 (https://clinicaltrials.gov/study/NCT05553522)

Optimizing Timing of rhPSMA-7.3 (18F) for Assessing Site(s) of Recurrent Disease Following Radical Prostatectomy
NCT ID: NCT05678322 (https://clinicaltrials.gov/study/NCT05678322)

AMNIOX CORD Study - Radical Prostatectomy With and Without Cryopreserved Umbilical Cord Allograft
NCT ID: NCT04263025 (https://clinicaltrials.gov/study/NCT04263025)

AGN-CognI.Q Acute Dose Safety and Pharmacokinetics Dose-Response in Prostate Cancer Patients
NCT ID: NCT05375539 (https://clinicaltrials.gov/study/NCT05375539)

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer
NCT ID: NCT06479239 (https://clinicaltrials.gov/study/NCT06479239)

Preventing Chemotherapy-Induced Peripheral Neuropathy With Acupuncture (PACT Trial)
NCT ID: NCT05528263 (https://clinicaltrials.gov/study/NCT05528263)

Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
NCT ID: NCT04918186 (https://clinicaltrials.gov/study/NCT04918186)

Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
NCT ID: NCT03420963 (https://clinicaltrials.gov/study/NCT03420963)

EXERT-BCH Exercise Regimen to Improve Muscle Mass After Treatment of Breast Cancer
NCT ID: NCT06115486 (https://clinicaltrials.gov/study/NCT06115486)

Evaluation of a Targeted Magnetic Resonance Imaging Contrast Agent in Prostate Cancer Patients
NCT ID: NCT06262139 (https://clinicaltrials.gov/study/NCT06262139)

Breast/Cyclosporin A/TNBC (Triple Negative Breast Cancer)
NCT ID: NCT06246786 (https://clinicaltrials.gov/study/NCT06246786)

Nano-SMART: Nanoparticles With MR Guided SBRT in Centrally Located Lung Tumors and Pancreatic Cancer
NCT ID: NCT04789486 (https://clinicaltrials.gov/study/NCT04789486)

Young Melanoma Family Facebook Intervention or Healthy Lifestyle Facebook Intervention in Improving Skin Examination in Participants With Melanoma and Their Families
NCT ID: NCT03677739 (https://clinicaltrials.gov/study/NCT03677739)

Standard of Care Chemotherapy With or Without Stereotactic Body Radiation Therapy for Oligometastatic Pancreatic Cancer
NCT ID: NCT04975516 (https://clinicaltrials.gov/study/NCT04975516)

Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors
NCT ID: NCT02611024 (https://clinicaltrials.gov/study/NCT02611024)

Impact of Vitamin D Supplementation on the Rate of Pathologic Complete Response in Vitamin D Deficient Patients
NCT ID: NCT04677816 (https://clinicaltrials.gov/study/NCT04677816)

High-Dose Vitamin D Supplementation for ADT-Induced Bone Loss in Older Prostate Cancer Patients
NCT ID: NCT05838716 (https://clinicaltrials.gov/study/NCT05838716)

Laboratory Study of Cancer & Immune Cells in Ascites Fluid of Ovarian Cancer Patients to Test Alternative Therapies
NCT ID: NCT03943316 (https://clinicaltrials.gov/study/NCT03943316)

(VELA) Study of BLU-222 in Advanced Solid Tumors
NCT ID: NCT05252416 (https://clinicaltrials.gov/study/NCT05252416)

A Study of DB-1311 in Advanced/Metastatic Solid Tumors
NCT ID: NCT05914116 (https://clinicaltrials.gov/study/NCT05914116)

SBRT Versus Hypofractionated Radiotherapy for Biochemically Recurrent or Oligometastatic Prostate Adenocarcinoma
NCT ID: NCT06205316 (https://clinicaltrials.gov/study/NCT06205316)

Profiling of Radiological Factors in Treatment and Outcomes in Prostate Cancer
NCT ID: NCT03354416 (https://clinicaltrials.gov/study/NCT03354416)

About FORCE

FORCE is a national nonprofit organization, established in 1999. Our mission is to improve the lives of individuals and families affected by adult hereditary cancers.